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Abstract 
Type 2 diabetes is a progressive disease characterised by raised blood glucose 
levels. Lowering of blood glucose is required to prevent symptoms of diabetes 
and to reduce the risk of people with type 2 diabetes developing diabetes-
related complications. 
Metformin is the initial drug of choice to lower blood glucose for most people. 
However, for many people metformin eventually fails to control blood glucose 
and additional medication is required. At least four different types of glucose-
lowering medication are recommended after metformin in current type 2 
diabetes treatment guidelines. Choosing the best medication is left to the 
clinician and patient and is a major clinical dilemma. 
The degree of glucose-lowering appears to vary greatly between people for all 
the medication options. The same medication may appear to have a marked 
effect in one patient but little effect in another. Similarly, only some people 
develop side-effects. Despite this apparent variation it is largely unknown 
whether differences in treatment response and risk of side-effects can be 
predicted based on an individual patient’s characteristics.  
The aim of this thesis is to establish whether simple patient characteristics are 
associated with differences in treatment effect for common glucose-lowering 
medications. If they are, this could inform a precision medicine approach in type 
2 diabetes, where medications are targeted to those people most likely to 
benefit. 
 
In Chapter 1 we review current type 2 diabetes treatment, the opportunity for 
precision medicine, and methodological challenges in studying precision 
medicine in type 2 diabetes. 
In Chapter 2 we describe the marked changes in prescribing patterns of 
glucose-lowering therapy in the United Kingdom in recent years, and 
demonstrate there have been relatively modest changes in important short-term 
patient outcomes including HbA1c reduction, weight change and hypoglycaemia 
over the same period. 
In Chapter 3 and 4 we demonstrate that simple patient characteristics are 
associated with response to DPP4 inhibitor therapy, and that simple patient 
characteristics can identify people with different patterns of response and risk of 
side-effects with sulfonylurea and thiazolidinedione therapy. 
In Chapter 5 we apply joint-longitudinal survival modelling to demonstrate 
important insights in the association between the benefits (glucose-lowering) 
and risks (side-effects) of metformin, sulfonylureas and thiazolidinedione 
therapy.  
In Chapter 6 we compare two precision medicine strategies: 1) a recently 
proposed strategy of using clinical features to assign people with type 2 
diabetes into five subgroups; 2) a strategy of using specific continuous clinical 
features to predict specific outcomes for individual people. We find the strategy 
using continuous clinical features has greater clinical utility.  
Chapter 7 presents an overview of main findings, conclusions, limitations and 
future work generated by this thesis.  
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Introduction 
 
Structure 
This chapter is divided into 6 sections. Part A states the structure and aims of 
the thesis. Part B presents an overview of type 2 diabetes and its treatment. 
Part C presents an overview of precision medicine. Part D discusses the 
opportunity for a precision medicine approach in type 2 diabetes. Part E outlines 
key methodological challenges for evaluating precision medicine in type 2 
diabetes. Part F introduces the datasets used in subsequent chapters of the 
thesis.  
   
Introduction part A: Structure and aims 
of thesis 
The overall aim of this thesis is to establish whether clinical patient 
characteristics are associated with differences in treatment effect for common 
glucose-lowering therapies, and can inform a precision medicine approach in 
type 2 diabetes. 
Chapter 1 presents an overview of type 2 diabetes and current clinical 
management, introduce precision medicine and the opportunity for a precision 
medicine approach in type 2 diabetes, and outline methodological challenges in 
defining such an approach. 
In Chapter 2 we aim to examine recent prescribing patterns in the United 
Kingdom. We describe recent trends in the prescribing of glucose-lowering 
therapy, and examine concomitant changes in important short-term patient 
outcomes including HbA1c reduction, weight change, blood pressure and 
hypoglycaemia. 
In Chapter 3 we examine whether markers of insulin resistance are associated 
with response to DPP4-inhibitor therapy. This study introduces a key concept of 
our methodological framework for evaluation of precision medicine: testing the 
validity of initial findings through replication in independent dataset.  
In Chapter 4 we aim to investigate whether simple patient characteristics can 
identify people with different patterns of response and risk of side-effects with 
sulfonylurea and thiazolidinedione therapy. This introduces a second key 
concept: that differences in the benefit of a drug should not be examined 
without consideration of differences in side-effects. 
In Chapter 5 we set out to apply joint-longitudinal survival modelling to directly 
test associations between the benefits (glucose-lowering) and risks (side-
effects) of three widely used glucose-lowering therapies: metformin, 
sulfonylureas and thiazolidinediones.  
In Chapter 6 we aim to test the clinical utility of a recently proposed precision 
medicine strategy of using clinical features to assign people with type 2 
diabetes into five subgroups. We also aim to compare this approach with a 
strategy of using specific continuous clinical features to predict specific 
outcomes for individual people.  
Chapter 7 is a discussion of the main findings, conclusions, limitations and 
future work generated by each chapter. 
  
Introduction part B: Type 2 diabetes and 
its treatment 
1.1 Diagnosis of type 2 diabetes 
Type 2 diabetes accounts for 90-95% of all diabetes and affects 425 million 
people worldwide, and over 4 million people in the United Kingdom (UK).(1) 
Diabetes care is estimated to account for up to 10% of current National Health 
Service (NHS) expenditure in the UK.(2) Type 2 diabetes is a progressive, 
multifactorial and heterogeneous condition characterised by chronic 
hyperglycaemia (raised blood glucose levels). People with type 2 diabetes have 
varying degrees of lower pancreatic beta cell function (meaning less insulin is 
produced) and higher levels of insulin resistance. This is in contrast to type 1 
diabetes, which is a chronic autoimmune disease characterised by absolute 
insulin deficiency caused by destruction of the pancreatic beta cells. In usual 
care in the UK type 2 diabetes is diagnosed using a blood test to measure 
Haemoglobin A1c (HbA1c), which provides a summary estimate of recent blood 
glucose levels over an approximately three month period. A HbA1c level of or 
over 48 mmol/mol (6.5%) is sufficient for diagnosing diabetes, although the test 
needs to be repeated if the patient does not have any symptoms of diabetes. 
HbA1c does not identify the type of diabetes, and type 2 diabetes is normally an 
exclusion based diagnosis, once less common forms such as type 1 diabetes, 
gestational diabetes, and rare genetic forms of diabetes have been ruled out. . 
1.2 The importance of good blood glucose control in type 2 diabetes  
Acute symptoms of elevated glucose levels include polyuria, polydipsia, weight 
loss and dehydration.(3) Long-term consequences of chronic hyperglycaemia 
are severe with an increased risk of microvascular complications (neuropathy, 
nephropathy and retinopathy) and cardiovascular disease, reduced quality of 
life, and increased mortality.(2)  
The majority of people with type 2 diabetes will at some point require drug 
treatment to lower their blood glucose to prevent symptoms and to reduce their 
risk of developing diabetes-related complications. The link between improved 
glycaemic control with glucose-lowering therapy and reduced progression of 
microvascular complications was first established in the 1990s in the UK 
Prospective Diabetes Study (UKPDS) study.(4) UKPDS also demonstrated a 
‘legacy’ effect of good early glycaemic control reducing the risk of long-term 
complications of diabetes.(5) 
1.3 Current type 2 diabetes treatment targets recommend an 
individualised approach 
HbA1c levels are the major driver of prescribing decisions for people with type 2 
diabetes. UK and the US/European type 2 diabetes treatment guidelines 
recommend an HbA1c target of 53 mmol/mol (7%) for most individuals.(2, 6) 
However, guidelines recommend that the HbA1c target is adjusted on an 
individual basis so as not to impact on quality of life, with the individual target 
informed by patient preference, patient characteristics (especially comorbidity 
and frailty), social factors, life expectancy, polypharmacy risks, and risk of 
adverse drug effects such as side-effects and weight change.(2, 3, 6)  
1.4 First-line drug therapy 
Metformin is the initial glucose-lowering drug recommended for most individuals 
in current guidelines, due to its low cost, glucose-lowering efficacy, and safety 
profile (Table 1).(2, 6, 7) Metformin is however contraindicated in people with 
advanced kidney disease (eGFR <30 mL/min/1.73m2), in this case other drug 
options are considered (see Section 2.5). UKPDS suggested a mortality benefit 
for metformin compared with diet alone,(4) although whether metformin reduces 
risk of cardiovascular disease still remains uncertain.(8)  
1.5 Drug options after metformin 
As type 2 diabetes is a progressive disease, for many individuals a single agent 
eventually becomes insufficient to achieve target glycaemic control and 
additional glucose-lowering therapy is required. In the UK type 2 diabetes 
treatment guidelines (NICE guidelines) recommend intensification is considered 
at an HbA1c threshold of 58 mmol/mol (7.5%), although again suggest this 
should be tailored to individual people.(2)  
Additional therapy is added in a stepwise fashion, and when a decision is made 
to intensify treatment there is now vast choice of drugs after metformin. Three 
new classes of drug have become available in recent years: glucagon-like 
peptide 1 (GLP-1) receptor agonists (first agent approved in 2005), dipeptidyl 
peptidase-4 (DPP4) inhibitors (approved 2006), and sodium glucose co-
transporter 2 (SGLT2) inhibitors (approved 2011). These add to the well-
established drug classes: sulfonylureas, thiazolidinediones (now only 
pioglitazone in the UK, although prescribing of rosiglitazone was previously 
common until around 2010), and insulin. Other drug classes include 
meglitinides and alpha-glucosidase inhibitors, but these have limited glucose-
lowering efficacy and are now rarely prescribed. Each of the major current drug 
classes recommended after metformin differ in mechanism of action, side-effect 
profile, and cost (see Table 1 for an overview of common non-insulin options). 
For glucose lowering, network meta-analysis, including the analysis 
underpinning NICE guidelines, suggest the average efficacy of most oral 
diabetes medications is similar, although head-to-head clinical trials are 
lacking.(7, 9-11) Durability of glycaemic response is lower with sulfonylureas   
compared to thiazolidinediones.(12) The ongoing GRADE trial (due 2021) will 
provide head-to-head long-term comparative effectiveness data for metformin 
treated participants randomised to sulfonylureas, DPP4 inhibitors, GLP-1 
receptor agonists, or insulin, although unfortunately not SGLT2 inhibitors.(13) 
1.6 Recent evidence for the cardiovascular benefit of SGLT2 inhibitors 
and GLP-1 receptor agonists in randomised trials 
A major recent development in type 2 diabetes has been clinical trials that have 
demonstrated a cardiovascular benefit, compared to placebo, for GLP-1 
receptor agonists (liraglutide and semaglutide and likely exenatide) and SGLT2 
inhibitors (empagliflozin, canagliflozin and likely dapagliflozin) in high-risk 
individuals with type 2 diabetes and established cardiovascular disease.(14-19) 
In the main these trials have assessed secondary prevention for participants 
who have experienced adverse cardiovascular events prior to the trial. Whether 
the cardiovascular benefit extends to primary prevention of cardiovascular 
events for individuals at lower cardiovascular risk is unknown.(20) In contrast, 
for DPP4 inhibitors, similar placebo-controlled cardiovascular outcome trials 
demonstrated cardiovascular safety but not benefit.(21-23). Evidence of 
cardiovascular safety or benefit for older therapies is lacking, as cardiovascular 
safety trials have only been required for new type 2 diabetes therapies since 
2008. Prior to this, approval of new drugs was based on demonstration only of 
glucose-lowering efficacy and safety profile.(24) Of the older therapies, 
pioglitazone has been shown to have an overall cardiovascular benefit in high-
risk individuals compared with placebo, but has been also associated with
Table 1: Overview of major non-insulin glucose-lowering therapies. For further detail see Davies et al. Diabetes Care 2018.(6) 
Drug class Drugs in class Primary mechanism of action 
Major contra-
indications Cost 
Weight 
gain 
Common side-
effects 
Cardiovascular & 
other effects 
(see Section 2.6) 
Biguanides Metformin Decreased hepatic glucose production 
Renal disease  
(eGFR <30) 
Low  
(off-patent) 
Limited 
weight loss 
Gastro-intestinal, Vitamin 
B12 deficiency Uncertain  
DPP4 inhibitors 
Alogliptin 
Linagliptin 
Saxagliptin 
Sitagliptin 
Vildagliptin* 
Increased insulin 
secretion, reduced 
glucagon secretion 
None High Weight neutral Well-tolerated 
Cardiovascular safety but 
not benefit 
GLP-1 receptor 
agonists 
Dulaglutide 
Exenatide 
Liraglutide 
Lixisenatide 
Semaglutide 
Increased insulin 
secretion, reduced 
glucagon secretion, 
improved satiety 
None High Weight loss Gastro-intestinal 
Cardiovascular benefit in 
high-risk people 
SGLT2 inhibitors 
Canagliflozin 
Dapagliflozin 
Empagliflozin 
Lowered glucose 
reabsorption in the kidney 
so increased urinary 
glucose excretion 
Renal disease  
(eGFR <45) High 
Weight 
loss 
Genital infections 
Polyuria 
Volume depletion 
Rare: amputation, 
fracture, DKA 
-Cardiovascular benefit 
in high-risk people 
-Improvement in blood 
pressure & renal function 
Sulfonylureas 
Glibenclamide 
Gliclazide* 
Glimepiride  
Gliplizide 
Increased insulin 
secretion 
None (caution required 
in those for whom 
hypoglycaemia a 
particular concern) 
Low  
(off-patent) 
Weight 
gain Hypoglycaemia Uncertain 
Thiazolidinediones Pioglitazone Rosiglitazone** 
Increased insulin 
sensitivity Existing heart failure 
Low 
(off-patent) 
Weight 
gain 
Oedema 
Fracture 
Heart failure 
Pioglitazone: 
cardiovascular benefit in 
high-risk people 
*not licensed in US for type 2 diabetes **no longer licensed in Europe for type 2 diabetes 
  
increased heart failure.(25) There has been concern that sulfonylureas increase 
the risk of cardiovascular death compared to other drug classes but no firm 
conclusions can be drawn from current evidence.(20) A recent unblinded trial 
found no difference in cardiovascular events between sulfonylureas and 
pioglitazone, when added to metformin.(26) 
1.7 Treatment pathways after metformin – current UK Guidelines  
Current UK NICE treatment guidelines leave the choice between drugs after 
metformin largely to the clinician and patient, making choosing the appropriate 
therapy a major clinical dilemma. Since 2017, NICE guidelines have 
recommended 4 oral agents inhibitors as second line therapy options: DPP4-
inhibitors, sulfonylureas, pioglitazone and SGLT2 inhibitors.(2)  Selection 
between these drug classes is recommended by matching individual people to 
the most appropriate therapy for them based on expected treatment effect, 
(glycaemic improvements, potential side-effects and weight change), patient 
preferences, comorbidities, polypharmacy risk, and cost.(2)  
1.8 Treatment pathways after metformin – current US and European 
Guidelines  
Although US and European treatment guidelines similarly recommend an 
individualised approach to the selection of therapy after metformin, they have 
recently been updated to provide more specific recommendations than NICE to 
match individuals with the most appropriate therapy based on their 
characteristics.(6) The key change has been that, based on the cardiovascular 
benefit shown in trials, these guidelines now recommend SGLT2 inhibitors and 
GLP-1 receptor agonists as add-on therapy for individuals who are over their 
HbA1c target and have established cardiovascular disease. This criteria would 
apply to around 15-20% of people with type 2 diabetes.(6, 27) For the 
remainder of individuals, patient preference, comorbidities, glycaemic control, 
side-effects (in particular risk of hypoglycaemia), weight change and cost 
remain the key considerations.(6) Specific updates in the recent guidelines 
around these include: 1) the recommendation for use of SGLT2 inhibitors 
(empagliflozin or canagliflozin) in people with established chronic kidney 
disease (CKD), as they may slow progression of CKD;(28) 2) the avoidance of 
sulfonylureas if there is a need to minimise hypoglycaemia; 3) the use of SGLT2 
inhibitors or GLP-1 receptor agonists if weight control is a priority; 4) the use of 
sulfonylureas or thiazolidinediones in settings where cost is the major issue.(6) 
1.9 Third-line intensification and beyond 
Treatment selection for further therapy intensifications follow the same general 
selection process as for second-line therapy, with insulin also considered. In the 
UK NICE guidance a key difference with the recent US/European guidelines is 
that GLP-1 receptor agonists are currently recommended only in individuals 
with BMI ≥35 kg/m², and at the earliest third-line.(2) NICE also recommend that 
GLP-1 receptor agonists are stopped at 6 months unless an individual has a 
HbA1c reduction of at least 11 mmol/mol (1%) and weight loss of at least 3%.(2) 
1.10 Guidelines reflect differences in average treatment effect, not 
differences between individuals in treatment effect 
Current guidelines highlight the importance of an individualised approach to 
selecting treatment, including a focus on likely treatment effectiveness.(2, 3, 6) 
However, estimates of treatment effectiveness are currently informed only by 
average effect sizes observed in clinical trials, rather than expected differences 
in treatment effect between individual people. Despite this, trials have shown 
there is substantial variability between people in glucose-lowering response to 
therapy.(29) Similarly, only some people develop side-effects. An example of 
the large variability between individual people in glucose-lowering is shown in 
Figure 1. Blood glucose (HbA1c) is lowered for most people, but some 
individuals appear to have a marked response to a drug, whilst for other 
individuals there appears to be little or no therapeutic response. Such inter-
individual variability is widely thought to represent true heterogeneity in 
treatment response between people, and as a result to have great clinical 
relevance.(29) However, the degree to which this heterogeneity differs for 
different drug classes or relates to the underlying characteristics of people with 
type 2 diabetes is largely unknown.(30) A key knowledge gap identified in 
guidelines has been whether the comparative effectiveness and safety of the 
different drug options varies by simple patient characteristics.(7) 
 
Figure 1: Distribution of individual changes in HbA1c at 6 months (6 month 
HbA1c minus baseline HbA1c) by drug in ADOPT randomised trial for 3,707 
participants with a measure of HbA1c at 6 months) (Dennis, Jones 
unpublished). Mean (standard deviation) improvement in HbA1c was greatest 
at 6 months for sulfonylureas -9.4 (8.6) mmol/mol [-0.9% (0.8%)], compared to 
metformin -7.5 (8.1) mmol/mol [-0.7% (0.8%)] and thiazolidinedione therapy -6.4 
(8.6) mmol/mol [-0.6% (0.8%)], although for each drug there was a large 
variability between individuals in change in HbA1c.  
1.11 Conclusions 
Choice of therapy after metformin when additional therapy is required to lower 
blood glucose levels is a major clinical dilemma for most people with type 2 
diabetes. Recent evidence of cardiovascular benefit with SGLT2 inhibitors and 
GLP-1 receptor agonists supports their use after metformin, but only for the 
relatively small proportion of high-risk people with established cardiovascular 
disease. This means that for the majority of people with type 2 diabetes likely 
treatment effect (glucose-lowering effect and risk of side-effects) remain an 
important consideration when choosing therapy, alongside consideration of 
patient preference, comorbidities, polypharmacy risk, and cost.  
Although average glucose-lowering of oral medication options after metformin is 
similar, there is known to be wide variability in treatment effect between 
individual people. It is unknown whether this variability has clinical utility. 
Similarly, although drugs are known to differ in side-effects, it is largely 
unknown to what extent individual people differ in risk of developing side-effects 
on specific therapies. As a result current guidelines and treatment decisions are 
based on estimates of average treatment effects for the different drug options, 
rather than estimates of likely differences in treatment effect between 
individuals. 
 
 
  
Introduction part C: Overview of 
precision medicine  
This section will introduce precision medicine and present examples of two 
successful applications of precision medicine in other diseases. 
1.12 Definition of precision medicine 
Precision medicine can be defined as the “targeting of treatment according to 
the biological or risk characteristics shared by people.”(31) The term precision is 
often used interchangeably with personalised or stratified medicine, although 
stratified medicine more typically refers to attempts to identify discrete 
subgroups of individuals rather than the targeting of treatment at the individual 
level.(32)  
Precision medicine aims to provide more tailored predictions of likely treatment 
effects for individual people or subgroups of people based on their genotypic or 
phenotypic characteristics, in contrast to the present “one size fits all” approach 
common for most diseases. The hope is that more accurate information on 
likely treatment effects will improve clinical decision making, maximising the 
potential benefit from treatment whilst minimising the potential harm. 
1.13 Successful applications of precision medicine 
The NHS England 2016 strategy highlighted the potential benefits of a precision 
medicine approach.(33) However, despite widespread interest, there have been 
relatively few clinically relevant applications of precision medicine to date. Two 
successful implementations in cancer and rare forms of diabetes are outlined 
below. Key to the success of both these precision medicine strategies has been 
the identification of discrete disease subtypes which can then inform treatment 
for individual people. The clinical efficacy of the precision medicine approach 
has then been demonstrated in prospective clinical trials. 
1.13.1 Application of precision medicine in cancer 
Precision medicine is now widely used in cancer where testing of malignant 
tissue for genetic mutations, expression or biomarkers can be used to reveal 
heterogeneity and identify discrete subtypes, rather than just the broad cancer 
type.(34) These subtypes can then be treated differently, with improved 
outcomes. A clear example is HER2 positivity in breast cancer. Data from 
multiple randomised control trials have shown that the 15-20% of people with 
HER2 positivity (HER2 protein overexpression) can be selected for treatment 
with HER2-directed drugs, which leads to marked improvements in disease-free 
survival.(35)  
1.13.2 Application of precision medicine in rarer types of diabetes  
A second successful application of precision medicine has been in monogenic 
and neonatal diabetes.(36) 2.5% of children with diabetes have monogenic 
diabetes.(37) Precise etiological subtypes of monogenic diabetes have been 
identified based on the underlying genetic aetiology. The most common genetic 
mutation is in HNF1A, and an important study demonstrated that individuals 
with this monogenic subtype differs in treatment response, having a marked 
sensitivity to sulfonylureas meaning they can be taken off insulin and maintain 
good blood-glucose control with sulfonylurea tablets.(36) Similarly, in neonatal 
diabetes due to KCNJ11 mutations, sulfonylureas have been shown to restore 
insulin secretion,(38) again meaning individuals can be treated long-term with 
these tablets instead of insulin with improved long-term glycaemic control.(39, 
40) 
 
  
Introduction part D: The opportunity for 
a precision medicine approach in type 2 
diabetes  
1.14 The potential for a precision medicine approach in type 2 diabetes 
Type 2 diabetes glucose-lowering therapy is an excellent candidate for a 
precision medicine approach for the following reasons: 1) There are many 
different medication options after metformin with different mechanisms of action 
but the same principal aim: to lower blood glucose; 2) Current treatment 
guidelines do not provide information which medication is best for lowering 
glucose, for which people; 3) There is great heterogeneity in clinical 
presentation of type 2 diabetes. This makes it plausible people with different 
underlying pathophysiology will vary in response to the different drug classes, 
and vary in susceptibility to side-effects, depending on the mechanism of action 
of the drug; 4) At the individual level glucose-lowering response and 
susceptibility to side-effects appears to vary greatly.  
Despite this, a precision medicine approach to select therapy based on 
assessment of individual or subgroup level characteristics, rather than broad 
differences between drugs, is not close to implementation in type 2 diabetes 
clinical care. The next sections outlines potential strategies for developing a 
precision medicine approach in type 2 diabetes. 
  
1.15 Precision medicine based on defining discrete subtypes of type 2 
diabetes will be difficult 
Any successful implementation of precision medicine in type 2 diabetes is likely 
to be very different to those established in cancer and other forms of diabetes. 
Unlike cancer, tissue is not available for testing, and unlike rare forms of 
diabetes, type 2 diabetes genetic testing does not allow clear definition of the 
underlying pathophysiology. This makes identification of discrete, non-
overlapping subtypes of type 2 diabetes with different treatment requirements 
much less likely.(41)  
Several approaches based on assigning individuals with type 2 diabetes into 
subgroups have however recently been proposed.(42-45) Most notable of these 
is a recent data-driven cluster analysis of Scandinavian registry data, which 
based on three routine clinical measures (HbA1c, BMI, and age at diagnosis) 
and three non-routine measures (GAD autoantibody positivity and HOMA-
measures of beta-cell function (HOMA2-B) and insulin resistance (HOMA2-
IR)),(46) identified five reproducible ‘novel subgroups’ of newly diagnosed adult 
diabetes, four of which represent a potential subclassification of type 2 
diabetes.(42) Although the clusters appeared to differ in risk of complications in 
observational follow-up, most notably diabetic kidney disease, a key point is that 
the clusters are non-discrete. This means they overlap in terms of their clinical 
characteristics. Although the potential clinical utility of the clusters to select 
glucose-lowering therapy was suggested in the original study, there was no 
evaluation of whether the clusters differed in treatment response with different 
drugs.(42) Similarly, the clinical utility of the other recent cluster-based 
approaches has not been assessed, or compared with alternative precision 
medicine approaches that do not assign individuals into subgroups.(43-45, 47, 
48) 
1.16 Precision medicine based on identifying variation between people in 
treatment effect for specific drug options 
An alternative precision medicine approach is, instead of attempting to assign 
people into subtypes of type 2 diabetes based on pathophysiology, to attempt to 
match individuals or subgroups with the drug with which they are likely to have 
the greatest glucose-lowering response and/or least risk of side-effects.(49) 
This requires demonstration of robust and clinically relevant differences in 
treatment effect between people with different underlying characteristics.  
There are several ways that this approach can be developed and tested. One 
way would be to design prospective clinical studies designed specifically to 
evaluate precision medicine, by assessing potential markers of differential 
response to different drug classes. An example is the ongoing TRIMASTER trial 
which is testing two hypotheses: 1) that a subgroup of individuals with BMI>30 
will, compared to a subgroup with BMI<30, have a greater response to the 
thiazolidinedione pioglitazone and a lesser response to the DPP4 inhibitor 
sitagliptin; 2) that a subgroup of people with reduced renal function (eGFR 60-
90) will, compared to a subgroup with eGFR>90, have greater response to 
sitagliptin but a lesser response to the SGLT2 inhibitor canagliflozin.(50) The 
principal disadvantages of such prospective trials are the considerable time and 
expense required. A further limitation of TRIMASTER is the fact only one clinical 
characteristic at a time is used to define the subgroups. 
In comparison, existing data resources such as individual-level patient data 
from existing clinical trials, and data from routine medical care (see Introduction: 
Section 6) may provide a more cost-effective and practical opportunity to 
evaluate precision medicine in type 2 diabetes. The next two subsections 
describe two possible approaches to evaluate differences in glucose-lowering 
response. Only the second approach is likely to provide useful information using 
standard trial and routine care datasets. 
1.16.1 Identifying true “responders” or “non-responders” to glucose-
lowering therapy is not possible with currently available data 
This strategy would aim to use the variability between people in glucose-
lowering response to therapy (Figure 1) to define individual “responders” or 
“non-responders” by applying clinically relevant HbA1c cut-offs (for example, 
responder defined as individuals with  ≥0.5% HbA1c improvement, non-
responder defined as <0.5% HbA1c improvement). Differences in characteristics 
between responders and non-responders could then be examined. However, 
Stephen Senn has demonstrated that identifying ‘true’ responders or non-
responders in this way at the individual-level is not possible in standard parallel-
arm randomised controlled trials, which are designed only to compare average 
differences in outcome between the treatment arms (the variation between 
treatments averaged over all people).(51, 52) The same issue applies in 
observational datasets. The reason is that it is not possible to separate the 
variation of interest (person by treatment variation in the degree of change in 
HbA1c i.e. heterogeneity in treatment effect or different people responding 
differently to the same specific drug) from two further sources of variation; 1) 
between person variation (the variation in response between people that would 
occur irrespective of the drug given; 2) the within person error (the variation 
from occasion to occasion when the same person is given the same treatment) 
(Table 2).(51, 52) This means that the apparent variability between people in 
glucose-lowering response observed in Figure 1 may in fact not represent true 
heterogeneity in treatment effect. Separating the sources of variation and 
identifying true responders or non-responders requires multi-period crossover 
trial designs where participants are randomised to two-or-more therapies at 
least twice. Only this design allows separation of the variation of interest: 
treatment by person interaction.(51-53) Multi-period cross-over trials are rare in 
medicine and have not yet been conducted in type 2 diabetes.(32) 
Table 2: Sources of variation in treatment response (Adapted from 
Senn)(52) 
Type of variation Definition 
Between treatments 
The variation between treatments averaged over all people 
(standard outcome tested in a trial) 
Between people 
The variation between people that would occur irrespective of 
the treatment given 
Treatment by person 
interaction 
The extent to which the effect of treatment varies from person-
to-person 
Within person 
The extent to which the effect of treatment varies from occasion 
to occasion when a person is given the same treatment 
 
1.16.2 Evaluating whether patient characteristics are associated with 
glucose-lowering response to therapy is possible with currently available 
data 
It is however possible to use standard parallel-arm trial and observational 
datasets to evaluate whether true, predictable differences in response to the 
different therapy options in type 2 diabetes exist. What is required is the 
demonstration of associations between clinical features and response at the 
subgroup level (for example demonstrating that response is different in males 
and females). By focusing on the subgroup-level, rather than individual-level, 
other people in the subgroup provide the replication required to establish the 
presence of subgroup by treatment variation. The same interpretation can be 
made for associations between continuous patient features (e.g. BMI) and 
treatment effects. If a clinical feature can be identified that has different 
associations with response with different drugs (for example if response to 
Therapy A is different in males and females, but there is no difference in 
response by sex for Therapy B), this may provide evidence of patient by drug 
variation that can inform a precision medicine strategy, although consideration 
should also be given to alternative explanations such as differences between 
individuals or subgroups in treatment inertia or in medication adherence. If a 
clinical feature is associated with greater or lesser response to a similar degree 
for all drugs, this provides evidence of between patient variation rather than 
patient by treatment variation, and the feature is not likely to be useful to target 
therapy. Features associated with outcomes irrespective of treatment are 
commonly termed “prognostic” factors.(31, 54) 
In summary, the basis of the approach detailed in this section is identification of 
patient-level characteristics that robustly and consistently predict differential 
glucose-lowering response across the different drug options. Most useful will be 
characteristics associated with greater response to one drug but lesser 
response to another drug, although characteristics associated with response to 
one or more drugs but not others will also have utility. Only such differential 
factors offer the potential to provide useful information to select the most 
effective treatment for individuals and inform a precision medicine approach in 
type 2 diabetes. 
 
1.17 Evidence for differential response to glucose-lowering agents  
Although establishing whether there are true differences between individuals in 
treatment response to the different glucose-lowering agents has been identified 
as a key area for future research, there is limited robust evidence in this area; 
many of the studies that have been conducted are small in size, have 
methodological limitations, and lack replication.(7, 41, 55, 56) Clinical drug 
efficacy trials are focused on average treatment effects and are severely 
underpowered for evaluating heterogeneity in treatment effects between 
subgroups (see Section 3.2 for an overview of the limitations of classical 
subgroup analysis in clinical trials).(57) This means the subgroup analyses 
commonly reported in clinical trials provide little credible evidence to evaluate 
the potential for a precision medicine approach to type 2 diabetes therapy. 
The following two subsections present an overview of the most robust current 
evidence from studies specifically designed to evaluate clinical features and 
genetic factors associated with glucose-lowering response to type 2 diabetes 
therapies. 
1.17.1 Clinical patient features associated with drug response 
Angus Jones and colleagues recently showed in the prospective Predicting 
Response to Incretin Based Agents in Type 2 Diabetes (PRIBA) study that 
reduced glucose-lowering efficacy of GLP-1 receptor agonists was associated 
with clinical markers of low beta cell function such as lower C-peptide and 
longer duration of diabetes in insulin-treated people.(58) It is not known whether 
these findings are applicable to non-insulin treated individuals, or if the same 
factors predict response to DPP4 inhibitors, the drug class with a similar 
glucose-lowering mechanism of action. A systematic review of studies 
published prior to the PRIBA analysis did not clearly identify any factors 
associated with glycaemic response to either DPP4 inhibitors or GLP-1 receptor 
agonists except baseline HbA1c.(59) Lower BMI, lower insulin resistance and 
Asian ethnicity were however associated with greater response to DPP4 
inhibitors in some studies. The review noted substantial weaknesses in the 
methodology of previous work, including a lack of adjustment for baseline HbA1c 
in many studies (see Section 5.1.2). 
An early observational analysis of the association between BMI and glucose-
lowering response with sulfonylureas and metformin in UK primary care data 
suggested that higher BMI was associated with a lesser glucose-lowering 
response with metformin but that the effect size did not reach clinical 
significance (mean decrease in HbA1c for obese individuals 14.6 mmol/mol 
(1.4%); non-obese individuals 15.9 mmol/mol (1.5%)).(60) There was no 
evidence of an association for sulfonylureas. A more recent observational study 
again using UK primary care data found differences in response between 
sulfonylureas and thiazolidinediones, with greater glucose-lowering with 
thiazolidinediones in obese females.(61) 
Baseline HbA1c is the major predictor of glucose-lowering response for all drug 
classes, with a higher baseline HbA1c associated with a greater HbA1c response 
if defined as absolute change from baseline HbA1c (see Section 5.1.1 for further 
discussion of this point).(62-65) A number of studies have examined whether 
HbA1c and glucose-lowering response differ by drug class and generally shown 
only modest differences between drug,(62, 65-67) although post-hoc analysis of 
two head-to-head trials have recently suggested there may be greater relative 
benefit with the SGLT2 inhibitor empagliflozin at higher baseline HbA1c levels 
compared to the DPP4 inhibitor sitagliptin and sulfonylurea glimepiride.(68) 
1.17.2 Genetic associations with drug response 
A recent review found over 120 studies evaluating gene-drug interactions in 
diabetes, with potential pharmacogenetic influences on glucose-lowering 
response in type 2 diabetes reported for metformin, sulfonylureas and 
thiazolidinediones.(69-73) However, the majority of studies have been small in 
size and lacked replication.(41) Several associations have been replicated in 
multiple independent studies, notably CYP2C9 and TCF7L2 variants for 
sulfonylureas and ATM for metformin (in some, but not all, populations), but the 
size of glucose-lowering effect has been relatively small.(49, 69) Very little is 
known about pharmacogenetic influences on glycaemic response for the newer 
drug classes DPP4 inhibitors, SGLT2 inhibitors and GLP-1 receptor 
agonists.(41) Given the high prevalence of type 2 diabetes, the cost of genetic 
testing, and the small effect sizes reported, the main utility of pharmacogenetics 
may well be in better understanding the underlying mechanisms by which the 
different drug classes influence glycaemic control, rather than for informing a 
precision medicine approach based on drug response. Genetic testing is more 
likely to be cost-effective if, instead of differences in drug response, it can 
identify people who are likely to derive particular cardiovascular benefit from 
specific therapies. 
 
1.18 Evidence for differences between people in risk of side-effects 
Few studies have systematically evaluated whether patient characteristics 
influence the risk of developing common drug specific side-effects. With 
thiazolidinediones, it has been established that bone fractures are more 
common in post-menopausal females.(74) Older age has long been considered 
to be a risk factor for hypoglycaemia with sulfonylureas,(75) although trials have 
shown older people can be safely treated with these agents.(76, 77) Similar 
approaches to those outlined above for glucose-lowering response will be 
required to evaluating the potential for a precision medicine approach to guide 
therapy based on individualised risk of side-effects. 
1.19 Evidence for differences between people in cardiovascular risk 
Subgroups of people with type 2 diabetes and established cardiovascular 
disease have been shown to have a cardiovascular benefit with SGLT2 
inhibitors and GLP-1 receptor agonists in placebo-controlled trials (see section 
2.6), although it is unclear whether this benefit extends to lower-risk people. It is 
also unknown whether older agents such as sulfonylureas would show similar 
or different effects if equivalent trials were conducted. Although simple 
subgroup analysis has been conducted within the trials, it is uncertain to what 
extent the cardiovascular benefit of SGLT2 inhibitors and GLP-1 receptor 
agonists may vary by participant characteristics. Similarly, as these agents are 
relatively new, there are limited follow-up data in primary care to evaluate ‘real-
world’ differences between people in cardiovascular outcomes. 
  
1.20 Conclusion 
There may be great potential to apply a precision medicine approach to select 
therapy for people with type 2 diabetes. Available drug options differ in 
mechanism of action and known side-effects, and at the individual-level there 
appears to be marked heterogeneity in treatment effect, in particular in glucose-
lowering response. If this apparent individual-level variation in treatment effect 
relates to underlying patient characteristics this could allow different drugs to be 
targeted to those most likely to benefit: a precision medicine approach. 
Although identifying true responders or non-responders to specific medications 
requires complex prospective trial designs, existing data (such as completed 
trial and observational datasets) offer the potential to evaluate associations 
between patient level characteristics and treatment effects with the different 
drug options. 
Current evidence supporting a precision medicine approach in type 2 diabetes 
is limited, and many studies reporting associations with response lack 
replication. Studies to date suggest the use of routine patient features, rather 
than genetic testing, is likely to provide the most practical way in which a 
precision medicine approach can inform selection of glucose-lowering therapy 
in clinical practice. 
 
 
  
Introduction part E: Further 
methodological considerations for 
evaluating precision medicine in type 2 
diabetes 
Methods to evaluate precision medicine approaches are not well-established. 
This section will provide an overview of considerations and challenges most 
relevant to evaluating a precision medicine approach to type 2 diabetes therapy. 
1.21 Modelling glucose-lowering response 
1.21.1 Definition of glucose-lowering response 
Glucose-lowering (glycaemic) response after starting therapy in diabetes is 
commonly defined in two ways in research studies. The first is whether an 
individual achieves a specified target HbA1c threshold (a binary outcome). The 
second is an individuals’ HbA1c change from baseline (a continuous outcome). 
Previously, Jones and colleagues have shown that these different definitions of 
response identify very different individuals as good responders to therapy (when 
good responders are defined as the top quartile of responders to each therapy 
under each definition).(78) This difference is due to the influence of baseline 
HbA1c.(78) Compared to individuals with high baseline HbA1c, people with a low 
baseline HbA1c are more likely to reach a target HbA1c threshold but are likely to 
have a lesser HbA1c change (a floor effect).  
HbA1c change is the more appropriate outcome for studies evaluating a 
precision medicine approach to therapy. The main drawback of using a 
threshold is that arbitrarily dichotomising a continuous variable such as HbA1c 
into two groups will result in substantial loss of statistical power to detect 
associations between baseline clinical features and response.(79, 80) 
1.21.2 Adjustment for baseline HbA1c 
Baseline HbA1c is strongly associated with response to glucose-lowering 
therapy,(62-64) and has been estimated to account for 36% of variability in 
HbA1c change from baseline irrespective of therapy (meta-analysis of 59 clinical 
trials: weighted R²=0.36).(62) Baseline HbA1c is therefore a major potential 
confounder when evaluating association between response and clinical features 
which are themselves likely to be correlated with baseline HbA1c, such as BMI 
and lipids. This suggests adjustment for baseline HbA1c is the appropriate 
strategy. However, adjustment for baseline has been shown to increase bias in 
certain cases in other fields, in particular when the association between 
baseline and response is largely explained by regression to the mean.(81) 
Jones and colleagues have recently assessed the impact of regression to the 
mean when evaluating type 2 diabetes treatment response, and showed that 
the effect of regression to the mean is relatively small compared to the true 
effect of baseline HbA1c on response.(64) Failure to adjust for baseline HbA1c 
led to associations between markers strongly associated with baseline HbA1c 
and response that bias adjustment suggested were likely to be false.(64) This 
study strongly suggests that adjustment for baseline HbA1c to evaluate potential 
predictors of response in studies of precision medicine in diabetes is both 
necessary and appropriate.  
 
  
1.21.3 Choice of time point for evaluating glycaemic response 
Glycaemic response is known to vary over time with different type 2 diabetes 
drug classes. In particular, in randomised trials sulfonylureas have been shown 
to have a greater initial response but less durable response than metformin and 
thiazolidinediones,(12) and the SGLT2 inhibitor canagliflozin.(82) Initial 
response is more likely to reflect the ‘pure’ pharmacological action of the drug, 
whilst long-term response is likely to reflect both pharmacological action and 
underlying disease progression. The extent to which choice of time point may 
influence findings in studies evaluating predictors of treatment response in type 
2 diabetes is unknown.  
1.22 The pitfalls of classical subgroup analysis to evaluate heterogeneity 
in treatment response 
The conventional approach to evaluate heterogeneity in trials is to examine 
differences in outcomes across large numbers of exploratory participant 
subgroups defined on the basis of single characteristics (e.g. sex) or by 
dichotomising continuous baseline measures (e.g. BMI </≥30).(83) Even when 
pre-specified in trial protocols, such analyses are typically severely 
underpowered as trials are powered only for the main effect, leading to the 
potential of false negative findings.(57, 84, 85) Trials with 80% power for the 
main effect have been estimated to have only 29% power to detect a subgroup 
effect of the same magnitude.(86) When multiplicity-adjusted significant 
associations have been observed these have been shown to be rarely validated 
in subsequent studies, suggesting they may be false positives.(84, 87) These 
studies suggest that classical, hypothesis-free, subgroup analysis is unlikely to 
the most efficient approach to evaluate whether differential treatment response 
to type 2 diabetes therapy exists. Although superior to subgroup analysis, 
testing interactions between continuous features and treatment response in trial 
data will still be underpowered.(84) 
1.23 Evaluation of multiple patient outcomes: the association between the 
benefits and risks of therapy 
A key but often overlooked question in precision medicine is: are the risks of a 
drug positively correlated with the benefits?(84) For glucose-lowering therapies, 
the relevant question is whether people with characteristics favouring good 
glycaemic response to a specific drug are also at increased risk of drug specific 
side-effects. This will be more likely if side-effects relate to the mechanism of 
action of the drug. A positive association may limit the clinical utility of a 
precision medicine approach in type 2 diabetes based on likely glucose-
lowering.  
Risk-benefit analysis has been suggested to evaluate associations between 
benefits and harms for precision medicine, but there have been no studies in 
type 2 diabetes and there have been few practical applications in other 
diseases.(84, 88, 89) It has been proposed that risks are reported at the same 
level as the benefits (for example if benefits are reported at subgroup level so 
should the risks).(84) However, no framework or modelling strategy has been 
proposed to directly evaluate potential associations between the benefits and 
risks of drug therapy. One potential strategy for precision medicine in type 2 
diabetes would involve directly testing the association between the HbA1c 
response to a drug over time (a longitudinal outcome) and the risk of developing 
a side-effect (a survival outcome).  
 
1.24 Strengths and weaknesses of available datasets to evaluate precision 
medicine in type 2 diabetes 
1.24.1 UK primary care data  
UK population based primary care databases, such as Clinical Practice 
Research Datalink (CPRD),(90) contain the anonymised routinely collected 
primary care records of consenting individuals registered with a broadly 
representative sample of general practices.  
UK primary care records provide several potential advantages for study of a 
precision medicine approach in type 2 diabetes. Primary care databases reflect 
‘real-world’ prescribing with no inclusion criteria, providing complete data on 
prescriptions issued (although no data on drug dispensation), and thus enabling 
head-to-head evaluation of all diabetes drugs currently used in clinical practice. 
Large sample size reduces concern about power when evaluating subgroups or 
predictors of response to patient outcomes. Pay-for-performance targets 
(introduced in 2004 through The Quality and Outcomes Framework (QOF)) 
have resulted in consistent high-quality clinical data entry about chronic 
disease, with incentivised annual monitoring of HbA1c levels in people with type 
2 diabetes.  
There are however significant limitations to the use of primary care data to 
evaluate differential treatment effects. The counterpoint to increased power 
from increased sample size is the risk of overly precise results and false 
positive findings. Biases in prescribing behaviour, in particular selective 
prescribing based on disease severity or prognosis (prescribing by indication), 
may limit head-to-head comparisons of different drug classes. If the reason 
underlying the prescribing decision is unrecorded in the primary care system 
standard analytical approaches cannot remove this systematic bias.(7) For 
comparison of drug-specific side-effects there is also likely to be recording bias. 
This will be present if clinicians are more likely to record a side-effect for people 
on a specific drug known to cause the side-effect, but are less likely to record 
the same side-effect if it occurs in people treated with other drugs. A further 
related weakness is missing data, which as primary care data is not collected 
for research is substantial. Analysis of only the subset of people with complete 
data (complete-case analysis) will be biased if people with missing data differ 
systematically to those with complete data.(90) 
A further confounder relevant for studies of precision medicine but not easily 
measured in primary care data is adherence to medication. Information on 
prescriptions issued is captured in the primary care record but no data are 
available on whether prescriptions were collected or medication was taken as 
prescribed. The medication possession ratio is a commonly used approach to 
estimate adherence in primary care records from prescriptions issued, and has 
been defined as the “number of days of available medication divided by the 
number of days between the first and last prescription dates, multiplied by 
100.”(91) Farmer and colleagues showed that reduced adherence is common in 
primary care (13% of CPRD people), varies by medication class, and is 
associated with smaller reductions in HbA1c.(91) 
1.24.2 Existing randomised clinical trial data 
Individual participant-level data from completed clinical trials are increasingly 
available upon application for researchers to answer secondary research 
questions. Data access portals include Clinical Study Data Request and The 
Yale University Open Data Access (YODA) Project.(7, 92) 
A current topic of debate is how best to use such existing clinical trial 
datasets,(93-96) the majority of which are drug efficacy trials. Type 2 diabetes 
randomised trial data have an advantage for evaluating predictors of response 
and side-effects to specific agents compared with observational data, as 
confounding is greatly reduced through randomisation. Further advantages are 
the availability of protocol-driven follow-up of both HbA1c and other clinical 
measures in participants randomly assigned to therapy, and the capture of 
standardised information on the occurrence of side-effects. However, there are 
important limitations to consider. These include a potential lack of 
representativeness due to trial inclusion criteria (for example people with high 
HbA1c values are typically excluded at screening), which might limit 
generalisability. A second key limitation for evaluating precision medicine is the 
fact there are relatively few head-to-head trials of current agents; the majority of 
efficacy trials are placebo controlled. This makes evaluating whether clinical 
factors are associated with response to a specific drug, or to all drugs, more 
challenging. Finally, as discussed in Section 5.2, trials are likely to be 
underpowered to detect drug by subgroup or drug by continuous measure 
interaction effects, and principled approaches to evaluate candidate markers 
are required as “post-hoc observations should be treated with scepticism.”(97) 
1.25 Triangulation using primary care and clinical trial datasets 
The different strengths and weaknesses of primary care and clinical trial data 
suggest the potential for a ‘triangulation’ like approach to evaluate precision 
medicine in type 2 diabetes.(97, 98) An example where this has been 
successfully applied include research to establish the causal effect of lower 
systolic blood pressure and coronary heart disease risk, for which prospective 
cohort, genetic, and randomised trial data were compared.(99) Each of these 
data sources have different biases and assumptions, and the demonstration of 
broadly consistent results increases confidence a true causal effect has been 
measured; in this case that lower systolic blood pressure reduces coronary 
heart disease risk. A further example is the use of prospective cohort studies, 
within-sibling studies and randomised trial data to establish there is unlikely to 
be a link between being breastfed and later life BMI. For precision medicine in 
type 2 diabetes,(98) the emphasis of a triangulation approach would be to test 
the reproducibility of associations between patient characteristics and treatment 
effects across trial and observational datasets from different sources. 
Demonstration of robust and reproducible associations in this way will greatly 
strengthen the credibility of any proposed precision medicine strategy based on 
clinical features.  
1.26 Conclusions 
Recent work has provided important information to inform study of a precision 
medicine approach in type 2 diabetes, although important methodological 
challenges remain. There may be great potential to use routine primary care 
and clinical trial datasets to evaluate predictors of glucose-lowering response 
and risk of side-effects for the different glucose-lowering therapy options. 
However, both primary care data and trial data have important limitations, and a 
key question is how to effectively harness both data sources to study precision 
medicine. 
 
  
Introduction part F: Data overview  
This section provides an overview of the different datasets used in subsequent 
chapters of the thesis. Both routine and trial datasets were used, enabling a 
triangulation-based approach, with replication of analyses in different datasets 
to strengthen the credibility of findings. 
1.27 Routine clinical data 
1.27.1 Clinical Practice Research Database (CPRD) 
CPRD was established in 1987 and is one of the world’s largest longitudinal 
general practice research databases.(90) CPRD is broadly representative of the 
wider UK population. The anonymised database of electronic health records 
includes demographic information, clinical diagnoses, symptoms, laboratory test 
results, primary care issued prescriptions, process of care codes (e.g. specialist 
referrals), and clinical measurements (e.g. body mass index (BMI)). As of mid-
2013 there were over 11.3 registered people (4.4 million actively registered) 
from 674 general practices across the UK.(90) CPRD has been used upwards 
of 2000 retrospective research studies (CPRD, unpublished), and people with 
type 2 diabetes have been widely studied using CPRD.(100) CPRD was used 
for this research as it provides comprehensive clinical records for over 400,000 
people with type 2 diabetes in the UK, including information on their 
sociodemographics, laboratory results including HbA1c, prescriptions issued, 
and occurrence of side-effects while taking medication. 
1.27.2 The Genetics of Diabetes Audit and Research Tayside Scotland 
database (GoDARTs)  
The Genetics of Diabetes Audit and Research Tayside Scotland database 
(GoDARTs) has been used extensively to study the epidemiology and 
pharmacoepidemiology of diabetes.(73) Similarly to CPRD, data are captured 
as part of routine clinical care. Data are available for around 10,000 people with 
diabetes from 1992 onwards. GoDARTs was used for this research to provide 
an independent “real-world” dataset with information on prescribing and 
outcomes to validate findings in CPRD. 
  
1.28 Individual-level participant data from randomised clinical trials 
1.28.1 A Diabetes Outcome Progression Trial (ADOPT)  
ADOPT (2000-2006) was a double-blind randomised trial designed to compare 
long-term blood glucose control (glycaemic durability) with thiazolidinedione 
(rosiglitazone), metformin and sulfonylurea (glibenclamide) therapy.(101) 
Participants were drug-naïve and close to diagnosis of type 2 diabetes. 
Participants were 88% Caucasian. 4,351 participants were randomised and 
received study medication, and over a median follow-up of 4 years the trial 
showed much greater glycaemic durability with thiazolidinedione therapy over 
the comparator drugs.(12) Data on HbA1c levels, other clinical measures such 
as weight change and kidney function, and occurrence of side-effects were 
recorded as part of protocol driven follow-up. ADOPT was used for this 
research as it provided blinded, randomised glycaemic outcome data for two of 
the four therapies recommended second-line in current guidelines (SUs and 
TZDs), making it the ideal dataset to validate findings on glycaemic response 
and side-effects from CPRD in controlled conditions. 
1.28.2 Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of 
Glycaemia in Diabetes (RECORD) trial 
RECORD (2001-2008) was a randomised trial designed to compare 
cardiovascular outcomes in participants adding a thiazolidinedione 
(rosiglitazone) to either metformin or sulfonylurea therapy, compared to 
participants moving onto metformin and sulfonylurea dual-therapy.(102) 
Participants were 99% Caucasian. In contrast to ADOPT, RECORD was an 
open-label rather than double blinded trial. Similarly to ADOPT, data on HbA1c 
levels, other clinical measures, and side-effects were recorded in protocol 
driven follow-up. 4,447 participants were randomised and followed up for a 
mean 5.5 years.(103) Although there was no difference in the primary outcome 
(cardiovascular hospitalisation or cardiovascular death), there was an increased 
risk of heart failure and fracture with thiazolidinedione therapy compared to the 
comparator drugs. RECORD was used for this research to provide a further trial 
replication dataset.  
1.29 Predicting Response to Incretin Based Agents in Type 2 Diabetes 
(PRIBA) prospective study 
PRIBA (2011-2014) was a prospective study of 957 participants designed to 
evaluate the relationship between measures of insulin secretion (as measured 
by blood C-peptide or Urinary C-peptide Creatinine Ratio (UCPCR)) and insulin 
resistance on glucose-lowering response in participants starting DPP4 inhibitors 
and GLP-1 receptor agonists as part of their usual diabetes care in the UK.(104) 
For GLP-1 receptor agonists, lower values of both C-peptide and UCPCR were 
associated with reduced glycaemic response at 6 months.(58) PRIBA was used 
for this research as it is one of the very few prospective cohort studies 
specifically designed to test a precision medicine hypothesis. Results from 
PRIBA for participants initiating DPP4 inhibitors have not yet been reported. 
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Abstract 
Aim 
Prescribing in type 2 diabetes has changed markedly in recent years, with 
increasing use of newer, more expensive glucose-lowering drugs. We aimed to 
describe population-level time trends in both prescribing patterns and short-term 
clinical outcomes (HbA1c, weight, blood pressure, hypoglycaemia and treatment 
discontinuation) after initiating new therapy. 
Methods 
We studied 81,532 UK people with type 2 diabetes initiating a first to fourth line 
drug in primary care between 2010-2017 inclusive (Clinical Practice Research 
Datalink). Trends in new prescriptions and subsequent six and twelve-month 
adjusted changes in glycaemic response (reduction in HbA1c), weight, blood 
pressure, and rates of hypoglycaemia and treatment discontinuation were 
examined.  
Results 
DPP4 inhibitor use second-line near doubled (41% of new prescriptions in 2017 
vs. 22% 2010), replacing sulfonylureas as the most common second-line drug 
(29% 2017 vs. 53% 2010). SGLT2 inhibitors, introduced in 2013, comprised 
17% of new first-fourth line prescriptions by 2017. First-line use of metformin 
remained stable (91% of new prescriptions in 2017 vs. 91% 2010). Over the 
study period there was little change in average glycaemic response and 
treatment discontinuation. There was a modest reduction in weight second and 
third-line (second line 2017 vs. 2010: -1.5 kg (95%CI -1.9;-1.1), p<0.001), and a 
slight reduction in systolic blood pressure first to third-line (2017 vs. 2010 
difference range -1.7 to -2.1 mmHg, all p<0.001). Hypoglycaemia rates 
decreased second-line (incidence rate ratio 0.94 per-year (95%CI 0.88;1.00, 
p=0.04)), mirroring the decline in use of sulfonylureas. 
Conclusions 
Recent changes in prescribing of therapy in type 2 diabetes have not led to a 
change in glycaemic response and have resulted in modest improvements in 
other population-level short-term clinical outcomes. 
  
Introduction 
Prescribing of glucose-lowering therapies for people with type 2 diabetes has 
changed markedly in recent years. International guidelines have been updated 
to include a much greater choice of agents when additional therapies after 
metformin are required to achieve glycaemic control.(1-4) Newer drug classes 
including DPP4 inhibitors, SGLT2 inhibitors and GLP-1 receptor agonists are 
now established alongside the longstanding options sulfonylureas, 
thiazolidinediones and insulin. Choice between these agents is left largely to the 
clinician and patient. Recent studies show that there have been marked 
changes in which agents are initiated after metformin, with a declining use of 
sulfonylureas and increasing and earlier use of DPP4 inhibitors and SGLT2 
inhibitors in both the US, Europe and UK.(5-8)  
Although studies have suggested the glucose-lowering effectiveness of agents 
typically added to metformin may be comparable,(1, 9, 10) there are well 
established differences between the different drug classes in weight change 
and side-effects. GLP-1 receptor agonists and SGLT2 inhibitors are associated 
with weight loss whereas DPP4 inhibitors are weight neutral and sulfonylureas 
can promote weight gain.(9, 10) Hypoglycaemia risk is greater with 
sulfonylureas and insulin relative to other agents.(9) Despite these known 
differences in non-glycaemic effects between agents, evidence of the impact of 
recent changes in prescribing on population-level clinical outcomes is limited.(5, 
7, 11, 12) In this study we aimed to describe changes in prescribing of glucose-
lowering drugs for people initiating first to fourth line therapy between 2010 and 
2017 in the UK, a setting where prescribing does not reflect the ability of people 
to pay. We further examined population-level time trends in the short-term 
clinical outcomes of glycaemic response, weight change, blood pressure 
change, hypoglycaemia, and treatment discontinuation. 
Materials and methods 
Data source and data extraction 
We conducted a population-based analysis of anonymized primary care data 
from the UK’s Clinical Practice Research Database (CPRD). CPRD is a 
population representative database containing demographic, clinical and 
prescription primary care records of individuals.(13) Although CPRD includes 
full prescription records no data on drug dispensation are available. CPRD has 
been extensively used to study drug prescribing and clinical outcomes in type 2 
diabetes.(14) We analysed data from the January 2018 release of CPRD, 
including all practices that were still contributing to CPRD in 2017 to ensure that 
changes in prescribing did not reflect changes in the practices captured in 
CPRD over the study period. We classified glucose-lowering drugs into drug 
classes according the British National Formulary sections 6.1.1 and 6.1.2.(15) 
Drugs were categorised as metformin, sulfonylureas, thiazolidinediones, DPP4 
inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, insulin or Other 
(Meglitinides and alpha-glucosidase inhibitors, which are prescribed very rarely 
in the UK). Scientific approval was granted by the CPRD Independent Scientific 
Advisory Committee (ISAC 13_177RA4R). 
Study population 
We extracted the clinical and prescription records of all people with type 2 
diabetes who started at least one glucose-lowering drug for the first time ever 
between 1st January 2010 and 31st December 2017 and met CPRD quality 
assurance criteria (n=78,857). Inclusion criteria and data ascertainment 
followed our previously reported CPRD cohort profile.(16) Type 2 diabetes was 
defined largely on the basis of prescriptions for non-insulin diabetes therapies 
rather than diagnostic medical codes to minimize coding errors.(17) We 
excluded people with diagnostic codes for other forms of diabetes or polycystic 
ovary syndrome which can be treated with metformin. To remove people with 
type 1 diabetes, who may be miscoded as Type 2, we excluded peoples with an 
age at diagnosis <35 or on insulin treatment within 12 months of diagnosis. 
Consequently, people with type 2 diabetes whose first-line therapy was insulin 
were not included. We defined date of diabetes diagnosis as the earliest of: first 
prescription for a non-insulin diabetes therapy; first HbA1c result >=6.5% (48 
mmol/mol); or first diabetes diagnostic code. 
Study design  
The study exposure was a new first to fourth line drug prescription record for an 
individual within the study period. New drug prescriptions (and their 
corresponding start dates) were defined as the first ever prescription of a drug 
in a class for a individual. First, second, third or fourth-line prescription 
categories were defined based on the order of new drug prescriptions for 
individuals. Every time an individual started a new drug class we assigned this 
to the next line of therapy, regardless of whether their concomitant therapy 
changed at a similar time point.  
 The primary unit of analysis was line of therapy. This meant individuals who 
started more than one new therapy over the study period contributed to the 
analysis more than once at different lines of therapy (see Supplementary 
Flowchart).  
 
 Study outcomes 
For each line of therapy, we evaluated annual time trends in the drug classes 
initiated, and time trends in changes in HbA1c, weight, systolic and diastolic 
blood pressure, hypoglycaemia rates and treatment discontinuation after 
therapy start. To evaluate all outcomes we used a ‘new user’ design which 
mitigated immortal time bias.(18) Patients were followed up from their drug start 
date until there was any change in diabetes therapy or the end of the study 
period specific to each outcome. A change in therapy could be the addition of a 
new glucose-lowering drug or the stopping of the drug of interest or any 
concomitant glucose-lowering drug. Patients were considered to have stopped 
a drug if there was a subsequent gap in prescribing of that drug for at least 6 
months.(16) 
We defined glycaemic response (the change in HbA1c), weight change and 
blood pressure change as the absolute change from baseline to 6 months (6 
month measure minus baseline measure). For glycaemic response, baseline 
HbA1c was defined as the closest HbA1c to the drug start date in the 3 months 
prior to the drug start date. Individuals with missing baseline HbA1c measures 
(9% of the cohort) were excluded from the complete case analysis of glycaemic 
response as the change from baseline in HbA1c could not be calculated. HbA1c 
at 6 months was defined as the closest HbA1c to 6 months after the drug start 
date (+/-3 months). Glycaemic response was only valid if there were no 
changes in glucose-lowering therapy between 2 months prior to the baseline 
HbA1c and the date of the 6 month HbA1c. The same approach was used for 
weight change and blood pressure change.  
We defined hypoglycaemia as the first Read code for hypoglycaemia up to 2 
years after starting a line of therapy, using a previously published Read code list 
for hypoglycaemia.(19) Due to the low number of hypoglycaemia events 
captured in primary care we grouped data into biannual categories representing 
four distinct periods (2010-11, 2012-13, 2014-15, 2016-17).  
We examined treatment discontinuation by estimating the proportion of people 
who stopped a therapy within 3 months, 6 months and 1 year. 6 months follow-
up after discontinuation was required to determine no new prescriptions were 
issued. 
Statistical analysis 
We examined annual time trends for each clinical outcome and each line of 
therapy in separate analysis. We described trends in baseline clinical 
characteristics as mean (standard deviation) per calendar year. All outcomes 
analyses were standardized to the mean baseline values of relevant measures 
for individuals starting that line of therapy in 2017. 
To evaluate changes in relative prescribing for each line of therapy we 
calculated the proportion of new prescriptions for each drug class in each 
calendar year as the: 
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑡𝑡𝑜𝑜 𝑛𝑛𝑛𝑛𝑛𝑛 𝑝𝑝𝑛𝑛𝑛𝑛𝑝𝑝𝑝𝑝𝑛𝑛𝑝𝑝𝑝𝑝𝑡𝑡𝑝𝑝𝑡𝑡𝑛𝑛𝑝𝑝 𝑡𝑡𝑜𝑜 𝑡𝑡ℎ𝑛𝑛 𝑑𝑑𝑛𝑛𝑛𝑛𝑑𝑑
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑡𝑡𝑜𝑜 𝑛𝑛𝑛𝑛𝑛𝑛 𝑝𝑝𝑛𝑛𝑛𝑛𝑝𝑝𝑝𝑝𝑛𝑛𝑝𝑝𝑝𝑝𝑡𝑡𝑝𝑝𝑡𝑡𝑛𝑛𝑝𝑝  
When describing first-line therapy all drugs except metformin and sulfonylureas 
were pooled. Within drug class trends for DPP4 inhibitors, GLP-1 receptor 
agonists, SGLT2 inhibitors and sulfonylureas (2014-2017) were estimated using 
the same approach.  
We evaluated non-linear time trends in glycaemic response, weight change and 
blood pressure change for each calendar year using linear regression with 
calendar year as a categorical covariate and adjustment for baseline HbA1c, age 
at therapy, duration of diabetes, and the baseline measure of the outcome for 
non-glycaemic outcomes. We used complete case analysis including people 
only if they had both a valid baseline measure and a valid 6 month measure. To 
assess the potential influence of missing data we compared the characteristics 
of individuals with missing data with those included in the analysis. Multiple 
imputation was not conducted as it is only valid under the missing at random 
assumption, meaning the differences between the observed and missing data 
could can be explained by other recorded measures. However, we felt outcome 
data were likely to depend on their actual value (missing not at random), which 
will be the case if, for example, individuals with poorest glycaemic control are 
also those most likely to miss a follow-up clinical appointment to have their 
HbA1c measured. Hypoglycaemia biannual time trends were estimated as rates 
per 1,000 person-years using Poisson regression, adjusted for age, duration, 
and baseline HbA1c.  
Summary measures for each outcome (including baseline HbA1c) were 
calculated as follows; 1) the 2017 vs. 2010 marginal contrast from the 
multivariable linear regression models described above;(20) 2) the linear time 
trend, as the beta coefficient from a multivariable linear regression treating 
calendar year as a continuous rather than categorical covariate.  
To evaluate changes in treatment discontinuation we calculated the proportion 
of new prescriptions that were stopped within 3 months, 6 months and 1 year 
for each line of therapy for each calendar year as: 
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑡𝑡𝑜𝑜 𝑛𝑛𝑛𝑛𝑛𝑛 𝑝𝑝𝑛𝑛𝑛𝑛𝑝𝑝𝑝𝑝𝑛𝑛𝑝𝑝𝑝𝑝𝑡𝑡𝑝𝑝𝑡𝑡𝑛𝑛𝑝𝑝 𝑝𝑝𝑡𝑡𝑡𝑡𝑝𝑝𝑝𝑝𝑛𝑛𝑑𝑑 𝑛𝑛𝑝𝑝𝑡𝑡ℎ𝑝𝑝𝑛𝑛 𝑡𝑡𝑝𝑝𝑛𝑛𝑛𝑛 𝑝𝑝𝑛𝑛𝑛𝑛𝑝𝑝𝑡𝑡𝑑𝑑 
𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑡𝑡𝑜𝑜 𝑛𝑛𝑛𝑛𝑛𝑛 𝑝𝑝𝑛𝑛𝑛𝑛𝑝𝑝𝑝𝑝𝑛𝑛𝑝𝑝𝑝𝑝𝑡𝑡𝑝𝑝𝑡𝑡𝑛𝑛𝑝𝑝  
For an overview of the flowchart for the study and outcomes evaluated please 
see Figure 1. 
All data extraction and analysis was conducted in Stata v14.0. 
Sensitivity analysis 
We repeated all outcomes analysis using change in each measure from 
baseline to 12 months as the outcome in a distinct cohort of people with 12 
month measures of each outcome (closest +/-3 months as for the definition of 6 
month change). Participants commencing therapy in 2017 were not included in 
this analysis as 12 months of follow-up had not accrued. We also evaluated the 
sensitivity of results to our definition of line of therapy by repeating all second-
line analyses in a subset of people who were initiated on metformin first-line and 
then added a different therapy to metformin (rather than stopping metformin). 
To assess whether changes in outcomes over time were likely to be due to 
changes in the drugs prescribed we compared time trends in weight change 
and hypoglycaemia using the same models described above, with drug as an 
additional covariate.
Figure 1: Overview of study design, and patients included in each analysis 
Results 
123,990 new first to fourth line prescriptions from 81,532 individuals were 
eligible for inclusion. 40% (50,215) were for a first-line prescription, 26% 
(32,071) were second-line, 20% (25,024) were third-line and 13% (16,680) were 
fourth-line (Figure 1). The baseline clinical characteristics of people starting 
each line of therapy in 2017 are shown in Supplementary Table 1. Average 
baseline HbA1c increased second to fourth-line over the study period; average 
baseline weight increased first-line but there was little difference for other lines 
of therapy. The proportion of people with valid data for analysis of each 
outcome is shown in the Supplementary Flowchart. 
Changing prescribing of glucose lowering therapy  
We found marked changes in relative prescribing of second to fourth-line 
therapy (Figure 2). DPP4 inhibitors were by 2017 the most commonly initiated 
second-line therapy (2017 41% of new second-line; 2010 22% of new second-
line), whilst second-line prescribing of sulfonylureas decreased (2017 29%; 
2010 53%). SGLT2 inhibitors were the most common fourth-line therapy in 2017 
(40% prescriptions) and their use second-line (19% of new 2017 prescriptions) 
and third-line (28% of new 2017 prescriptions) increased rapidly following their 
introduction in 2013. Fourth-line prescribing of injectable therapy decreased 
(GLP-1 receptor agonists: 2017 11%, 2010 20%; insulin: 2017 17%, 2010 21%), 
and remained low second and third-line. First-line use of metformin remained 
stable (2017 91%; 2010 91%).   
Evaluating new first to fourth line drug initiations as a whole (Supplementary 
Figure 2), we found SGLT2 inhibitors (17% of total new prescriptions in 2017) 
were more commonly initiated in 2017 than sulfonylureas (14% in 2017). New 
prescribing of insulin (2017 5%; 2010 5%) and GLP-1 receptor agonists (range 
4% to 3%) remained constant over the study period. 
Figure 2: Time trends in new drug prescriptions for a) first-line b) second-
line c) third-line d) fourth-line therapy. The prescriptions for each drug class 
each year are given as a percentage of total new drug prescriptions for that 
year.   
a) first-line  
 
  
b) second-line 
 
c) third-line 
 
d) fourth-line 
 
Changes in within class prescribing 
In addition to changes in class of agent there have been marked recent 
changes in prescription of individual agents within a class. Over 2014 to 2017 
for DPP4 inhibitors, there was decreasing use of sitagliptin (2017 37%; 2014 
56%), but increasing use of alogliptin (2017 25%; 2014 1%) and linagliptin 
(2017 31%; 2014 25%) (Supplementary Figure 2a). For GLP-1 receptor 
agonists use of once-weekly dulaglutide increased to 51% of the class total 
following its introduction in 2015. For SGLT-2 inhibitors there was increasing 
use of empagliflozin (2017 46%; 2015 8%) but decreasing use of dapagliflozin 
(2017 41%; 2014 92%) (Supplementary Figure 2c). Gliclazide use has 
remained stable (2017 91% of all sulfonylureas; 2010 89%) (Supplementary 
Figure 2d).  
 
  
Reduction in HbA1c 
Average reductions in HbA1c at 6 months were relatively constant over 2010 to 
2017 across all lines of therapy (Figure 3). There was no evidence of a change 
in glycaemic response for second-line therapy (2017 vs. 2010 change 0.0% (-
0.1 mmol/mol), p=0.80). For first, third, and fourth-line therapy there was 
evidence of a statistically significant trend towards improved glycaemic 
response, although this translated to a modest absolute improvement in 
reduction in HbA1c (2017 vs. 2010 change range 0.2-0.3% (1.3 to 2.5 
mmol/mol), all p<0.05).  
Figure 3: Mean HbA1c response at 6 months, 2010-2017 for a) first-line b) 
second-line c) third-line d) fourth-line. Error bars are 95% confidence 
intervals. Data are standardised to the average baseline HbA1c, age at 
diagnosis and duration of diabetes, specific to each drug line in 2017. 
 
  
Weight change 
Although there was a trend towards greater weight loss at 6 months for all lines 
of therapy, this was most marked second and third-line (2017 vs. 2010 second-
line -1.5kg and third-line -1.2kg, both p<0.001; overall time trends for 
improvement in weight change p<0.001 for all lines of therapy) (Figure 4). 
Patients starting second-line therapy on average lost rather than gained weight 
when comparing 2017 with 2010.  
Figure 4: Mean change in weight at 6 months, 2010-2017 for a) first-line b) 
second-line c) third-line d) fourth-line. Error bars are 95% confidence 
intervals. Data are standardized to the average baseline weight, baseline 
HbA1c, age at diagnosis and duration of diabetes, specific to each drug line in 
2017. 
 
  
Blood pressure 
We found a trend towards a modest improvement in systolic blood pressure at 6 
months for all lines of therapy (2017 vs. 2010 range -1.7 to -2.1 mmHg, all 
p<0.001, Supplementary Figure 3a). There was no change in diastolic blood 
pressure (Supplementary Figure 3b). 
Hypoglycaemia 
We observed a decrease in hypoglycaemia rates for people starting second-line 
therapy (2017 rate 5.7 (95% CI 3.5; 7.9) per 1,000 person-years; 2010 rate 8.2 
(95% CI 6.3; 10.1) per 1,000 person-years (Figure 5, Supplementary Table 2).  
Figure 5: Hypoglycaemia rates per 1,000 person-years by 2 year period for 
a) first-line b) second-line c) third-line d) fourth-line therapy. Rates 
represent the occurrence of hypoglycaemia over the first two years after starting 
a line of therapy. 
 
  
Treatment discontinuation 
Treatment discontinuation at 3 months, 6 months and 1 year after initiating 
therapy was stable over 2010-2017 (Supplementary Table 3). The proportion of 
people discontinuing within 3 months in 2017 compared to 2010 was as follows: 
first-line 4% vs 3%; second-line 7% vs 9%; third-line 12% vs 9%; fourth-line 
10% vs 9%.  
Sensitivity analysis  
Baseline characteristics of people excluded as they did not have valid clinical 
measures were similar to those included in analysis (Supplementary Table 4). 
Time trends for outcomes at 12 months were similar to at 6 months for 
glycaemic response (Supplementary Figure 4), weight change (Supplementary 
Figure 5), and blood pressure (Supplementary Figure 6). Second-line 
prescribing trends and clinical outcomes in the subset of people adding a 
second-line drug to continued first-line metformin therapy (73% of people 
included in the primary analysis) were near identical to the primary analysis 
(Supplementary Figure 7). Differences in weight change trends became minimal 
when models were adjusted for drug therapy as a covariate (Supplementary 
Table 5a), and after adjustment for drug there was no evidence of a difference 
in risk of hypoglycaemia over time (Supplementary Table 5b). 
Discussion 
Our study describes, for the first time, recent population-level time trends in 
clinical outcomes after initiating glucose-lowering therapy over 2010 to 2017, a 
period where there was drastic changes in type 2 diabetes prescribing patterns. 
There were modest population-level improvements in weight change and rates 
of hypoglycaemia for people starting additional therapy after metformin, but little 
change in glycaemic response, blood pressure change or treatment 
discontinuation. Data on these important short-term clinical outcomes provide 
timely context to the worldwide trend towards prescribing of newer more costly 
glucose-lowering agents. We also provide updated information on UK 
prescribing trends: 1) increased and earlier initiation of DPP4 inhibitors; 2) 
reduced initiation of sulfonylureas second-line; 3) a rapid increase in initiation of 
SGLT2 inhibitors; and 4) decreased initiation of injectable therapy (GLP-1 
receptor agonists and insulin). 
Whilst our retrospective analysis precludes causal inference and can only show 
temporal correlation, the time trends in outcomes reflect the known effects of 
the different drug classes on clinical outcomes. As might be expected from 
previous comparative analysis,(9, 10) there was an improvement in weight 
change and reduction in rates of hypoglycaemia where there was a rapid 
increase in the use of SGLT2 inhibitors and DPP4 inhibitors in place of 
sulfonylureas. These changes were attenuated by adjustment for drug, 
supporting the suggestion that the population-level improvements relate to 
changes in prescribing. Although recent meta-analyses have found little 
difference in glycaemic response when comparing therapies added to 
metformin,(1, 9) some studies have reported increased response with 
sulfonylureas compared with other agents,(21-23) or lower response with DPP4 
inhibitors,(24) and so it is reassuring that we found second-line glycaemic 
response was stable despite the shift in prescribing. Newer agents, in particular 
SGLT2 inhibitors, have been associated with modestly lower blood 
pressure.(25-28) However whilst there were small improvements over time in 
blood pressure change with second to fourth-line therapy there were also 
improvements first-line where prescribing was unaltered. This suggests that 
improvements do not solely reflect prescribing changes. 
The trends in new prescribing in this study are consistent with previous studies 
of UK primary care data,(7) including a recent analysis which documented 
extensive geographical variation in UK prescribing.(6) Comparison with US data 
suggest newer therapies have been adopted more quickly in the UK than in the 
US; in the US sulfonylureas remain the most common second-line therapy.(5) 
However, trends in new prescribing are similar in the US, with decreasing 
second-line use of sulfonylureas (46% of new second-line prescribing in 2016 
compared to 55% in 2010) and increasing use of DPP4 inhibitors (20% in 2016; 
14% in 2010). The increased cost of newer agents may explain their relatively 
slower uptake in the US.(5) 
There are limited recent studies in time trends of clinical outcomes. A recent 
analysis of 1.7 million individuals with US Medicare found no overall change in 
glycaemic control or rates of hypoglycaemia over 2006 to 2013, but unlike our 
study did not study people initiating new therapy.(12) Although overall hospital 
admission rates for hypoglycaemia in England were stable from 2010 to 
2014,(29) a different study observed declining overall rates of hypoglycaemia 
requiring hospitalization in UK patients over, but not under, 65 from 2009 to 
2013 in the context of declining use of sulfonylureas in this older age group,(30) 
The changes observed in these studies examining the overall population of 
people with type 2 diabetes will lag considerably behind those observed in our 
analysis of new therapy initiation, as once initiated a glucose lowering therapy 
may be continued for decades.  
Strengths of the study include our approach examining new prescribing, which 
allowed interrogation of time trends whilst accounting for the increasing 
prevalence of type 2 diabetes, which in the UK is due more recently to declining 
mortality rather than increasing incidence,(31, 32) and means prescribing of 
glucose-lowering therapy is increasing in absolute terms.(6, 33) Our definition of 
type 2 diabetes should minimize misclassification.(16) Our study provides a 
near complete picture of UK prescribing, as in the UK type 2 diabetes is largely 
managed in primary care. Even new therapy initiated on the advice of a 
specialist will usually be prescribed by the patients’ primary care physician. A 
limitation of this study is the weakness in the way hypoglycaemia is recorded. It 
is likely that many episodes of hypoglycaemia will be missing from an 
individuals’ primary care record, as mild hypoglycaemia or more severe 
hypoglycaemia requiring attendance in secondary care are poorly recorded. 
However, previous studies have provided useful insight into hypoglycaemia 
using similar definitions in the same dataset.(34) Although the missing records 
mean the absolute rates of hypoglycaemia in this study will be an 
underestimate, the specificity of our key finding, a relative decrease in 
hypoglycaemia rates second-line where use of sulfonylureas has markedly 
declined, is reassuring. A further limitation is the complete case analysis used, 
as there were a significant amount of missing data for each of the clinical 
outcomes evaluated (Figure 1). A complete case analysis has however been 
used in other recent descriptive studies evaluating the comparative 
effectiveness of diabetes therapies in primary care data.(24, 35) In our opinion 
multiple imputation would not be appropriate in this dataset as the missing at 
random assumption required for this analysis is very unlikely to be met – for 
example an individuals’ glycaemic control may influence their likelihood of 
repeat HbA1c testing, and so likelihood of study inclusion. We used sensitivity 
analysis rather than multiple imputation to check the robustness of our findings, 
demonstrating consistent findings for both 6 and 12 month clinical outcomes, 
with each analysis including distinct cohorts of individuals. Whilst our study 
provides timely information on population-level trends, further observational 
studies, building on recent work, will be needed to establish the real-world 
comparative effectiveness of individual drug classes at different lines of 
therapy.(10, 35) 
 Our results show that prescribing of glucose lowering therapy in Type 2 
diabetes is rapidly changing towards newer, more expensive agents. Changes 
in prescribing appear to have pre-empted rather than reflected changes to 
clinical guidelines.(1) In particular second-line prescribing of DPP4 inhibitors 
increased rapidly long before treatment guidelines were updated to position 
them along sulfonylureas and pioglitazone as second-line options.(36)  The 
positive trends in weight change, hypoglycaemia and blood pressure are likely 
to have improved the quality of life for patients, and a reduction in 
hypoglycaemia is also likely to have a cost benefit.(37)  However, given the 
much higher cost of newer drug options, the modest improvement we observed 
in clinical outcomes suggests further studies are needed to evaluate cost-
effectiveness of the newer glucose-lowering agents. Recent evidence suggests 
there may be potential for a more stratified approach to prescribing of type 2 
diabetes therapy, meaning prescribing decisions can be better informed through 
identification of individuals or subgroups who differ in their likely glycaemic 
response or risk of side-effects with individual agents.(38-40)  
We did not evaluate microvascular or macrovascular outcomes in this study, but 
a cardiovascular benefit in select participants with established cardiovascular 
disease or at high risk, has recently been demonstrated in individual trials for 
the SGLT2 inhibitors empagliflozin and canagliflozin, and GLP-1 receptor 
agonist liraglutide.(25, 41, 42) A recent meta-analysis of randomized trials 
suggested that in contrast to SGLT2 inhibitors and GLP-1 receptor agonists 
there is no short term mortality benefit with DPP4 inhibitors.(43) Given the 
recent changes in treatment guidelines to consider cardiovascular risk when 
choosing therapy,(4) and the fact all three classes have now been prescribed in 
significant numbers for some years, an evaluation of longer-term trends in 
microvascular and macrovascular complications would be of considerable 
interest. 
Conclusions 
The trend towards prescribing of newer, more expensive, glucose-lowering 
medication in the UK has coincided, for people initiating new therapy, with a 
likely reduction in hypoglycaemia rates and a modest improvement in weight 
and blood pressure, but little change in glycaemic response or treatment 
discontinuation. These results demonstrate the potential population-level impact 
of the rapid changes which are occurring in prescribing of glucose-lowering 
therapy worldwide. 
 
  
References 
1. National Institute for Health and Care Excellence (2015) Type 2 diabetes in adults: 
management. NICE guideline (NG28). . 
2. American Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment. 
Diabetes Care. 2017;40(Suppl 1):S64-S74. 
3. Qaseem A, Barry MJ, Humphrey LL, Forciea MA, Clinical Guidelines Committee of the 
American College of P. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical 
Practice Guideline Update From the American College of Physicians. Ann Intern Med. 
2017;166(4):279-90. 
4. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. 
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American 
Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 
Diabetes Care. 2018;41(12):2669-701. 
5. Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK. Long-term Trends in Antidiabetes 
Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 
Diabetes. Diabetes Care. 2018;41(1):69-78. 
6. Curtis HJ, Dennis JM, Shields BM, Walker AJ, Bacon S, Hattersley AT, et al. Time trends 
and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. 
Diabetes Obes Metab. 2018;20(9):2159-68. 
7. Wilkinson S, Douglas I, Stirnadel-Farrant H, Fogarty D, Pokrajac A, Smeeth L, et al. 
Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017. BMJ Open. 
2018;8(7):e022768. 
8. Persson F, Bodegard J, Lahtela JT, Nyström T, Jørgensen ME, Jensen ML, et al. Different 
patterns of second-line treatment in type 2 diabetes after metformin monotherapy in 
Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. 
Endocrinology, Diabetes & Metabolism. 2018;1(4):e00036. 
9. Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse 
events associated with glucose-lowering drugs in patients with type 2 diabetes: A meta-
analysis. JAMA Intern Med. 2016;316(3):313-24. 
10. Wilding J, Godec T, Khunti K, Pocock S, Fox R, Smeeth L, et al. Changes in HbA1c and 
weight, and treatment persistence, over the 18 months following initiation of second-line 
therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice 
Research Datalink. BMC medicine. 2018;16(116). 
11. Heald AH, Livingston M, Malipatil N, Becher M, Craig J, Stedman M, et al. Improving 
type 2 diabetes mellitus glycaemic outcomes is possible without spending more on 
medication: Lessons from the UK National Diabetes Audit. Diabetes, Obesity and Metabolism. 
2018;20(1):185-94. 
12. Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, et al. Trends in Drug 
Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013. Diabetes Care. 
2017;40(4):468-75. 
13. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data 
Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827-
36. 
14. CPRD Bibliography. https://www.cprd.com/Bibliography/. Accessed May 15th 2018. 
15. Joint Formulary Committee. British National Formulary (online) London: BMJ Group 
and Pharmaceutical Press. http://www.medicinescomplete.com. Accessed on 15/05/2018. 
16. Rodgers LR, Weedon MN, Henley WE, Hattersley AT, Shields BM. Cohort profile for the 
MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate 
stratification of response to treatment in patients with type 2 diabetes. BMJ Open. 
2017;7(10):e017989. 
17. Seidu S, Davies MJ, Mostafa S, de Lusignan S, Khunti K. Prevalence and characteristics 
in coding, classification and diagnosis of diabetes in primary care. Postgraduate Medical 
Journal. 2014;90(1059):13-7. 
18. Farmer R, Mathur R, Bhaskaran K, Eastwood SV, Chaturvedi N, Smeeth L. Promises and 
pitfalls of electronic health record analysis. Diabetologia. 2018;61(6):1241-8. 
19. Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and 
Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 
and Type 2 Diabetes: A Cohort Study. Diabetes Care. 2015;38(2):316-22. 
20. Williams R. Using the margins command to estimate and interpret adjusted predictions 
and marginal effects. Stata Journal. 2012;12(2):308-31. 
21. Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, et al. 2-year 
efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes 
inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. The 
Lancet. 2012;380(9840):475-83. 
22. Cefalu WT, Leiter LA, Yoon K-H, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of 
canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with 
metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-
inferiority trial. The Lancet. 2013;382(9896):941-50. 
23. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic 
Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. New England Journal of 
Medicine. 2006;355(23):2427-43. 
24. Wilding J, Godec T, Khunti K, Pocock S, Fox R, Smeeth L, et al. Changes in HbA1c and 
weight, and treatment persistence, over the 18 months following initiation of second-line 
therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice 
Research Datalink. BMC Medicine. 2018;16(1):116. 
25. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, 
Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 
2015;373(22):2117-28. 
26. Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of Sodium-Glucose Cotransport-2 
Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and 
Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients. J Am Heart Assoc. 
2017;6(6). 
27. Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, et al. Impact of GLP-1 receptor agonists on blood 
pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic 
review and network meta-analysis. Diabetes Research and Clinical Practice. 2015;110(1):26-37. 
28. Zhang X, Zhao Q. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in 
patients with type 2 diabetes: A systematic review and meta-analysis. Journal of Hypertension. 
2016;34(2):167-75. 
29. Zaccardi F, Davies MJ, Dhalwani NN, Webb DR, Housley G, Shaw D, et al. Trends in 
hospital admissions for hypoglycaemia in England: a retrospective, observational study. Lancet 
Diabetes Endocrinol. 2016;4(8):677-85. 
30. Zhong VW, Juhaeri J, Cole SR, Kontopantelis E, Shay CM, Gordon-Larsen P, et al. 
Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 
Diabetes in England, 1998–2013: A Retrospective Cohort Study. Diabetes Care. 
2017;40(12):1651-60. 
31. Read SH, Kerssens JJ, McAllister DA, Colhoun HM, Fischbacher CM, Lindsay RS, et al. 
Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. 
Diabetologia. 2016;59(10):2106-13. 
32. Zghebi SS, Steinke DT, Carr MJ, Rutter MK, Emsley RA, Ashcroft DM. Examining trends 
in type 2 diabetes incidence, prevalence and mortality in the UK between 2004 and 2014. 
Diabetes, Obesity and Metabolism. 2017;19(11):1537-45. 
33. NHS Digital. Prescribing for Diabetes, England - 2006/07 to 2016/17. 
https://digital.nhs.uk/data-and-information/publications/statistical/prescribing-for-
diabetes/prescribing-for-diabetes-england-2006-07-to-2016-17. Published August 1, 2017. 
Accessed May 15, 2018. 
34. van Dalem J, Brouwers MC, Stehouwer CD, Krings A, Leufkens HG, Driessen JH, et al. 
Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal 
function and sulphonylurea metabolite group: population based cohort study. BMJ. 
2016;354:i3625. 
35. Khunti K, Godec TR, Medina J, Garcia-Alvarez L, Hiller J, Gomes MB, et al. Patterns of 
glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after 
metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom 
and Germany. Diabetes Obes Metab. 2018;20(2):389-99. 
36. McCarthy MI. Painting a new picture of personalised medicine for diabetes. 
Diabetologia. 2017;60(5):793-9. 
37. Farmer A J, Brockbank K J, Keech M L, England E J, Deakin C D. Incidence and costs of 
severe hypoglycaemia requiring attendance by the emergency medical services in South 
Central England. Diabetic Medicine. 2012;29(11):1447-50. 
38. Hattersley AT, Patel KA. Precision diabetes: learning from monogenic diabetes. 
Diabetologia. 2017;60(5):769-77. 
39. Dennis JM, Shields BM, Hill AV, Knight BA, McDonald TJ, Rodgers LR, et al. Precision 
Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered 
Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care. 
2018;41(4):705-12. 
40. Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, et al. Sex and 
BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A 
Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. 
Diabetes Care. 2018;41(9):1844-53. 
41. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. 
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 
2016;375(4):311-22. 
42. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin 
and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 
2017;377(7):644-57. 
43. Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium-glucose 
cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 
inhibitors with all-cause mortality in patients with type 2 diabetes: A systematic review and 
meta-analysis. JAMA. 2018;319(15):1580-91. 
 
  
Acknowledgements 
The MASTERMIND consortium is supported by the Medical Research Council 
(UK) (MR/N00633X/1). ATH and RHH are NIHR Senior Investigators. ERP is 
Wellcome Trust New Investigator (102820/Z/13/Z), ATH is a Wellcome Trust 
Senior Investigator (098395/Z/12/Z). AGJ is supported by an NIHR Clinician 
Scientist award. NS acknowledges support by Innovative Medicines Initiative 
Joint Undertaking under grant agreement no. 115372, the resources of which 
comprise financial contribution from the European Union's Seventh Framework 
Programme (FP7/2007-2013) and EFPIA companies' in kind contribution. ATH, 
BMS, APM and JMD are supported by the NIHR Exeter Clinical Research 
Facility. 
  
Supplementary Material 
Supplementary table 1: Average baseline clinical characteristics by calendar year and 
therapy (2010-2017) 
a) first-line 
  2010 2011 2012 2013 2014 2015 2016 2017 
N 6682 6252 6170 6341 5993 6719 6709 5349 
Baseline HbA1c (mmol/mol) 71 (22) 72 (22) 73 (22) 72 (22) 71 (22) 72 (23) 72 (22) 71 (22) 
Age at therapy (years) 62 (12) 62 (12) 62 (12) 62 (12) 62 (12) 62 (12) 62 (12) 62 (12) 
Duration of diabetes (years) 2 (3) 2 (3) 2 (3) 2 (3) 2 (3) 2 (3) 2 (3) 2 (3) 
Sex (% Male) 59% 59% 59% 58% 58% 58% 58% 59% 
Ethnicity (% White/missing) 94% 93% 94% 93% 92% 93% 92% 92% 
BMI (kg/m²) 33 (7) 33 (7) 33 (7) 33 (7) 33 (7) 33 (7) 33 (7) 33 (7) 
Weight (kg) 93 (21) 93 (21) 94 (21) 94 (22) 94 (22) 95 (22) 95 (22) 96 (22) 
eGFR (mL/min/1.73 m²) 80 (19) 81 (19) 82 (19) 83 (19) 83 (19) 83 (19) 83 (19) 83 (18) 
Systolic blood pressure (mmHG) 137 (16) 136 (16) 136 (16) 136 (16) 135 (15) 136 (16) 136 (16) 135 (16) 
Diastolic blood pressure (mmHG) 80 (10) 80 (10) 80 (10) 79 (10) 79 (10) 79 (10) 79 (10) 80 (10) 
HDL (mmol/L) 2.8 (1) 2.8 (1.1) 2.9 (1) 2.8 (1.1) 2.8 (1) 3 (1.2) 3.3 (1.3) 3.3 (1.3) 
LDL (mmol/L) 1.2 (0.4) 1.2 (0.4) 1.2 (0.3) 1.2 (0.4) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 
Triglycerides (mmol/L) 2.5 (2.2) 2.5 (2.2) 2.4 (2.2) 2.5 (2.3) 2.5 (2.3) 2.5 (2) 2.5 (2.3) 2.5 (1.9) 
   
b) second-line 
  2010 2011 2012 2013 2014 2015 2016 2017 
N 4387 3960 3875 3792 3745 4276 4258 3778 
Baseline HbA1c (mmol/mol) 72 (19) 74 (20) 75 (20) 76 (20) 76 (19) 76 (20) 75 (20) 75 (20) 
Age at therapy (years) 63 (12) 63 (12) 63 (12) 63 (13) 63 (12) 63 (12) 63 (12) 63 (12) 
Duration of diabetes (years) 5 (4) 5 (4) 5 (4) 5 (4) 5 (4) 5 (4) 6 (5) 6 (5) 
Sex (% Male) 60% 59% 59% 60% 58% 59% 58% 60% 
Ethnicity (% White/missing) 94% 94% 94% 93% 93% 94% 93% 93% 
BMI (kg/m²) 32 (7) 32 (7) 32 (7) 32 (7) 33 (7) 33 (7) 33 (7) 33 (7) 
Weight (kg) 93 (22) 93 (22) 92 (21) 92 (22) 93 (22) 94 (22) 94 (22) 94 (21) 
eGFR (mL/min/1.73 m²) 80 (21) 81 (21) 80 (21) 81 (21) 81 (21) 82 (21) 82 (21) 81 (21) 
Systolic blood pressure (mmHG) 135 (16) 134 (15) 134 (15) 134 (15) 133 (14) 133 (14) 134 (14) 134 (15) 
Diastolic blood pressure (mmHG) 78 (10) 78 (10) 78 (10) 78 (10) 77 (9) 77 (9) 78 (9) 78 (9) 
HDL (mmol/L) 2.3 (0.9) 2.4 (0.9) 2.4 (1) 2.4 (1) 2.4 (1) 2.6 (1.1) 2.8 (1.1) 2.9 (1.2) 
LDL (mmol/L) 1.2 (0.4) 1.2 (0.4) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 
Triglycerides (mmol/L) 2.3 (1.9) 2.5 (2.3) 2.4 (2.2) 2.4 (1.9) 2.5 (2.2) 2.5 (2) 2.4 (1.8) 2.5 (2.1) 
 
c) third-line 
  2010 2011 2012 2013 2014 2015 2016 2017 
N 3455 3045 2871 2701 2912 3413 3462 3165 
Baseline HbA1c (mmol/mol) 73 (18) 76 (18) 76 (18) 77 (19) 77 (19) 78 (18) 77 (19) 77 (19) 
Age at therapy (years) 63 (11) 64 (12) 64 (12) 64 (12) 65 (12) 64 (12) 64 (12) 64 (12) 
Duration of diabetes (years) 8 (5) 8 (5) 8 (5) 8 (5) 8 (5) 8 (5) 8 (5) 9 (5) 
Sex (% Male) 60% 59% 58% 59% 59% 59% 59% 58% 
Ethnicity (% White/missing) 94% 94% 94% 93% 94% 94% 93% 92% 
BMI (kg/m²) 33 (7) 33 (7) 33 (7) 33 (7) 33 (7) 33 (7) 33 (7) 33 (7) 
Weight (kg) 94 (21) 94 (22) 95 (23) 93 (22) 93 (22) 94 (21) 95 (22) 93 (21) 
eGFR (mL/min/1.73 m²) 79 (21) 78 (22) 78 (23) 77 (23) 77 (23) 79 (22) 79 (22) 78 (23) 
Systolic blood pressure (mmHG) 135 (16) 135 (16) 135 (16) 134 (15) 133 (15) 133 (15) 133 (14) 134 (15) 
Diastolic blood pressure (mmHG) 77 (10) 77 (10) 77 (9) 77 (9) 76 (9) 77 (9) 77 (9) 77 (9) 
HDL (mmol/L) 2.2 (0.8) 2.2 (0.9) 2.2 (0.9) 2.2 (0.9) 2.2 (0.9) 2.4 (1) 2.8 (1.1) 2.7 (1.2) 
LDL (mmol/L) 1.2 (0.4) 1.2 (0.4) 1.1 (0.3) 1.1 (0.3) 1.2 (0.3) 1.1 (0.3) 1.1 (0.3) 1.1 (0.3) 
Triglycerides (mmol/L) 2.2 (1.8) 2.3 (1.8) 2.3 (1.7) 2.3 (1.6) 2.3 (1.8) 2.3 (1.6) 2.5 (2) 2.4 (1.6) 
 
 
 
d) fourth-line 
  2010 2011 2012 2013 2014 2015 2016 2017 
N 2083 2031 1943 1805 1980 2374 2321 2143 
Baseline HbA1c (mmol/mol) 76 (19) 78 (19) 79 (19) 81 (20) 81 (19) 81 (19) 81 (19) 80 (18) 
Age at therapy (years) 63 (11) 64 (10) 64 (11) 64 (11) 64 (11) 65 (11) 64 (11) 64 (11) 
Duration of diabetes (years) 10 (5) 10 (5) 10 (5) 10 (6) 10 (6) 11 (6) 11 (6) 11 (6) 
Sex (% Male) 59% 58% 58% 57% 58% 59% 59% 59% 
Ethnicity (% White/missing) 94% 94% 95% 93% 94% 95% 93% 92% 
BMI (kg/m²) 34 (7) 34 (7) 33 (7) 33 (7) 33 (7) 33 (7) 33 (7) 33 (7) 
Weight (kg) 95 (22) 96 (22) 96 (22) 95 (22) 96 (21) 95 (22) 94 (21) 94 (21) 
eGFR (mL/min/1.73 m²) 77 (21) 77 (21) 76 (23) 77 (23) 76 (24) 78 (22) 78 (23) 77 (23) 
Systolic blood pressure (mmHG) 135 (15) 135 (15) 135 (16) 134 (15) 133 (15) 133 (15) 133 (14) 133 (14) 
Diastolic blood pressure (mmHG) 77 (9) 77 (9) 76 (10) 76 (10) 76 (10) 76 (9) 76 (9) 77 (9) 
HDL (mmol/L) 2.2 (0.8) 2.2 (0.8) 2.2 (0.9) 2.1 (0.8) 2.1 (0.9) 2.3 (1) 2.6 (1) 2.7 (1.1) 
LDL (mmol/L) 1.1 (0.4) 1.2 (0.4) 1.1 (0.3) 1.2 (0.3) 1.1 (0.3) 1.1 (0.3) 1.1 (0.3) 1.1 (0.3) 
Triglycerides (mmol/L) 2.3 (2.3) 2.2 (1.6) 2.2 (1.8) 2.2 (1.6) 2.3 (1.8) 2.3 (1.5) 2.4 (2.1) 2.4 (1.7) 
 
 
 
  
Supplementary Table 2: Time trends in hypoglycemia rates for a) first-line b) second-line c) 
third-line d) fourth-line therapy. 
a) first-line 
  
Person-time 
at risk 
Number of 
events 
Rate (per 1000 
person-years) 
95% 
Confidence intervals 
2010-2011 15453 48 2.91 2.08;3.75 
2012-2013 15953 51 2.98 2.14;3.81 
2014-2015 16631 46 2.60 1.83;3.36 
2016-2017 7903 25 2.93 1.77;4.10 
 
b) second-line 
  
Person-time 
at risk 
Number of 
events 
Rate (per 1000 
person-years) 
95% 
Confidence intervals 
2010-2011 9198 74 8.22 6.32;10.13 
2012-2013 8297 84 10.23 8.03;12.42 
2014-2015 8396 48 5.75 4.12;7.38 
2016-2017 4373 25 5.70 3.46;7.94 
 
c) third-line 
  
Person-time 
at risk 
Number of 
events 
Rate (per 1000 
person-years) 
95% 
Confidence intervals 
2010-2011 6116 63 10.62 7.94;13.31 
2012-2013 5457 47 8.78 6.26;11.30 
2014-2015 5974 49 8.26 5.95;10.58 
2016-2017 3348 30 9.01 5.79;12.24 
 
d) fourth-line 
  
Person-time 
at risk 
Number of 
events 
Rate (per 1000 
person-years) 
95% 
Confidence intervals 
2010-2011 2637 22 8.41 4.76;12.07 
2012-2013 2405 22 9.00 5.18;12.82 
2014-2015 2909 19 6.57 3.60;9.55 
2016-2017 1726 13 7.53 3.42;11.65 
 
 
 
 
Supplementary Table 3: Percentage of patients discontinuing a new drug a) within 3 months 
b) within 6 months c) within 12 months, by calendar year and line of therapy 
a) within 3 months 
 2010 2011 2012 2013 2014 2015 2016 2017 
First line 3% 3% 3% 3% 3% 3% 3% 4% 
Second line 9% 8% 9% 8% 9% 8% 9% 7% 
Third line 9% 9% 8% 9% 10% 9% 11% 12% 
Fourth line 9% 10% 10% 10% 10% 9% 11% 10% 
 
b) within 6 months 
 2010 2011 2012 2013 2014 2015 2016 2017 
First line 4% 5% 4% 4% 4% 4% 5% NA 
Second line 12% 12% 13% 11% 13% 13% 14% NA 
Third line 14% 14% 13% 14% 14% 14% 15% NA 
Fourth line 15% 15% 14% 16% 14% 14% 14% NA 
 
c) within 12 months 
 2010 2011 2012 2013 2014 2015 2016 2017 
First line 6% 6% 6% 5% 6% 6% 6% NA 
Second line 17% 17% 18% 17% 18% 19% 19% NA 
Third line 20% 20% 18% 20% 20% 20% 20% NA 
Fourth line 21% 20% 18% 22% 20% 20% 19% NA 
 
Supplementary Table 4: Baseline characteristics of included and excluded patients (analysis of HbA1c reduction at 6 months) 
  First-line Second-line Third-line Fourth-line 
  Included Excluded Included Excluded Included Excluded Included Excluded 
N 26295 23920 17124 14947 13428 11596 8560 8120 
Baseline HbA1c (mmol/mol) 71 (21) 73 (24) 75 (19) 75 (21) 76 (18) 77 (20) 79 (18) 80 (20) 
Age at therapy (years) 62 (12) 62 (13) 63 (12) 63 (13) 64 (11) 64 (12) 64 (10) 64 (11) 
Duration of diabetes (years) 2 (3)  2 (3) 5 (4)  5 (5)  8 (5) 8 (5) 10 (5) 11 (6) 
Sex (% Male) 59% 58% 60% 58% 60% 58% 61% 57% 
BMI (kg/m²) 33 (7) 33  (7) 33 (7) 32  (7) 33  (7) 33  (7) 33  (7) 33  (7) 
Weight (kg) 94 (21) 94 (22) 93 (21) 93 (22) 94 (21) 93 (23) 96 (21) 95 (22) 
eGFR (mL/min/1.73 m²) 83 (18) 82 (19) 82 (20) 80 (22) 79 (22) 78 (23) 78 (22) 76 (23) 
Systolic blood pressure (mmHG) 136 (15) 136 (16) 134 (14) 134 (15) 134 (15) 134 (15) 134 (15) 134 (15) 
Diastolic blood pressure (mmHG) 79 (10) 80 (11) 78 (9) 78 (10) 77 (9) 77 (10) 76 (9) 76 (10) 
Supplementary Table 5: 6 month weight change and risk of hypoglycemia with and 
without adjustment for drug as an additional covariate 
a) Weight change 
Line of therapy Annual weight change 
improvement (kg/year) 
Drug adjusted annual weight 
change improvement (kg/year) 
1st -0.09 (-0.13;-0.15), p<0.001 -0.05 (-0.06;-0.05), p<0.001 
2nd -0.22 (-0.26;-0.18), p<0.001 -0.03 (-0.03;-0.02), p<0.001 
3rd -0.20 (-0.24;-0.15), p<0.001 -0.05 (-0.05;-0.04), p<0.001 
4th -0.20 (-0.26;-0.14), p<0.001 -0.04 (-0.05;-0.03), p<0.001 
 
b) Risk of hypoglycemia 
Line of therapy Incidence rate ratio (per year) Drug adjusted incidence rate 
ratio (per year) 
1st 1.00 (0.93-1.08), p=0.99 1.01 (0.94-1.09), p=0.79 
2nd 0.94 (0.88-1.00), p=0.04 0.98 (0.92-1.04), p=0.49 
3rd 0.96 (0.90-1.02), p=0.21 1.02 (0.95-1.09), p=0.62 
4th 0.95 (0.85-1.06), p=0.35 0.99 (0.88-1.12), p=0.90 
Supplementary Figure 1: Time trends (2010-2017) in new drug prescriptions across 
lines 1-4of therapy (n=123,990).The prescriptions for each drug class each year are given 
as a percentage of total new drug prescriptions for that year.  
 
 
  
Supplementary Figure 2: Time trends (2014-2017) in new within class drug 
prescriptions across all lines of therapy for a) DPP4 inhibitors b) GLP-1 agonists c) 
SGLT2 inhibitors d) sulfonylureas. The prescriptions for each drug subtype each year are 
given as a percentage of total new prescriptions of the drug class for that year.   
a) DPP4 inhibitors (n=29,835) 
 
b) GLP-1 receptor agonists (n=6,989) 
 
 
 
 
c) SGLT2 inhibitors (n=11,255) 
 
d) Sulfonylureas (n=24,506) 
  
Supplementary Figure 3a: Mean change in systolic blood pressure (SBP) at 6 months, 
2010-2017 for a) first-line b) second-line c) third-line d) fourth-line. Error bars are 95% 
confidence intervals. Data are standardised to the mean baseline systolic blood pressure, 
baseline HbA1c, age at diagnosis and duration of diabetes over the entire study period, 
specific to each drug line. 
 
 
Supplementary Figure 3b: Mean change in diastolic blood pressure (DBP) at 6 
months, 2010-2016 for a) first-line b) second-line c) third-line d) fourth-line therapy. 
Error bars are 95% confidence intervals. Data are standardised to the mean baseline 
diastolic blood pressure, baseline HbA1c, age at diagnosis and duration of diabetes over the 
entire study period, specific to each drug line. 
 
Supplementary Figure 4: Mean change in HbA1c at 12 months, 2010-2016 for a) first-
line b) second-line c) third-line d) fourth-line. Error bars are 95% confidence intervals. 
Data are standardised to the mean baseline HbA1c, age at diagnosis and duration of 
diabetes over the entire study period, specific to each drug line. 
 
Supplementary Figure 5: Mean change in weight at 12 months, 2010-2016 for a) first-
line b) second-line c) third-line d) fourth-line. Error bars are 95% confidence intervals. 
Data are standardised to the mean baseline weight, baseline HbA1c, age at diagnosis and 
duration of diabetes over the entire study period, specific to each drug line. 
 
 
 
Supplementary Figure 6a: Mean change in systolic blood pressure (SBP) at 12 
months, 2010-2016 for a) first-line b) second-line c) third-line d) fourth-line. Error bars 
are 95% confidence intervals. Data are standardised to the mean baseline systolic blood 
pressure, baseline HbA1c, age at diagnosis and duration of diabetes over the entire study 
period, specific to each drug line. 
 
 
Supplementary Figure 6b: Mean change in diastolic blood pressure (DBP) at 12 
months, 2010-2016 for a) first-line b) second-line c) third-line d) fourth-line therapy. 
Error bars are 95% confidence intervals. Data are standardised to the mean baseline 
diastolic blood pressure, baseline HbA1c, age at diagnosis and duration of diabetes over the 
entire study period, specific to each drug line. 
 
Supplementary Figure 7: Second-line prescribing trends and patient outcomes in the 
subset of patients adding a second-line drug to continued first-line metformin therapy 
(73% of patients included in the primary analysis) 
 
a) Time trends in new drug prescriptions. The prescriptions for each drug class each year 
are given as a percentage of total new drug prescriptions for that year.   
 
b) Mean change in HbA1c at 6 months, 2010-2017. Error bars are 95% confidence 
intervals. Data are standardised to the average baseline HbA1c, age at diagnosis and 
duration of diabetes in 2017. 
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c) Mean change in weight at 6 months, 2010-2017 for a) first-line b) second-line c) 
third-line d) fourth-line. Error bars are 95% confidence intervals. Data are standardised to 
the average baseline HbA1c, age at diagnosis and duration of diabetes in 2017. 
 
 
 
d) Hypoglycemia rates per 1,000 years by 2 year period. Rates represent the occurrence 
of hypoglycemia over the first two years after starting second-line therapy. 
 
 
-3
-2.5
-2
-1.5
-1
-.5
0
.5
1
M
ea
n 
6 
m
on
th
 w
ei
gh
t c
ha
ng
e
(k
g)
2010 2011 2012 2013 2014 2015 2016
Chapter 3 
Precision medicine in Type 2 diabetes: 
Clinical markers of insulin resistance 
are associated with altered short and 
long-term glycaemic response to DPP4 
inhibitor therapy 
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Abstract 
Objective 
A ‘precision’ approach to type 2 diabetes therapy would aim to target treatment 
according to patient characteristics. We examined if measures of insulin 
resistance and secretion were associated with glycaemic response to DPP4 
inhibitor therapy. 
Research Design and Methods 
We evaluated whether markers of insulin resistance and insulin secretion were 
associated with 6 month glycaemic response in a prospective study of non-
insulin treated participants starting DPP4 inhibitor therapy (PRIBA, n=254), with 
replication for routinely available markers in UK electronic healthcare records 
(CPRD, n=23,001). In CPRD we evaluated associations between baseline 
markers and 3 year durability of response. To test the specificity of findings we 
repeated analyses for GLP-1 receptor agonists (PRIBA n=339, CPRD n=4,464). 
Results 
In PRIBA markers of higher insulin resistance (higher fasting C-peptide 
(p=0.03), HOMA2 insulin resistance (p=0.01) and triglycerides (p<0.01)) were 
associated with reduced 6 month HbA1c response to DPP4 inhibitors. In CPRD 
higher triglycerides and BMI were associated with reduced HbA1c response 
(both p<0.01). A subgroup defined by obesity (BMI≥30kg/m2) and high 
triglycerides (≥2.3mmol/L) had reduced 6 month response in both datasets 
(PRIBA HbA1c reduction 5.3[95%CI 1.8,8.6]mmol/mol (0.5%) (obese, high 
triglycerides) vs 11.3[8.4,14.1] mmol/mol (1.0%) (non-obese, normal 
triglycerides), p=0.01. In CPRD the obese, high triglycerides subgroup also had 
less durable response (hazard ratio 1.28[1.16,1.41], p<0.001). There was no 
association between markers of insulin resistance and response to GLP-1 
receptor agonists.  
Conclusions 
Markers of higher insulin resistance are consistently associated with reduced 
glycaemic response to DPP4 inhibitors. This finding provides a starting point for 
the application of a precision diabetes approach to DPP4 inhibitor therapy.  
PRIBA ClinicalTrials.gov identifier: NCT01503112 
  
Introduction 
Type 2 diabetes is a heterogeneous condition characterised by varying degrees 
of reduced beta cell function and higher levels of insulin resistance. Most of the 
400 million people with type 2 diabetes worldwide will at some point require 
glucose lowering medication (1). Major international treatment guidelines 
recommend at least 4 oral treatment options after initial metformin has failed to 
achieve control, with choice between these informed predominantly by method 
of administration, overall side effect profile and cost (2-5). 
Individual response to glucose lowering therapies in type 2 diabetes varies 
greatly. Identification of clinical phenotypic features or biomarkers robustly 
associated with glycaemic response or other potentially beneficial effects for 
example reduced weight gain, or side effects for each therapy, may allow 
treatment of people with the agent that is most likely to be effective for them, an 
approach known as ‘precision’ or ‘stratified’ medicine (6, 7). While much 
research has focused on identifying genetic or novel biomarker predictors of 
response, precision diabetes is most likely to be cost effective and have clinical 
impact using simple inexpensive biomarkers or routinely available clinical 
phenotypic features (8, 9).  
DPP4 inhibitors are common (20% of U.S. and 40% of UK second-line 
prescriptions in 2016) (10) (J.M Dennis, B.M Shields, personal communication), 
well-tolerated (11), oral therapy options recommended in all clinical guidelines 
(2-5). Beyond baseline HbA1c and fasting glucose it is unclear if other factors 
are associated with glycaemic response to DPP4 inhibitors (12, 13). A major 
mechanism of action of DPP4 inhibitors is potentiation of beta cell insulin 
secretion. We aimed to establish if measures of insulin secretion and insulin 
resistance were associated with short-term glycaemic response and long-term 
durability of response in people with type 2 diabetes starting DPP4 inhibitor 
therapy.  
Research Design and Methods 
We assessed whether clinical features and biomarkers associated with insulin 
secretion and insulin resistance were predictive of short-term 6 month 
glycaemic response in analysis of a prospective study of people starting DPP4 
inhibitor therapy as part of routine care (PRIBA). To validate our findings we 
tested the consistency of associations between routinely recorded factors 
associated with response in PRIBA in a retrospective analysis of a much larger 
group of people from UK Clinical Practice Research Datalink (CPRD), 
evaluating both 6 month glycaemic response and long term durability of 
response to 3 years. 
Study setting and assessment  
PRIBA prospective study 
The PRIBA study was designed to test the hypothesis that those who have low 
insulin secretion, as measured by C-peptide, will have poor glycaemic response 
to incretin based treatments (https://clinicaltrials.gov/ct2/show/NCT01503112), 
with associations between glycaemic response and other clinical features, islet 
autoantibodies and Homeostasis Model Assessment (HOMA) 2 estimates of 
beta cell function and insulin sensitivity evaluated in pre-specified secondary 
analysis. 305 participants due to start DPP4 inhibitor therapy as part of their 
usual care were recruited from primary and secondary care across 17 National 
Institute of Health Research (NIHR) clinical research network centres in the UK 
from April 2011 to October 2013 as previously described (14).  
At baseline (immediately prior to starting therapy) we measured HbA1c, fasting 
glucose, clinical markers of insulin resistance and insulin secretion (fasting C-
peptide and post meal urine C-peptide Creatinine ratio (UCPCR) (15, 16); BMI, 
triglycerides and HDL-cholesterol (HDL-c) (17); sex-hormone binding globulin 
(SHBG), GAD and IA2 islet autoantibodies) and other clinical characteristics 
(age at therapy, sex, duration of diabetes, eGFR, ethnicity, LDL-cholesterol 
(LDL-c), number of diabetes therapies). We calculated HOMA-estimates of 
beta-cell function (HOMA2%B) and insulin resistance (HOMA2 IR) from fasting 
glucose and C-peptide measures using the HOMA2 calculator available 
from http://www.dtu.ox.ac.uk/homacalculator/ (18). Laboratory analysis was 
conducted as previously reported (14). Participants were included in the 
analysis if they were not insulin treated and had at least 3 months follow up with 
>75% adherence to therapy and limited co-treatment change (see study profile 
supplementary figure 1a). Ethics approval was granted by the South West 
National Research Ethics committee, and all participants gave written informed 
consent.  
Retrospective analysis of UK primary care data (CPRD database) 
CPRD is the world’s largest longitudinal database of anonymised primary care 
electronic health records (19). We included 23,001 non-insulin treated people 
with type 2 diabetes with prescription records of starting a DPP4 inhibitor for the 
first time from June 2007 to September 2016, and followed them up whilst they 
remained on DPP4 inhibitor therapy without the addition or cessation of any 
other anti-hyperglycaemic medication (see study profile supplementary figure 
1b). We extracted baseline routine clinical characteristics (age at therapy, 
duration of diabetes, sex and BMI) and biomarkers (HbA1c, triglycerides, HDL-c, 
LDL-c and eGFR), with baseline defined as the most recent record in the 3 
months prior to the drug start date. Ethics approval was granted by the CPRD 
Independent Scientific Advisory Committee (ISAC 13_177R). 
Analysis 
Outcome definitions 
Short-term glycaemic response (PRIBA & CPRD) 
The primary outcome was the absolute change from baseline in HbA1c 6 
months after starting therapy, adjusting for baseline HbA1c. Where a 6 month 
HbA1c was not available or eligible in the PRIBA study (see supplementary 
figure 1a) we used a 3 month HbA1c measure, as previously described (14). In 
CPRD a valid 6 month HbA1c was defined as the closest HbA1c to 6 months after 
the drug start date +/-3 months for people on unchanged anti-hyperglycaemic 
therapy.  
Durability of glycaemic response (CPRD) 
In CPRD where long-term follow-up data were available we assessed durability 
of response as the time to glycaemic failure over 3 years in a complete case 
analysis of people with baseline HbA1c between 53-97 mmol/mol (7-11%) and at 
least 3 months on DPP4 inhibitor therapy (n=15,616). Glycaemic failure was 
defined as a) two consecutive HbA1c’s greater than 69 mmol/mol (8.5%) b) a 
single HbA1c greater than 69 mmol/mol (8.5%) followed by the addition of 
another anti-hyperglycaemic therapy. To examine the sensitivity of results to 
this definition we repeated the analysis using HbA1c thresholds of a) 
53mmol/mol (7.5%) and b) the baseline HbA1c level specific to each individual 
patient. 
  
Statistical analysis 
Short-term response (PRIBA & CPRD) 
We examined associations between each standardised marker of insulin 
resistance and insulin secretion and 6 month HbA1c response in a series of 
linear regression models adjusted for baseline HbA1c and, in PRIBA, co-therapy 
change (12, 19). Non-normally distributed variables were log-transformed. We 
conducted a complete case analysis for each marker, including all people with 
valid data even if they had missing data for other markers. To evaluate model fit 
we examined normality of residuals and linearity of associations for continuous 
variables. In both datasets we tested the independence of initial associations for 
each marker of insulin resistance and insulin secretion with 6 month response in 
further multivariable analysis, controlling for baseline HbA1c and other routinely 
recorded characteristics: age at therapy, duration of diabetes, sex, eGFR, LDL-
c, ethnicity (CPRD only: white, non-white, missing) and co-therapy change 
(PRIBA only, CPRD people all on unchanged therapy). 
To further assess the robustness of findings we repeated the baseline adjusted 
analysis of 6 month response for males and females separately in both 
datasets, and in PRIBA with additional adjustment for fasting glucose. In CPRD 
we repeated the baseline adjusted analysis using 12 month response as the 
outcome in a distinct cohort of people with 12 month (closest +/-3 months as for 
definition of 6 month response) HbA1c record (n=16,166).  
Subgroup analysis of short-term response (PRIBA & CPRD) 
Based on the initial results we defined 3 patient subgroups by standard clinical 
cut-offs for obesity (BMI>=30 kg/m2) and high triglycerides (>=2.3mmol/L) (20) - 
Group A: non-obese and normal triglycerides, Group B: non-obese OR normal 
triglycerides, Group C: obese and high triglycerides.  We estimated the mean 6 
month HbA1c response for each subgroup using linear regression models 
adjusted for baseline HbA1c and, in PRIBA, co-therapy change. We 
standardised baseline HbA1c to the mean PRIBA baseline level of 74mmol/mol 
(8.9%) for all subgroups in both datasets.  
Durability of response (CPRD) 
For three subgroups defined by the same BMI and triglyceride thresholds we 
compared mean durability in response to three years after starting therapy 
using a flexible parametric time to failure survival model. We included all people 
with at least three months on therapy after starting a DPP4 inhibitor with valid 
baseline records of all covariates (baseline HbA1c, age at therapy, duration of 
diabetes, sex and eGFR). The use of flexible parametric models allowed 
prediction of the probability of therapy failure over three years as well as hazard 
ratios consistent with Cox proportional hazards regression (21). We tested 
continuous variables for non-linearity, and evaluated proportional hazards 
assumptions using Schoenfeld residuals. To estimate the probability of therapy 
failure (the inverse of survival) for each subgroup a predicted survival curve was 
calculated for each patient in the dataset before the individual survival curves 
for all people within a subgroup were averaged (22). Each curve was 
standardised to the mean CPRD values of other clinical covariates (baseline 
HbA1c = 72mmol/mol (8.7%), age at therapy = 64 years, duration of diabetes = 8 
years, eGFR = 82 ml/min/1.73m2). Point estimates for the failure probability at 3 
years by subgroup were calculated using the same approach. 
Replication analysis with GLP-1 receptor agonists (PRIBA and CPRD) 
To test the specificity of findings for DPP4 inhibitors we repeated the analyses 
of short-term response and durability of response for non-insulin treated 
subjects starting GLP-1 receptor agonists, the other glucose-lowering drug 
evaluated in PRIBA (PRIBA n=339, CPRD n=4,464). We have previously 
reported the PRIBA primary analysis of predictors of glycaemic response for the 
full PRIBA GLP-1 receptor agonist cohort, which included an additional 209 
insulin treated participants (14).  All data extraction and analysis were 
conducted using Stata v14.0 (StataCorp, College Station, TX). 
Results 
Patient characteristics & response to DPP4 inhibitor therapy 
Baseline characteristics and biomarker measures were similar for subjects 
starting DPP4 inhibitors in both datasets (Table 1). In both cohorts the majority 
of people started Sitagliptin. 254 people were included in PRIBA and 23,001 (for 
analysis of 6 month glycaemic response) in CPRD (for study profiles see 
supplementary figure 1). Mean (standard deviation (SD)) 6 month HbA1c change 
was -8.3 (13.5) mmol/mol (-0.7% (1.2%)) in PRIBA and -7.6 (15.1) mmol/mol (-
0.7% (1.4%)) in CPRD.  
  
Table 1: Subject baseline characteristics  
  PRIBA (n=254) CPRD (n=23,001) 
Characteristics      
mean (SD) unless stated   
Baseline HbA1c (mmol/mol)  74 (12) 72 (15) 
Baseline HbA1c (%)  8.9 (1.1) 8.7 (1.3) 
Age at therapy start (years)  63 (10) 64 (11) 
Age at diagnosis (years)  54 (10) 56 (10) 
Male sex (%)  63% 61% 
Duration of diabetes (years)  9 (6) 8 (5) 
BMI - median (IQR); mean(SD)  32 (29-37); 33 (6) 32 (28-36); 33 (6) 
Ethnicity (%)    
White  97% 45% 
Non-White  3% 6% 
Missing  0% 49% 
    
Biomarkers   
median (IQR); mean (SD) unless stated   
*=log-transformed    
Triglycerides (mmol/L)  1.7 (1.2-2.4); 1.8 (0.9)* 1.8 (1.3-2.6); 1.9 (1.0)* 
HDL-c (mmol/L)  1.1 (0.9-1.3); 1.1 (0.3)* 1.1 (0.9-1.3); 1.1 (0.3)* 
LDL-c (mmol/L)  1.9 (1.5-2.3); 1.9 (0.8)* 2.1 (1.6-2.6); 2.0 (0.8)* 
SHBG (nmol/L)  27 (19-41); 27 (16)* NA 
Fasting C-peptide (pmol/L)  1150 (820-1460); 1090 (480)* NA 
HOMA2-%B   54 (37-73); 51 (27)* NA 
HOMA2 IR  3.1 (2.3-4.2); 3.1 (1.5)* NA 
UCPCR nmol/mmol  3.4 (2.0-5.0); 3.0 (2.3)* NA 
eGFR (ml/min/1.3m2)  85 (70-98); 85 (24) 82 (66-97); 82 (23) 
GAD or IA2 positive (%)  3% NA 
    
Therapy      
Number of concomitant therapies at 
therapy start (% of total) 
 
  
0  3% 6% 
1  35% 51% 
2  57% 42% 
3+  5% 2% 
DPP4 type (% of total)    
Sitagliptin  87% 72% 
Alogliptin  0% 2% 
Linagliptin  4% 10% 
Saxagliptin  6% 12% 
Vildagliptin  2% 4% 
 
  
Higher baseline fasting C-peptide and HOMA measured insulin resistance 
are associated with reduced glycaemic response to DPP4 inhibitors  
In the PRIBA cohort mean HbA1c response was reduced by 1.67 mmol/mol for 
every 1 SD higher baseline fasting C-peptide (standardised β 1.67 [95% CI 0.17 
to 3.17] mmol/mol/SD, p=0.03) (Figure 1). We observed the same direction and 
similar size of effect for UCPCR (response reduction per SD higher 1.65 [95% 
CI -0.07 to 3.37] mmol/mol, p=0.06). Higher baseline HOMA measured insulin 
resistance (HOMA2-IR) was also associated with reduced response (response 
reduction per SD higher: 2.17 [95% CI 0.62 to 3.72], mmol/mol, p=0.01), but 
there was no evidence of an association between beta-cell function (HOMA2-
%B) and response (response reduction per SD higher 0.16 [95% CI -1.49 to 
1.81] mmol/mol, p=0.85). Islet autoantibody prevalence was low (2.8% GAD or 
IA2 positive; response reduction for presence of autoantibodies: 5.6 [95% CI -
3.6, 14.7] mmol/mol, p=0.23). 
Other markers of insulin resistance are consistently associated with 
glycaemic response to DPP4 inhibitors in PRIBA and CPRD  
In PRIBA higher triglycerides was associated with reduced glycaemic response 
(response reduction per SD increase 2.54 [95% CI 0.99 to 4.08] mmol/mol, 
p<0.001), with a consistent direction of association for higher BMI (response 
reduction per  higher BMI 0.96 [95% CI -0.54 to 2.46] mmol/mol, p=0.21) and 
lower SHBG (response reduction per SD higher SHBG -1.19 [95% CI -2.81 to 
0.42] mmol/mol, p=0.15) (Figure 1, supplementary table 1). In CPRD higher 
triglycerides and BMI were associated with reduced HbA1c response (Figure 1, 
supplementary table 1). HDL-c was not associated with response in either 
dataset (p=0.81 in PRIBA, p=0.46 in CPRD). 
Figure 1: DPP4 inhibitors - associations between markers of insulin resistance and HbA1c response at 6 months. Circles (black 
= PRIBA, white = CPRD) denote the mean HbA1c change (mmol/mol) at 6 months per 1 standard deviation (SD) higher baseline value of 
each marker. Error bars denote 95% confidence intervals.  
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Markers of insulin resistance are associated with glycaemic response to 
DPP4 inhibitors independently of other routine clinical characteristics 
Results were consistent when a) stratifying by sex (supplementary table 1), b) 
controlling for baseline HbA1c, age at therapy, sex, duration of diabetes, eGFR, 
LDL-c, ethnicity (CPRD only) and co-therapy change (PRIBA only) in 
multivariable analysis of each dataset (supplementary table 2), c) in PRIBA 
controlling for fasting glucose (supplementary table 3) and d) in CPRD with 12 
month HbA1c response as the outcome (supplementary table 4). 
Standard clinical criteria of obesity and high triglycerides can identify 
people likely to have markedly reduced glycaemic response to DPP4 
inhibitors 
Higher triglycerides was associated with reduced glycaemic response 
independently of BMI in both datasets, and higher BMI was associated with 
reduced response independently of triglycerides in CPRD (supplementary table 
5). To examine the potential clinical implication of this finding we compared 
mean baseline HbA1c adjusted response in 3 patient subgroups defined by 
standard clinical cut-offs for obesity (BMI>=30 kg/m2) and high triglycerides 
(>=2.3mmol/L) - Subgroup A: non-obese and normal triglycerides, Subgroup B: 
non-obese OR normal triglycerides, Subgroup C: obese and high triglycerides).   
In PRIBA we found mean 6 month baseline HbA1c standardised glycaemic 
response was halved for the obese and high triglycerides subgroup (Subgroup 
C -5.2 [95% CI -1.8 to -8.6] mmol/mol (-0.5% [95% CI -0.2;-0.8])) compared to 
the non-obese and normal triglycerides subgroup (Subgroup A -11.3 [95% CI -
8.4 to -14.1] mmol/mol (-1.0% [95% CI -0.8;-1.3])) and was significantly reduced 
compared to intermediate Subgroup B (-9.9 [95% CI -7.6 to -12.2] mmol/mol (-
0.9% [95% CI -0.7;-1.1])) (Figure 2a). Direction of effect was replicated in 
CPRD, albeit with smaller differences in mean response between subgroups 
(Subgroup A mean baseline adjusted HbA1c response -10.3 [95% CI -9.8 to -
10.7] mmol/mol (-0.9% [95% CI -0.9;-1.0]), Subgroup B -8.8 [95% CI -8.5 to -
9.1] mmol/mol (-0.8% [95% CI -0.8;-0.8]), Subgroup C -7.5 [95% CI -7.0 to -7.9] 
mmol/mol (-0.7% [95% CI -0.6;-0.7]), Figure 2b). 
Obesity and high triglycerides are associated with less durable glycaemic 
response to DPP4 inhibitors over 3 years  
15,616 people were followed up in this analysis for a mean time of 1.5 years. 
Over the 3 year study period 3,514 (23%) people had glycaemic failure 
(confirmed HbA1c ≥ 69 mmol/mol (8.5%). We observed an increased relative 
risk of glycaemic failure , reflecting a less durable response) in the same obesity 
and high triglycerides defined subgroups, standardising for other clinical 
characteristics (hazard ratios for glycaemic failure: Subgroup C obese AND high 
triglycerides versus Subgroup A non-obese and normal triglycerides 1.28 [95% 
CI 1.16-1.41], p<0.001; Subgroup B obese OR high triglycerides versus 
Subgroup A 1.17 [95% CI 1.08-1.27], p<0.001; Subgroup C versus Subgroup B 
1.09 [95% CI 1.01-1.18], p=0.04; supplementary table 6). Consistent relative 
differences between subgroups were observed at HbA1c failure thresholds of 
7.5% and the baseline HbA1c specific to each individual patient (supplementary 
table 7-8). These results translated into significant differences between 
subgroups in the absolute probability of glycaemic failure at three years 
(Subgroup C: obese AND high triglycerides 39% [95% CI 37-42%]; Subgroup B: 
obese OR high triglycerides 37% [95% CI 35-38%]; Subgroup A: non-obese 
and normal triglycerides 32% [95% CI 31-34 %] supplementary figure 2). 
Figure 2: DPP4 inhibitors - predicted mean absolute HbA1c change from baseline at 6 months in a) PRIBA b) CPRD across 
subgroups defined by the presence or absence of obesity (BMI>=30 kg/m2) and high triglycerides (TRGs >=2.3mmol/L) - 
Subgroup A: non-obese and normal triglycerides, Subgroup B: non-obese OR normal triglycerides, Subgroup C: obese and 
high triglycerides. Baseline HbA1c is standardised to the mean PRIBA baseline level of 74mmol/mol (8.9%) for all subgroups. Error 
bars denote 95% confidence intervals.  
 
 
 
 
 
 
 
There is no evidence of an association between markers of insulin 
resistance and glycaemic response to GLP-1 receptor agonists 
We found no evidence of an association between any marker of insulin 
resistance and 6 month glycaemic response to GLP-1 receptor agonists in 
PRIBA (n=339) or CPRD (n=4,464) on continuous analysis (Figure 3, 
supplementary tables 8-9). There was also no evidence for a difference in 
response to GLP-1 receptor agonists across the obesity and triglyceride defined 
subgroups (all subgroup comparisons p>0.40; supplementary table 10, 
supplementary figure 3), although there were few subjects in the non-obese, 
normal triglyceride subgroup starting GLP-1 receptor agonist therapy in both 
datasets (PRIBA 2%, CPRD 5%). Similarly, in CPRD we found no evidence of 
an association between durability of glycaemic response and BMI (HR per unit 
increase 1.01 (95% CI 1.00-1.02, p=0.29) or triglyceride levels (HR per unit 
increase 0.99 (95% CI 0.95-1.04, p=0.80) (supplementary table 11), or of a 
difference in durability of response across obesity and triglyceride defined 
subgroups (supplementary table 12, supplementary figure 4).
Figure 3: GLP-1 receptor agonists - associations between markers of insulin resistance and HbA1c response at 6 months. 
Circles (black = PRIBA, white = CPRD) denote the mean HbA1c change (mmol/mol) at 6 months per 1 standard deviation (SD) higher 
baseline value of each marker. Error bars denote 95% confidence intervals. 
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Conclusions 
Our results show that markers of higher insulin resistance are consistently 
associated with reduced glycaemic response to DPP4 inhibitor therapy. In our 
UK-representative cohort 22% of people were obese with high triglycerides 
(≥2.3mmol/L) and these people had both markedly reduced short-term 
glycaemic response and shorter durability of response on DPP4 inhibitor 
treatment. With GLP-1 receptor agonists we found no evidence of an 
association between markers of insulin response and either 6 month glycaemic 
response or durability of response to 3 years. Findings were robustly 
demonstrated in a prospective study and validated in real-world data and 
provide a starting point for the application of a precision diabetes approach with 
DPP4 inhibitor therapy.  
Strengths of this study include that we have shown consistent findings across 
several clinical features and markers of insulin resistance in a prospective study 
and large dataset of electronic healthcare records. We have shown findings are 
robust with adjustment for baseline HbA1c (12, 23), and potential confounders, 
and by definition of glycaemic response, with similar associations for short term 
(6 and 12 month) and long term (3 year durability) glycaemic outcomes. We 
evaluated only adherent individuals (≥75% self-reported adherence) in PRIBA 
but results were consistent in CPRD where non-adherent individuals were not 
excluded. Our study is the first to identify characteristics associated with 
durability of response to DPP4 inhibitor therapy, an area where evidence is 
limited (24). 
Limitations of this study include that we were only able to partially replicate our 
results from the PRIBA study cohort, as measures such as C-peptide were not 
available in our replication dataset. Our effect size for triglycerides is notably 
smaller in our replication dataset. It is possible this relates to differences in 
triglyceride measurement (we were unable to confirm if measured triglycerides 
were fasted in these real-world data) or to increased error in electronic 
healthcare records in comparison to the prospective study (25), or to the effect 
of statistical chance in the smaller dataset. The observational analysis 
precludes causal inference, and in particular measured or unmeasured baseline 
differences between people are a potential explanation for results in the routine 
data. The only long-term follow-up data we had to evaluate durability of 
glycaemic response was from the routine primary care dataset CPRD, further 
evaluation in a trial setting with greater follow-up than PRIBA would be of 
considerable interest. An additional important limitation is that this study has 
examined response to only two of the available therapies. Evidence is limited 
for other therapies, although a previous study found no evidence of a 
relationship between clinical insulin resistance or dyslipidaemia markers and 
glycaemic response with the SGLT-2 inhibitor dapaglifozin (26).  High BMI and 
triglycerides have both been shown to be associated with modest increases in 
the rate of diabetes progression (27). While this is unlikely to be relevant to our 
finding for 6 month glycaemic response this could influence our findings for 
treatment durability, and replication looking at other comparison therapies is 
therefore particularly important in this context. While we have only examined 
relatively crude measures of insulin resistance, for clinical practice we consider 
it very unlikely that more complex measures would ever be feasible (28).  
Existing studies of the association between insulin resistance and short-term 
glycaemic response to DPP4 inhibitors have not shown consistent findings and 
are constrained by methodological and reporting limitations, as recently 
reviewed by Bihan and colleagues (12). Meta-regression of study level data 
have suggested reduced glycaemic response in people with higher BMI in one 
study (29), but no relationship in another analysis (30). These studies should be 
interpreted with some caution due to risk of ecological bias (31, 32). A number 
of individual clinical trials of DPP4 inhibitors have commented on consistency of 
glucose response across subgroups defined by baseline BMI or insulin 
resistance, reduced glycaemic response with high HOMA measured insulin 
resistance was reported in 2 of 7 studies, and reduced response with high BMI 
in 6 of 36 studies, as reviewed in Bihan et al (12). No studies reported an 
opposite direction of effect.  These reports are very limited, with the vast 
majority providing no statistical comparison or details of what analysis was 
undertaken.  An important issue for analysis of this nature is accounting for the 
influence of baseline HbA1c, the strongest predictor of glycaemic response, 
which may confound true associations, especially as baseline HbA1c and insulin 
resistance are positively correlated (23, 33, 34). There are limited data 
examining the relationship between triglycerides and response to DPP4 
inhibitors, however one study stratified people by baseline triglycerides 
(</>1.7mmol/l) and found the odds of achieving an HbA1c target of 53mmol/mol 
(7%) were doubled in the low triglyceride subgroup (OR 2.2 [95% CI 1.0-4.7], 
p=0.04) (35). 
While it is plausible our finding of reduced glycaemic response in those with 
high BMI or high triglycerides directly relates to insulin resistance through 
reduced effect of drug potentiated insulin secretion, this effect is not apparent in 
other drugs with effects on insulin secretion, for example previous studies have 
observed no association between obesity and response to sulfonylurea therapy 
or GLP-1 receptor agonists (14, 36). An alternative explanation would be a 
direct effect of lipotoxicity, or indirect associations with other (unmeasured) 
factors important to DPP4 inhibitor response. A direct mechanism for lipotoxicity 
in reducing response to incretin based therapy has been previously suggested, 
with expression of GLP1 receptors diminished in islets exposed to elevated fatty 
acid levels in animal models, and beta cell response to GLP1 restored following 
fatty acid reduction with fibrate pharmacotherapy, however this mechanism 
would not explain the  lack of an association between these features and GLP-1 
Receptor Agonist response(37). It has also been shown that GLP-1 response is 
blunted in obese insulin resistant individuals with high liver fat and also blunted 
in individuals with high fasting triglycerides (38, 39), therefore impaired GLP-1 
secretion in obese insulin resistant individuals represents a potential indirect 
mechanism that could also account for the lack of a similar relationship for 
injected GLP-1 receptor agonist therapy. While the lack of association for HDL-c 
may be considered unexpected, we note HDL-c has a much weaker relationship 
with insulin resistance than either triglycerides or fasting insulin/C-peptide, 
which may explain this finding (17).  
Our findings have potential implications for clinical practice, as both BMI and 
triglycerides are routinely available at no additional cost. Stratification of 
treatment based on these criteria may therefore be cost effective even with the 
more modest differences in treatment effect seen in our replication cohort.  
Although our own and previous research suggests these findings may be 
specific to DPP4 inhibitors further work examining the relationship between 
these, and other, factors and response to comparator drugs is needed. Our 
study design, emphasising the importance of replication across datasets, 
provides an exemplar for such future analyses. In addition while simple 
categorisation by subgroup may provide a starting point for prediction of therapy 
response in type 2 diabetes, we anticipate a more sophisticated precision 
diabetes approach combining continuous clinical features into a multivariable 
response calculator will have greatest clinical utility, and this this is an important 
area for future research (8, 40). 
In conclusion, our study shows simple markers of higher insulin resistance are 
consistently associated with reduced glycaemic response to DPP4 inhibitor 
therapy. This finding was robustly demonstrated in a prospective study and 
validated in real-world data and provide a starting point for the application of a 
precision diabetes approach to DPP4 inhibitor therapy in type 2 diabetes.  
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 Supplementary figure 1a: PRIBA study Profile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Analysis inclusion criteria: no additional of non DPP4 glucose lowering 
therapy, or discontinuation of >1 co-therapy, between baseline and follow up 
HbA1c. Self-reported DPP4 adherence (over 2 weeks prior to HbA1c) ≥75%. 
Participant not receiving insulin treatment at study baseline. 
  
Commenced DPP4 therapy 
n=305 
On treatment at 3months 
 n=279 
Stopped treatment n=21 
Withdrew prior to follow up visit n=5 
On treatment at 6 months 
 n=254 
Stopped treatment n=8 
Withdrew prior to follow up visit n=17 
 
Met analysis criteria*  
at 6 months  
n=215 
Met analysis criteria*  
at 3 months but not 6 months 
 n=39 
Valid HbA1c outcome for 
inclusion in analysis 
n=254 
 
Supplementary Figure 1b: CPRD study profile 
 
 
 
Supplementary table 1: Associations between markers of insulin resistance and HbA1c response after 6 months, overall 
(Data table for Figure 1) and stratified by sex in a) PRIBA and b) CPRD.  Beta coefficients represent the change in HbA1c per 
standard deviation higher predictor level, a positive coefficient represents an association with reduced response. 
 
a) PRIBA 
  All participants   Males (64%) Females (36%)  
  
Number with 
valid baseline 
data 
Beta coefficient (95% CI) p-value  Beta coefficient (95% CI) p-value Beta coefficient (95% CI) p-value 
HOMA-IR* 242 2.17 (0.62 to 3.72) 0.01   1.69 (-0.26 to 3.64) 0.09 2.87 (0.22 to 5.52) 0.03 
Fasting C-peptide 251 1.67 (0.17 to 3.17) 0.03   1.44 (-0.49 to 3.36) 0.14 1.91 (-0.56 to 4.39) 0.13 
UCPCR** 203 1.65 (-0.07 to 3.37) 0.06  3.35 (1.05 to 5.65) <0.01 -0.56 (-3.16 to 2.04) 0.67 
Fasting Triglycerides 240 2.54 (0.99 to 4.08) <0.01   2.20 (0.35 to 4.05) 0.02 3.31 (0.33 to 6.29) 0.03 
BMI 254 0.96 (-0.54 to 2.46) 0.21   1.23 (-0.89 to 3.35) 0.25 0.29 (-1.98 to 2.56) 0.80 
HDL 243 0.20 (-1.36 to 1.75) 0.81   0.56 (-1.1 to 2.62) 0.60 -0.95 (-3.60 to 1.70) 0.48 
SHBG*** 214 -1.19 (-2.81 to 0.42) 0.15   -1.19 (-3.35 to 0.97) 0.28 -1.23 (-3.79 to 1.33) 0.34 
         
* HOMA2 measured insulin resistance **UCPCR = post meal urine C-peptide Creatinine ratio; ***SHBG = sex-hormone binding globulin 
 
b) CPRD 
   All patients     Males (61%) Females (39%) 
 
Number with 
valid baseline 
data 
Beta coefficient (95% CI) p-value  Beta coefficient (95% CI) p-value Beta coefficient (95% CI) p-value 
BMI 19,430 0.96 (0.78 to 1.15) <0.01   1.04 (0.78 to 1.30) <0.01 0.78 (0.51 to 1.05) <0.01 
Triglycerides 15,404 0.72 (0.50 to 0.93) <0.01   0.82 (0.56 to 1.09) <0.01 0.57 (0.21 to 0.95) <0.01 
HDL 17,058 -0.08 (-0.28 to 0.13) 0.46   -0.22 (-0.49 to 0.05) 0.11 -0.21 (-0.55 to 0.13) 0.22 
 Supplementary table 2: Effect sizes for insulin resistance markers controlling 
for routine clinical characteristics (baseline HBA1c, age at therapy, sex, 
duration of diabetes, eGFR, ethnicity (CPRD only: white, non-white, missing) 
and co-therapy change (PRIBA only, CPRD patients all on unchanged therapy). 
Beta coefficients represent the change in HbA1c at 6 months per standard deviation 
increase in the predictor, a positive coefficient represents an association with 
reduced response. 
a) PRIBA 
 
Number of 
patients Beta coefficient (95% CI) p-value 
HOMA-IR 205 2.57 (0.73 to 4.40) <0.01 
Fasting C-peptide 212 2.13 (0.33 to 3.94) 0.02 
Fasting Triglycerides 215 2.34 (0.44 to 4.25) 0.02 
BMI 215 0.67 (-1.15 to 2.50) 0.47 
HDL-c 215 0.09 (-1.69 to 1.86) 0.92 
SHBG 185 -1.04 (-3.00 to 0.91) 0.29 
 
b) CPRD 
  Number of 
patients Beta coefficient (95% CI) p-value 
Triglycerides 13,089 0.67 (0.41 to 0.94) <0.01 
BMI 11,683 0.87 (0.61 to 1.12) <0.01 
HDL-c 13,187 -0.11 (-0.35 to 0.14) 0.40 
  
Supplementary table 3: Associations between triglycerides and BMI and 
HbA1c response after 6 months adjusted for baseline HbA1c, fasting glucose 
and co-therapy change in PRIBA. Beta coefficients represent the change in HbA1c 
at 6 months per standard deviation increase in the predictor, a positive coefficient 
represents an association with reduced response.  
  Number of 
patients Beta coefficient (95% CI) p-value 
HOMA-IR* 242 1.76 (0.15 to 3.38) 0.03 
Fasting C-peptide 242 1.71 (0.21 to 3.21) 0.03 
UCPCR** 195 1.50 (-0.22 to 3.21) 0.09 
Fasting Triglycerides 231 2.39 (0.84 to 3.94) <0.01 
BMI 244 1.10 (-0.41 to 2.61) 0.15 
HDL-c 233 0.20 (-1.36 to 1.76) 0.80 
SHBG*** 206 -0.90 (-2.53 to 0.73) 0.28 
    
* HOMA2 measured insulin resistance **UCPCR = post meal urine C-peptide Creatinine ratio; 
***SHBG = sex-hormone binding globulin 
 
Supplementary table 4: Associations between routine markers of insulin 
resistance and HbA1c response after 12 months in CPRD. For each predictor 
we ran a separate linear regression model, adjusted for baseline HbA1c. Beta 
coefficients represent the change in HbA1c at 12 months per standard deviation 
increase in the predictor, a positive coefficient represents an association with 
reduced response. 
 
 
 
 
 
Supplementary table 5: Associations between triglycerides and BMI and 
HbA1c response after 6 months in a combined model adjusted for baseline 
HbA1c, and (PRIBA only) co-therapy change in a) PRIBA and b) CPRD. Beta 
coefficients represent the change in HbA1c at 6 months per standard deviation 
increase in the predictor, a positive coefficient represents an association with 
reduced response. 
 a) PRIBA (n=240) b) CPRD (n=13,543) 
  Beta coefficient    
(95% CI) p-value 
Beta coefficient      
(95% CI) p-value 
Triglycerides 2.33 (0.71 to 3.94) <0.01 0.56 (0.32 to 0.79) <0.01 
BMI 0.44 (-1.17 to 2.04) 0.59 0.96 (0.73 to 1.18) <0.01 
 
  
  Number of 
patients Beta coefficient (95% CI) p-value 
Triglycerides 13,942 0.70 (0.45 to 0.96) <0.01 
BMI 11,206 0.81 (0.59 to 1.04) <0.01 
HDL-c 12,273 -0.32 (-0.57 to -0.08) 0.01 
Supplementary table 6: CPRD hazard ratios for time to glycaemic failure (confirmed 
HbA1c ≥69 mmol/mol (8.5%)) for each predictor in the multivariable survival model 
(n=15,616) 
 Hazard ratio 95% CI p-value 
BMI & Triglyceride subgroup    
BMI<30 & TRGS<2.3 1 (reference)   
BMI≥30 OR TRGS≥2.3 1.17 1.08-1.27 <0.001 
BMI≥30 & TRGS≥2.3 1.28 1.16-1.41 <0.001 
    
Clinical characteristics    
Baseline HbA1c (mmol/mol)* 1.061  1.058-1.064 <0.001 
Age at therapy start (year)* 0.990 0.986-0.994 <0.001 
Duration of diabetes (year)* 1.004 0.997-1.011 0.29 
Female vs male sex 1.075 0.999-1.152 0.04 
eGFR (ml/min/1.3m2)* 1.001 0.999-1.002 0.49 
 
*For continuous variables the hazard ratio represents the change in hazard ratio for a 1 unit increase 
in the predictor. A hazard ratio > 1 indicates a higher value of that variable is associated with shorter 
durability of glycaemic response 
  
Supplementary Figure 2: Probability of glycaemic failure (confirmed HbA1c 
≥8.5%) over 3 years in CPRD in subgroups defined by the presence or absence 
of obesity (BMI>=30 kg/m2) and high triglycerides (TRGs >=2.3mmol/L) - 
Subgroup A: non-obese and normal triglycerides, Subgroup B: non-obese OR 
normal triglycerides, Subgroup C: obese and high triglycerides).   
 
  
Supplementary table 7: CPRD hazard ratios by BMI & Triglyceride subgroup 
for time to glycaemic failure defined as  
a) Confirmed HbA1c ≥53 (7.5%) (n=15,616)* 
 Hazard ratio 95% CI p-value 
BMI & Triglyceride subgroup    
BMI<30 & TRGS<2.3 1 (reference)   
BMI≥30 OR TRGS≥2.3 1.08 1.02-1.14 0.01 
BMI≥30 & TRGS≥2.3 1.17 1.09-1.25 <0.001 
 
b) Confirmed return to baseline HbA1c level specific to each patient 
(n=15,616)* 
 Hazard ratio 95% CI p-value 
BMI & Triglyceride subgroup    
BMI<30 & TRGS<2.3 1 (reference)   
BMI≥30 OR TRGS≥2.3 1.14 1.05-1.24 0.002 
BMI≥30 & TRGS≥2.3 1.29 1.16-1.42 <0.001 
 
*adjusted for baseline HbA1c, age at therapy, duration of diabetes, sex and eGFR 
  
GLP-1 receptor agonist comparison analysis  
 
Supplementary table 8: GLP-1 receptor agonists - subject baseline 
characteristics  
 
  PRIBA (n=339) CPRD (n=4,464) 
Characteristics      
mean (SD) unless stated   
Baseline HbA1c (mmol/mol)  83 (18) 79 (17) 
Baseline HbA1c (%)  9.7 (1.7) 9.4 (1.6) 
Age at therapy start (years)  55 (10) 59 (9) 
Age at diagnosis (years)  47 (10) 51 (8) 
Male sex (%)  56% 58% 
Duration of diabetes (years)  8 (5) 8 (5) 
BMI - median (IQR); mean(SD)  38 (35-44); 40 (8) 37 (34-42); 38 (7) 
Ethnicity (%)    
White  95% 46% 
Non-White  5% 3% 
Missing  0% 51% 
    
Biomarkers    
median (IQR); mean (SD) unless stated    
*=log-transformed    
Triglycerides (mmol/L)  1.9 (1.4-2.6); 2 (1.1)* 2.0 (1.4-2.8); 2.0 (0.5)* 
HDL-c (mmol/L)  1.1 (0.9-1.2); 1.1 (0.3)* 1.1 (0.9-1.2); 1.1 (0.2)* 
LDL-c (mmol/L)  2.2 (1.8-2.8); 2.2 (0.8)* 2.0 (1.6-2.6); 2.0 (0.4)* 
SHBG (nmol/L)  23 (17-36); 24 (14)* NA 
Fasting C-peptide (pmol/L)  1310 (962-1700); 1255 (594)* NA 
HOMA2-%B   49 (32-75); 48 (29)* NA 
HOMA2 IR  4.1 (3.0-5.3); 4.0 (2.1)* NA 
UCPCR nmol/mmol  3.5 (1.9-6.0); 3.1 (2.8)* NA 
eGFR (ml/min/1.3m2)  92 (77-111); 95 (27) 88 (74-102); 88 (22) 
GAD or IA2 positive (%)  1% NA 
    
Therapy    
Number of concomitant therapies at 
therapy start (% of total)    
0  1% 2% 
1  26% 36% 
2  51% 54% 
3+  22% 8% 
    
GLP-1 type (% of total)    
Dulaglutide  0% 1% 
Exenatide  40% 44% 
Liraglutide  60% 50% 
Lixisenatide  0% 6% 
    
    
 
 
  
Supplementary table 9: GLP-1 receptor agonists - Associations between markers of insulin resistance and HbA1c 
response after 6 months, overall (Data table for Supplementary Figure 2) in a) PRIBA and b) CPRD.  Beta coefficients 
represent the change in HbA1c per standard deviation higher predictor level, a positive coefficient represents an association with 
reduced response. 
 
  PRIBA   CPRD 
  
Number with 
valid baseline 
data 
Beta coefficient  
p-value 
  Number with 
valid baseline 
data 
Beta coefficient 
p-value 
(95% CI)   (95% CI) 
HOMA-IR* 300 0.73 (-0.99 to 2.44) 0.41   NA NA NA 
Fasting C-peptide 333 0.24 (-1.38 to 1.85) 0.78   NA NA NA 
UCPCR** 245 0.45 (-1.37 to 2.26) 0.63   NA NA NA 
Triglycerides 316 0.07 (-1.59 to 1.73) 0.93   2,848 -0.07 (-0.65 to 0.49) 0.80 
BMI 337 0.11 (-1.49 to 1.70) 0.90   4,016 -0.19 (-0.66 to 0.28) 0.43 
HDL 315 1.08 (-0.55 to 2.71) 0.19   3,126 0.01 (-0.53 to 0.55) 0.97 
SHBG*** 317 0.56 (-1.09 to 2.21) 0.50   NA NA NA 
 
 
 
 
  
Supplementary table 10: Mean (95% CI) 6 month baseline HbA1c standardised glycaemic response (mmol/mol) for DPP4 
inhibitors and GLP receptor agonists in PRIBA and CPRD. Baseline HbA1c is standardised to the mean PRIBA baseline level 
of 74mmol/mol (8.9%) for all subgroups. 
 DPP4 inhibitors   GLP-1 receptor agonists 
BMI & Triglyceride subgroup PRIBA CPRD   PRIBA CPRD 
BMI<30 & TRGS<2.3 -11.26 (-14.1 to -8.43) -10.28 (-10.72 to -9.85)   -9.64 (-22.75 to 3.48) -9.49 (-12.2 to -6.78) 
BMI≥30 OR TRGS≥2.3 -9.94 (-12.24 to -7.64) -8.79 (-9.12 to -8.47)   -14.7 (-17.11 to -12.29) -10.16 (-10.91 to -9.4) 
BMI≥30 & TRGS≥2.3 -5.23 (-8.62 to -1.84) -7.47 (-7.95 to -6.99)   -13.54 (-16.69 to -10.39) -9.64 (-10.65 to -8.63) 
 
Supplementary Figure 3: GLP-1 receptor agonists - predicted mean absolute HbA1c change from baseline at 6 months in 
a) PRIBA b) CPRD across subgroups defined by the presence or absence of obesity (BMI>=30 kg/m2) and high 
triglycerides (TRGs >=2.3mmol/L) - Subgroup A: non-obese and normal triglycerides, Subgroup B: non-obese OR normal 
triglycerides, Subgroup C: obese and high triglycerides. Baseline HbA1c is standardised to the mean PRIBA baseline level of 
74mmol/mol (8.9%) for all subgroups. Error bars denote 95% confidence intervals. 
  
Supplementary table 11: GLP-1 receptor agonists - CPRD hazard ratios for 
time to glycaemic failure (confirmed HbA1c ≥69 mmol/mol (8.5%) for each 
predictor in the multivariable survival model (n=2,795) 
 
 Hazard ratio 95% CI p-value 
BMI* 1.01 1.00-1.02 0.29 
Triglycerides* 0.99 0.95-1.04 0.80 
Baseline HbA1c (mmol/mol)* 1.05  1.04-1.06 <0.001 
Age at therapy start (year)* 0.98 0.97-0.99 <0.001 
Duration of diabetes (year)* 1.01 0.99-1.03 0.21 
Female vs male sex 0.78 0.67-0.91 0.001 
eGFR (ml/min/1.3m2)* 1.00 1.00-1.00 0.63 
 
*For continuous variables the hazard ratio represents the change in hazard ratio for a 1 unit 
increase in the predictor. A hazard ratio > 1 indicates a higher value of that variable is 
associated with shorter durability of glycaemic response 
 
  
Supplementary table 12: GLP-1 receptor agonists - CPRD hazard ratios 
for time to glycaemic failure (confirmed HbA1c ≥69 mmol/mol (8.5%)) for 
each predictor in the multivariable survival model (n=2,795) 
 Hazard ratio 95% CI p-value 
BMI & Triglyceride subgroup    
BMI<30 & TRGS<2.3 1 (reference)   
BMI≥30 OR TRGS≥2.3 1.21 0.85-1.73 0.29 
BMI≥30 & TRGS≥2.3 1.13 0.79-1.63 0.50 
    
Clinical characteristics    
Baseline HbA1c (mmol/mol)* 1.05  1.04-1.06 <0.001 
Age at therapy start (year)* 0.98 0.97-0.99 <0.001 
Duration of diabetes (year)* 1.01 0.99-1.03 0.22 
Female vs male sex 0.79 0.68-0.92 0.002 
eGFR (ml/min/1.3m2)* 1.00 1.00-1.00 0.60 
 
*For continuous variables the hazard ratio represents the change in hazard ratio for a 1 unit 
increase in the predictor. A hazard ratio > 1 indicates a higher value of that variable is 
associated with shorter durability of glycaemic response 
Supplementary Figure 4: GLP-1 receptor agonists - Probability of 
glycaemic failure (confirmed HbA1c ≥8.5%) over 3 years in CPRD in 
subgroups defined by the presence or absence of obesity (BMI>=30 
kg/m2) and high triglycerides (TRGs >=2.3mmol/L) - Subgroup A: non-obese 
and normal triglycerides, Subgroup B: non-obese OR normal triglycerides, 
Subgroup C: obese and high triglycerides).   
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Abstract 
Objective 
The choice of therapy for type 2 diabetes after metformin is guided by overall 
estimates of glycemic response and side-effects seen in large cohorts. A 
stratified approach to therapy would aim to improve on this by identifying 
subgroups of people whose glycaemic response or risk of side-effects differ 
markedly. We assessed if simple clinical characteristics could identify people 
with differing glycemic response and side-effects with sulfonylureas and 
thiazolidinediones. 
Research design and methods 
We studied 22,379 individuals starting sulfonylurea or thiazolidinedione therapy 
in U.K. Clinical Practice Research Datalink (CPRD) to identify features 
associated with increased one-year HbA1c fall with one therapy class and 
reduced with the second. We then assessed if pre-specified subgroups defined 
by the differential clinical factors showed differing five-year glycemic response 
and side-effects with sulfonylureas and thiazolidinediones using individual 
randomised trial data from ADOPT (first-line therapy, n=2,725) and RECORD 
(second-line therapy, n=2,222). Further replication was conducted using routine 
clinical data from the GoDARTS (n=1,977). 
Results 
In CPRD male sex and lower BMI were associated with greater glycemic 
response with sulfonylureas and a lesser response with thiazolidinediones (both 
p<0.001). In ADOPT and RECORD non-obese males had a greater overall 
HbA1c reduction with sulfonylureas than thiazolidinediones (p<0.001); in 
contrast obese females had a greater HbA1c reduction with thiazolidinediones 
than sulfonylureas (p<0.001). Weight gain and oedema risk with 
thiazolidinediones were greatest in obese females however hypoglycaemia risk 
with sulfonylureas was similar across all subgroups. 
Conclusions 
Subgroups defined by sex and BMI have a different pattern of benefits and risks 
on thiazolidinedione and sulfonylurea therapy. Subgroup specific estimates can 
inform discussion about the choice of therapy after metformin for an individuals. 
Our approach using routine and shared trial data provides a framework for 
future stratification research in type 2 diabetes. 
  
Introduction 
In type 2 diabetes there is limited guidance to help clinicians and patients 
choose between the different glucose-lowering therapy options recommended 
after metformin.(1-3) Guidelines suggest a discussion of the benefits, adverse 
effects, and costs of therapy to select the most appropriate medication for a 
particular patient.(1) Estimates of important clinical outcomes such as HbA1c, 
weight change and risk of side-effects are at present derived from whole trial 
populations and a key question is whether they vary across patient subgroups 
defined by simple characteristics.(1) If estimates do vary by simple 
characteristics this may provide a starting point for a stratified approach in type 
2 diabetes; the ‘targeting of treatments according to the biological or risk 
characteristics shared by patients’.(4)  
Sulfonylureas and thiazolidinediones are recommended second and third line 
therapy options in all major type 2 diabetes guidelines.(1, 2) They represented 
50% of new second line prescriptions in 2016 in the U.S (sulfonylureas 46%, 
thiazolidinediones 4%).(5) As the only generic oral agents they are over 10-fold 
cheaper than the common alternatives DPP4 inhibitors and SGLT2 inhibitors.(1, 
6) Glycemic response, weight change and common side effects have been well 
described in whole trial populations for both therapies.(7-11) Differences in 
glycemic response by sex and BMI with thiazolidinediones and sulfonylureas 
have been previously suggested in observational studies,(12, 13) but no study 
has systematically compared whether the benefits and risks of these therapies 
vary across subgroups defined by simple clinical patient characteristics.  
Sulfonylureas and thiazolidinediones have, in contrast to newer therapies, been 
evaluated head-to-head in two long-term, randomized trials, ADOPT and 
RECORD.(7, 14) ADOPT showed there was a greater durability of response up 
to 5 years with the thiazolidinedione rosiglitazone compared to either the 
sulfonylurea glyburide or metformin.(7)The full individual participant data of both 
trials are now available through Clinical Study Data Request,(15) and a current 
topic of debate is how to improve the output of secondary research projects 
using such shared trial datasets.(16) In this study we present a practical and 
cost-effective framework for stratification research using shared trial datasets 
alongside routine clinical data. We applied this framework to systematically 
evaluate whether simple clinical patient characteristics can be used to stratify 
therapy with sulfonylureas and thiazolidinediones. 
Research Design and Methods 
Framework for stratification research  
In discovery analysis we explored routine clinical data to identify simple 
characteristics associated with glycemic response to sulfonylureas and 
thiazolidinediones, and used the results to define subgroups likely to show 
differential response. In validation analysis we evaluated differences in 
response within subgroups as a pre-specified hypothesis in ADOPT and 
RECORD, the two largest head-to-head randomized trials of sulfonylureas and 
thiazolidinediones available via Clinical Study Data Request.(7, 9, 14, 17, 18) 
We also evaluated the secondary outcomes of weight change and risk of the 
common side effects of hypoglycemia, oedema and fracture within each 
subgroup (see Supplementary Figure 1 for our framework for stratification 
research using routine clinical and shared trial data). 
  
Datasets 
We analysed four datasets. Due to its large sample size, discovery analysis was 
conducted in routine clinical data from UK Clinical Practice Research Datalink 
(CPRD), with validation in trial datasets (ADOPT and RECORD) and a further 
routine clinical dataset (GoDARTs). Scientific approval for the use of CPRD 
data was granted by the CPRD Independent Scientific Advisory Committee 
(ISAC 13_177R) and permission to use the GoDARTs data was granted by the 
East of Scotland Regional Ethics Committee (09/21402/44).  Data for both 
ADOPT and RECORD trials were accessed through the Clinical Trial Data 
Transparency Portal under approval from GSK (Proposal 930). 
CPRD 
CPRD is the world’s largest database of anonymized primary care electronic 
health records.(19) Our study protocol for CPRD data ascertainment has been 
previously reported.(20) We studied 22,379 non-insulin treated people with type 
2 diabetes and prescription records for a sulfonylurea or thiazolidinedione from 
the February 2014 build of CPRD GOLD (see CPRD data supplement for 
product codes). We included people with a duration of diabetes over one year 
(to minimise effect of lifestyle change following diagnosis) and at least one year 
on-therapy without change in co-prescribed glucose lowering therapy (see 
Supplementary Figure 2 for CPRD patient flow diagram).(20)  
Trials 
ADOPT and RECORD were prospective type 2 diabetes trials over at least 5 
years of, respectively, glycemic durability and cardiovascular outcomes, in 
participants randomized to thiazolidinedione, sulfonylurea or metformin 
therapy.(7, 9, 14, 17, 18) In ADOPT we included participants in the intention to 
treat population with a valid baseline BMI randomized to sulfonylurea 
(glibenclamide) or thiazolidinedione (rosiglitazone) therapy (n=2,725). In 
RECORD we included participants in the intention to treat population on 
background metformin randomized to sulfonylurea (glibenclamide (18%), 
gliclazide (30%) or glimepiride (52%) according to local practice) or 
thiazolidinedione (rosiglitazone) add-on therapy (n=2,222).  
Genetics of Diabetes Audit and Research in Tayside Study (GoDARTs) 
GoDARTs contains information from the medical records of 18,276 people 
resident in eastern Scotland. We examined 1,977 individuals with type 2 
diabetes and valid prescription records for a sulfonylurea or thiazolidinedione. 
Analysis – data extraction and definitions 
CPRD – discovery analysis  
The primary outcome was one year glycemic response in people starting 
therapy with a sulfonylurea (any) or thiazolidinedione (pioglitazone or 
rosiglitazone) for the first time.  
We extracted HbA1c at therapy start and at one year to calculate initial HbA1c 
response (one year HbA1c – baseline HbA1c; see CPRD data supplement for 
HbA1c codes), and baseline clinical characteristics: sex, BMI, age at diagnosis, 
duration of diabetes and eGFR.(20) Baseline HbA1c was defined as the closest 
HbA1c to the drug start date in the 91 days prior to the drug start date. One year 
HbA1c was defined as the closest HbA1c to one year after drug start date (+/-3 
months). HbA1c response was only valid if there were no changes to diabetes 
medications between 60 days prior to the baseline HbA1c and the date of the 
one year HbA1c.(20) No adjustment was made for dose. To evaluate the 
secondary outcomes of long-term response and side effects we extracted 
measures of body weight, HbA1c, and records of fracture and oedema (see 
CPRD data supplement for fracture and oedema codes) over five years from 
the start of therapy. People with a fracture or oedema record in the two years 
prior to the drug start date were excluded from fracture and oedema analyses. 
We defined adherence as a Medication Possession Ratio (the number of days 
of available medication divided by the number of days between the first and last 
prescription dates, multiplied by 100). Due to the association between 
adherence and response,(21) only people issued sufficient prescriptions 
(medical possession ratio of between 80% and 120%) were included in 
analysis. 
Trials – validation analysis 
We used individual participant data from the trials to validate initial findings in 
CPRD. Based on the CPRD results we pre-specified four subgroups defined by 
sex and obesity (BMI>30kg/m2). For each subgroup we compared average 
glycemic response by therapy over five years as the difference in area under 
the HbA1c response curve. This is equivalent to the time-updated HbA1c 
measure used in the UKPDS outcomes model.(22)  At years one, three and five 
we also estimated the difference between therapies in average glycemic 
response. We assessed annual weight change (percentage change from 
baseline) using the same approach. We also compared durability of response 
by therapy as measured by time to therapy failure. Failure was defined as in the 
original trials (ADOPT: confirmed fasting plasma glucose ≥180 mg/dl; RECORD 
confirmed HbA1c ≥8.5%). To evaluate side effects over five years we estimated 
the on-therapy risk of fracture (any), clinically determined peripheral oedema (all 
events, moderate/severe events (as defined as in the original trials as sufficient 
to, respectively, interfere with or prevent normal everyday activities)) and 
clinically determined hypoglycemia (all, moderate/severe as defined in the 
original trials).(9, 17) In ADOPT we excluded people with a history of oedema 
from oedema analysis, in RECORD history of oedema was not available.  
GoDARTs 
We evaluated average glycemic response by therapy over five years using the 
same approach used for CPRD. 
Statistical Analysis 
Short-term response: CPRD 
We assessed associations between baseline clinical characteristics (BMI, sex, 
age at diagnosis, duration of diabetes, eGFR) and one year glycemic response 
in linear regression models. A series of baseline HbA1c-adjusted models 
examined each clinical characteristic in turn, separately for each therapy.(23) 
We conducted a complete case analysis for each variable of interest, including 
all people with valid data even if they had missing data for other clinical 
characteristics. Diagnostic plots of residuals were examined to check model 
assumptions were met. Based on the initial analysis we defined four subgroups 
defined by sex and obesity (BMI>30 v BMI<30kg/m2) and for each therapy 
calculated baseline HbA1c adjusted least-square mean estimates of one-year 
response for each subgroup. To test for an overall effect of heterogeneity by 
sex and obesity subgroup we used a likelihood ratio test to compare a model 
with a drug:subgroup interaction with a nested model without an interaction 
term. 
  
Long-term response, weight gain and side effects: trial data 
We compared how each outcome was altered by therapy in each subgroup 
separately. We conducted response and weight change analysis in each trial 
separately, but pooled the data for side effects to increase study power. To 
estimate glycemic response over time we fitted baseline adjusted repeated 
measures mixed effect models using on-therapy HbA1c values at each study 
visit (n=22 ADOPT, n=19 RECORD) up to five years, including fixed effects for 
study visit, baseline HbA1c, therapy, visit by therapy interaction and visit by 
baseline HbA1c interaction, and individual-level random effects with an 
unstructured covariance matrix. Missing on-therapy HbA1c records were 
assumed to be missing at random. We calculated point estimates and 95% 
confidence intervals (CI) for the difference in average glycemic response by 
therapy at years one, three and five through contrasts of least-squares mean 
HbA1c change. We tested for an overall effect of heterogeneity by subgroup 
using the same interaction test as in CPRD. Weight change was modelled using 
the same approach. 
To measure the net difference in HbA1c response between therapies we 
calculated the cumulative area under the HbA1c response curve (AUC) for each 
participant at every study visit using the trapezoidal rule. Participant AUC was 
then used as the outcome in repeated measures mixed effects models of the 
same structure as for glycemic response. A least-squares mean point estimate 
(95% CI) was calculated at year five to contrast overall response by therapy.  
Time to therapy failure and side effects were estimated using the Kaplan-Meier 
method and Cox proportional hazards regression. Proportional hazards 
assumptions were evaluated using Schoenfeld residuals and were satisfied for 
all analyses. For each side effect the hazard ratio contrasting thiazolidinedione 
therapy with sulfonylurea therapy was estimated for each subgroup using an 
individual participant meta-analysis of data from both trials.  
Long-term response, weight gain and side effects: CPRD  
In CPRD we replicated analyses using the same models as described above for 
all outcomes except hypoglycemia. For analysis of long-term HbA1c response, 
we extracted all HbA1c records between 60 days prior to the drug start date up 
to five years after the drug start date whilst on unchanged therapy. HbA1c 
records were categorised to three monthly intervals (nearest HbA1c record +/-
1.5 months) to enable comparison with the trials. Where data points were 
missing, results were interpolated to ensure each time point reflected the same 
population. The same approach was used for weight change, but with weights 
extracted at 6 monthly intervals (+/- 3months). For time to failure analysis, 
therapy failure was defined as two consecutive HbA1cs ≥8.5% or one HbA1c 
≥8.5% followed by the addition of another therapy (the same definition of 
glycemic failure used in RECORD). Data were censored if prescription records 
ended before a change in therapy. We excluded people with changes to 
diabetes therapy without a prior HbA1c ≥8.5% as these changes were unlikely to 
relate to glycemic failure.  
CPRD data extraction was conducted using Stata v13.0. All other analyses 
were conducted using R. 
  
Results 
Routine clinical data: sex and obesity are associated with differential 
glycemic response with sulfonylureas and thiazolidinediones 
In CPRD we examined clinical factors associated with one year glycemic 
response amongst 22,379 eligible individuals (10,960 thiazolidinedione; 11,419 
sulfonylurea) (see Supplementary Table 1 for baseline characteristics). Sex and 
BMI showed the greatest differential response to therapy (Supplementary 
Figure 3). Compared to males, females had a greater response with 
thiazolidinediones, but a lesser response with sulfonylureas (both p<0.001). 
Higher BMI was associated with greater response with thiazolidinediones, but a 
lesser response with sulfonylureas (both p<0.001). Older age at diagnosis and 
lower eGFR were associated with a greater response to both therapies, there 
was greater response to thiazolidinediones with shorter diabetes duration, and 
greater response to sulfonylureas with longer diabetes duration and higher HDL 
(Supplementary Figure 3). 
As sex and BMI showed the greatest differential response we specified four 
subgroups defined by sex and obesity (BMI>30 v BMI<30kg/m2) for use in 
subsequent analysis. We found evidence of heterogeneity of response by 
subgroup (p<0.001). Figure 1 shows one year glycemic response by therapy for 
the four subgroups. Non-obese males had a greater one year response with 
sulfonylureas than thiazolidinediones (baseline adjusted change in HbA1c: -13.2 
(95% CI -13.6;-12.8) v -9.7 (95% CI -10.1;-9.3) mmol/mol, p<0.001), whereas 
obese females had a greater one year response with thiazolidinediones than 
sulfonylureas (-13.8 (95% CI -14.3;-13.3) v -9.4 (95% CI -9.9.1;-8.9) mmol/mol, 
p<0.001). Obese males and non-obese females showed similar responses with 
both therapies (both p=0.6). Results were consistent for pioglitazone and 
rosiglitazone when analysed separately, and for gliclazide and non-gliclazide 
sulfonylureas (Supplementary Figure 4). 
Figure 1: CPRD: One year glycemic response (baseline adjusted change 
in HbA1c) with thiazolidinediones (red dots) and sulfonylureas (blue 
triangles), by sex and obesity defined subgroup.  Data are presented as 
least square means adjusted for baseline HbA1c ± 95% CI. A reduction 
(improvement) in HbA1c is represented as a negative value. 
 
 
Trial data: non-obese males have greater glycemic response with 
sulfonylureas, obese females with thiazolidinediones  
We went on to assess if the sex and obesity defined subgroups also showed 
differential response when randomly allocated to therapy in the ADOPT 
(n=2,725) and RECORD (n=2,222) trials. Randomisation resulted in well 
matched individuals for each therapy within each subgroup (see Supplementary 
Tables 2 and 3 for baseline characteristics). There were marked differences in 
response with both therapies in the four subgroups with a clear similarity 
between the two trials (test for heterogeneity in ADOPT and RECORD both 
p<0.001, Figure 2a and 2b). Over five years there was a greater overall 
glycemic response for non-obese males with sulfonylureas (both trials p<0.001), 
relating to the greater earlier benefit with sulfonylureas over thiazolidinediones 
that persisted beyond 2 years in both trials. In contrast there was a greater 
overall glycemic response for obese females with thiazolidinediones over 
sulfonylureas (both trials p<0.001), and there was little early benefit with 
sulfonylureas. 
Trial data: absolute risk of therapy failure differs markedly by subgroup 
We assessed the risk of monotherapy and dual-therapy failure, respectively, in 
ADOPT and RECORD. In both trials for non-obese males there was no 
difference in the five year risk of failure on the two therapies but all other 
subgroups were less likely to fail with thiazolidinediones than sulfonylureas 
(Hazard ratios 0.23-0.72, test for heterogeneity ADOPT p<0.001, RECORD 
p=0.01, Table 1, Supplementary Figures 5-6). In ADOPT, risk of monotherapy 
failure at five years with thiazolidinediones was lower for obese females (11%) 
than non-obese males (22%), whilst with sulfonylureas failure risk was lower for 
non-obese males (22%) than obese females (42%) (Table 1).  
Trial data: increased risk of weight gain and oedema with 
thiazolidinediones for all subgroups 
Weight was increased for all subgroups with thiazolidinediones compared to 
sulfonylureas but this was much more marked in obese females (Figure 2c, 
Supplementary Figure 7). Oedema was more common with thiazolidinediones 
compared to sulfonylureas for all subgroups; this resulted in the largest 
difference in absolute risk for obese females who are most likely to develop 
oedema regardless of therapy (Table 2, Supplementary Figure 8). 
Figure 2: 5 year glycemic response (change from baseline in HbA1c) and 
weight change (percentage change from baseline) with thiazolidinediones 
(TZD, red dots) and sulfonylureas (SU, blue triangles), by sex and obesity 
defined subgroup. Data are presented as means at each study visit ± standard 
error from mixed effects models. A reduction (improvement) in HbA1c is 
represented as a negative value. For AUC and treatment difference estimates 
positive values favour SU, negative values favour TZD. For RECORD weight 
change data see Supplementary Figure 7. 
a) ADOPT trial: absolute glycemic response (mmol/mol) 
 
  
b) RECORD trial: absolute glycemic response (mmol/mol) 
 
c) ADOPT trial: weight change from baseline (%) 
Table 1: Absolute and relative risk of glycemic failure with thiazolidinediones (TZD) and sulfonylureas (SU) in trial 
data, by sex and obesity defined subgroup.  Failure defined according to original trial protocol (ADOPT trial (monotherapy) 
defined as fasting plasma glucose>180mg/dl; RECORD (dual therapy with metformin) defined as HbA1c>8.5%. Relative risks 
presented as hazard ratios (95% CI) for TZD compared to SU.  
 
ADOPT monotherapy failure No. of participants 
No.                              
of events 
Absolute                         
5 year risk (%) 
Hazard             
ratio (95% CI) 
(TZD vs. SU) 
p value 
  TZD SU TZD SU TZD SU   
Non-obese males 373 395 47 63 21.7% 21.9% 0.78 (0.54-1.14) 0.21 
Obese males 402 387 44 108 15.0% 43.8% 0.32 (0.23-0.46) <0.001 
Non-obese females 208 174 16 34 10.9% 31.5% 0.34 (0.19-0.62) <0.001 
Obese females 407 379 31 93 11.6% 42.2% 0.23 (0.16-0.35) <0.001 
                
RECORD dual-therapy failure No. of participants 
No.                              
of events 
Absolute                         
5 year risk (%) 
Hazard             
ratio (95% CI) 
(TZD vs. SU) 
p value 
  TZD SU TZD SU TZD SU   
Non-obese males 240 228 66 70 33.6% 34.0% 1.00 (0.72-1.40) 0.94 
Obese males 361 356 92 132 30.7% 41.4% 0.72 (0.55-0.94) 0.02 
Non-obese females 137 127 26 45 20.7% 38.8% 0.52 (0.32-0.84) 0.01 
Obese females 379 394 72 142 22.7% 40.5% 0.52 (0.38-0.68) <0.001 
 
 Trial data: increased risk of fracture with thiazolidinediones only for 
females  
Fracture was more common with thiazolidinediones compared to sulfonylureas 
but only for females. Absolute risk was similar for obese and non-obese females 
(Table 2, Supplementary Figure 9).  
Trial data: increased risk of hypoglycemia with sulfonylureas for all 
subgroups 
Sulfonylureas, compared with thiazolidinediones, increased the risk of 
moderate/severe hypoglycemia for all subgroups (Table 2, Supplementary 
Figure 10). Hazard ratios for hypoglycemia of any severity were consistent with 
those for moderate/severe events (Supplementary Tables 4-5). For all side 
effects there was a similar differences between therapies when the trials were 
analysed separately (Supplementary Tables 4-5). 
Routine clinical data: results for long-term glycemic response, time to 
failure and side effects were consistent with trial data 
In CPRD and GoDARTs (see Supplementary Table 6 for GoDARTs baseline 
characteristics), five year glycemic response results were consistent with the 
trials (Supplementary Figures 11 & 16). In CPRD differences by therapy in time 
to failure results were similar to the trials although absolute failure rates were 
higher (Supplementary Figure 12). Weight gain, oedema and fracture results in 
CPRD were comparable to trial data (Supplementary Figures 13-15). 
 
 
Summary of results 
For subgroup data summaries of glycemic response, weight change and risk of 
side effects estimates specific to each sex and obesity defined subgroup see 
the Subgroup data summary (Supplementary material). 
Table 2: Absolute and relative risk of side effects over 5 years with thiazolidinediones (TZD) and sulfonylureas (SU) in 
ADOPT & RECORD combined, by sex and obesity defined subgroup.  Relative risks presented as hazard ratios (95% CI) 
for TZD compared to SU. HRs and p values from meta-analysis of both trials. 
Side effect No. of participants No.                                           of events 
Absolute                                      
5 year risk (%) 
Hazard  ratio (95% CI) 
(TZD vs. SU) p value 
 TZD SU TZD SU TZD SU   
Non-obese males 
Oedema 
(Moderate/Severe) 607 620 13 4 3% 1% 3.57 (1.16-10.94) 0.03 
Fracture                      
(All) 613 623 26 18 7% 4% 1.59 (0.87-2.89) 0.16 
Hypoglycaemia 
(Moderate/Severe) 613 623 14 90 3% 16% 0.15 (0.09-0.27) <0.001 
Obese males 
Oedema 
(Moderate/Severe) 740 719 37 16 7% 3% 2.45 (1.34-4.47) <0.01 
Fracture                      
(All) 763 743 30 28 6% 5% 1.02 (0.61-1.71) 0.94 
Hypoglycaemia 
(Moderate/Severe) 763 743 13 70 2% 11% 0.17 (0.09-0.31) <0.001 
Non-obese females 
Oedema 
(Moderate/Severe) 340 293 13 5 5% 2% 2.10 (0.75-5.89) 0.16 
Fracture                      
(All) 345 301 31 8 14% 3% 3.15 (1.45-6.87) <0.01 
Hypoglycaemia 
(Moderate/Severe) 345 301 10 44 4% 17% 0.17 (0.09-0.35) <0.001 
Obese females 
Oedema 
(Moderate/Severe) 749 746 60 25 10% 5% 2.16 (1.35-3.45) <0.01 
Fracture                      
(All) 786 773 77 33 14% 6% 2.14 (1.42-3.23) <0.001 
Hypoglycaemia 
(Moderate/Severe) 786 773 18 83 3% 13% 0.19 (0.11-0.31) <0.001 
 Conclusions 
Stratification of therapy with sulfonylureas and thiazolidinediones is 
possible using sex and BMI 
We have robustly demonstrated across four datasets that sex and BMI alter the 
benefits and risks of type 2 diabetes therapy with sulfonylureas and 
thiazolidinediones. We show in non-obese males the glycemic response with 
sulfonylureas is better on average in the first 5 years than on thiazolidinediones, 
without excess weight gain, but with an increased risk of hypoglycemia. For 
obese females there is a clear glycemic benefit over the first 5 years with 
thiazolidinediones compared to sulfonylureas, but there is increased weight gain 
and susceptibility to oedema and fracture. Our findings will allow for much more 
informed discussion of the benefits and risks of these therapies than the present 
‘one size fits all’ approach (see supplementary Subgroup Data Summary for 
estimates specific to each sex and obesity defined subgroup). 
Our results provide one of the first examples of stratification of therapy in type 2 
diabetes based on simple clinical characteristics.(24) A recent data-driven 
cluster analysis proposed five subgroups of diabetes with differing disease 
progression and risk of complications, but did not evaluate whether subgroups 
differed in their response to therapy.(25) To-date successful stratification in 
other conditions has involved expensive genetic testing, as applied in cancer 
and single gene diseases such as monogenic diabetes.(26, 27) Expensive 
testing is unlikely to become practical or justified in type 2 diabetes, a highly 
prevalent condition with relatively inexpensive therapy. Type 2 diabetes genetic 
studies have identified polymorphisms associated with drug response but the 
impact of these, at present, are too small to guide clinical management, in 
contrast to our results.(28-32) 
 A framework for stratification research using shared trial data alongside 
routine clinical data 
This study is an early and important demonstration of how shared trial data can 
be harnessed to meaningfully benefit patients.(16) We propose a novel and 
cost-effective framework to use shared trial data in stratification research. Our 
framework can be applied to study other type 2 diabetes therapies and to study 
stratification in other chronic conditions. It has great potential to improve the 
output of future studies using shared trial data. 
Comparison to previous studies 
Whilst no existing studies have systematically assessed whether both the 
benefits and risks of these two therapies are altered by clinical characteristics, 
previous analyses have suggested sex and BMI are associated with glycemic 
response to both therapies. In ADOPT, risk of therapy failure were lower for 
obese and female subgroups with thiazolidinediones compared to 
sulfonylureas, but an interaction was not tested for and the difference in 
glycemic trajectory was not examined.(7) Increased response for obese female 
patients with thiazolidinediones and for male patients with sulfonylureas has 
been found in observational studies.(12, 13) but the impact of this in terms of 
stratification has not been assessed. We have previously shown that markers of 
insulin resistance including BMI are associated with reduced glycemic response 
to DPP4 inhibitors but not glucagon-like peptide 1 (GLP-1) receptor 
agonists,(33, 34) but evidence for other agents is limited.(35, 36)  
Previous studies have also found sex and BMI alter the risk of side effects. The 
increase in fracture risk with thiazolidinediones applies mainly to post-
menopausal women and is consistent within trials.(10, 11, 14, 37) We found 
hypoglycemia risk with sulfonylureas was similar across subgroups even though 
 glycemic response differed, and this needs further investigation. Whilst our 
study shows absolute risk of oedema with thiazolidinediones was highest in the 
obese female subgroup that had the greatest response, further study is required 
to fully evaluate the association between glycemic response and the risk of 
common side effects for these therapies. 
 Limitations 
Our study has limitations. The results do not allow prediction at an individual 
level, however we present subgroup estimates that will better reflect the likely 
outcome for an individual patient within that subgroup than outcome estimates 
derived from whole trial populations. Rosiglitazone, the thiazolidinedione used 
in both trials analysed in our study, has been withdrawn in many countries due 
to concerns over cardiovascular safety.(38) Routine clinical data support a 
thiazolidinedione class effect of differential response by sex and obesity but trial 
data were not made available to repeat our analysis for pioglitazone. Previous 
meta-analyses suggest that the risks of oedema and fracture are similar with 
both drugs, further supporting the generalizability of our findings to 
pioglitazone.(37, 39) For sulfonylureas, a similar pattern of results was 
observed in ADOPT (glibenclamide), RECORD (52% glimepiride, 30% 
gliclazide, 18% glibenclamide), and routine clinical data (including a gliclazide 
only analysis), supporting a sulfonylurea class effect. In CPRD, for the one year 
glycemic response analysis we excluded non-adherent patients and those 
whose anti-hyperglycemic therapy was altered (potentially due to poor 
response, very good response, or poor tolerance) within the first year, and this 
could have accounted for the differences we observed when comparing 
sulfonylurea and thiazolidinedione therapy. However, we saw a similar pattern 
of glycemic response differences using time to failure and mixed effect models 
 which both included all individuals with at least one on-therapy HbA1c measure 
for up to five years. The CPRD time to failure analysis was also limited as 
individuals whose treatment was intensified below the HbA1c failure threshold of 
8.5% were censored rather than defined as experiencing therapy failure. A 
strength of the CPRD analysis is the demonstration of consistent results with all 
three analytical approaches, each with their own strengths and weaknesses. 
Measured or unmeasured baseline differences between individuals could have 
explained findings in the routine data, but are very unlikely to explain the 
differences we observed in the randomized clinical trials, further highlighting the 
strength of our study design. Over 90% of people in the datasets studied were 
White Caucasian, limiting the applicability of our findings to other racial groups, 
a common problem with trials in type 2 diabetes. Additional data would be 
required to answer whether there are differences in people of South Asian, 
Hispanic or Black origin, where fat distribution can be markedly different and a 
different obesity cut-off may be appropriate.(40) A particular benefit in 
cardiovascular outcome for non-white ethnicities has recently been 
demonstrated for SGLT2 inhibitors,(41, 42) emphasising the importance of 
considering ethnicity when undertaking stratified medicine research. We found 
both older age at diagnosis and lower eGFR were associated with greater 
response to both therapies. This may relate to increased medication adherence 
in older individuals (renal function declines with age), but further study is 
required to interrogate this and to establish if associations with the same 
directions of effect are observed for other type 2 diabetes therapies. 
The ideal stratified approach would be based on cardiovascular endpoints 
rather than the intermediary measure of glycemic response. In this analysis we 
were underpowered to detect differences for cardiovascular outcomes in 
 RECORD (the primary trial analysis showed no difference between 
rosiglitazone and sulfonylureas or metformin), or rarer side effects such as heart 
failure.(14) Given recent trials demonstrating cardiovascular benefits with 
SGLT2 inhibitors and GLP-1 receptors agonists each required over 7000 high-
risk participants,(42, 43) it may be that impractically large trials are required for 
stratification of cardiovascular endpoints. 
 
 
Future research 
Evaluation of the risks and benefits of newer therapies such as DPP4 inhibitors, 
SGLT2 inhibitors and GLP-1 receptor agonists will require routine clinical data 
from large numbers of people alongside shared head-to-head drug trial data, 
and will be possible in the near future. Given the greater expense of newer 
therapies cost-effectiveness evaluation will be necessary in this work. The 
ongoing GRADE study will give important long-term head-to-head comparative 
effectiveness data on second-line treatment with insulin, DPP4 inhibitor, GLP-1 
receptor agonist and sulfonylurea therapy.(44) 
Further mechanistic studies are required to interrogate the mechanisms 
underlying differential response to sulfonylureas and thiazolidinediones. 
Thiazolidinediones act through the adipocyte and so it is likely any increase in 
the number of adipocytes will improve glycemic response. This provides a 
potential explanation for our findings as women, compared to men, have more 
adipocytes as they have a higher whole body percentage fat mass and obese 
subjects have more adipocytes than non-obese subjects.(45) The reduced 
insulin sensitivity seen in obesity is likely to explain the reduced response to 
 sulfonylureas that predominantly stimulate insulin secretion by the beta-cell. 
The consistently better response seen in males to sulfonylureas was 
unexpected and further studies are required to define the mechanism of this 
observation. 
Clinical Implications 
The sex and obesity subgroup-specific estimates presented in this study will 
allow a much more informed discussion between clinicians and patients of the 
benefits and risks of sulfonylureas and thiazolidinediones, at no cost. We 
recommend this discussion with an individual is based around the appropriate 
sex and obesity subgroup-specific estimates presented for the two therapies in 
the Subgroup data summary (Supplementary material). Whether this alters a 
decision on therapy will depend on the individual circumstances of the patient, 
as the trade-off between early-response, long-term durability and risk of side-
effects will be different. In current guidelines sulfonylureas and 
thiazolidinediones are the two therapies recommended after metformin in 
settings where cost is the major issue,(46) and so our results may be especially 
applicable for the 80% of people with type 2 diabetes who live in low or middle 
income countries. 
Conclusion 
Simple clinical characteristics alter the benefits and risks of type 2 diabetes 
therapy with sulfonylureas and thiazolidinediones. Our novel and practical 
framework for stratification research can be applied in type 2 diabetes and other 
chronic conditions, and has great potential to improve output from future studies 
using shared trial data. 
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 Supplementary Material  
Supplementary Figure 1: A framework for stratification research using routine clinical and shared trial data 
  
 Supplementary Figure 2: Flow diagram showing the determination of the final CPRD datasets used in analysis, based 
on patients treated with thiazolidinediones (TZD) or sulfonylureas (SU).  Adherence measured by the medicine 
possession ratio. 
  
  
 Supplementary Table 1: CPRD population baseline characteristics split by cohorts treated with thiazolidinediones 
(TZD) and sulfonylureas (SU).  Data presented for the whole group and 4 subgroups defined by obesity (BMI>30kg/m2) and 
sex. 
 
All Non Obese Male Non Obese Female Obese Male Obese Female 
TZDs n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) 
Age diag (y) 10960 57.0 (9.9) 2825 57.6 (9.7) 1521 61.1 (9.9) 3030 54.7 (9.3) 2064 56.1 (9.7) 
Age (y) 10960 63.7 (10.4) 2825 65.3 (10.0) 1521 68.6 (10.1) 3030 60.6 (9.6) 2064 62.0 (10.0) 
Duration Diabetes* (y) 10960 5.4 (2.6, 10.9) 2825 6.2 (3.0, 12.8) 1521 6.0 (2.9, 12.4) 3030 4.8 (2.4, 9.4) 2064 4.7 (2.4, 9.4) 
BMI* (kg/m
2
) 9443 30.9 (25.8, 37.0) 2825 26.7 (24.4, 29.2) 1521 26.2 (23.6, 29.1) 3030 34.6 (30.9, 38.8) 2064 35.9 (31.3, 41.3) 
Male (%) 10960 62% 2825 100% 0 0% 3030 100% 0 0% 
Dose (weighted mean % max)** 10703 50 (50, 66.7) 2761 50 (50, 66.7) 1488 50 (49.8, 66.7) 2963 50 (50, 66.7) 2011 50 (50, 66.7) 
Adherence (%) 10960 101.1 (8.0) 2825 101.0 (8.0) 1521 101.4 (7.9) 3030 100.9 (8.1) 2064 101.2 (7.9) 
HbA1c (mmol/mol) 10960 71.0 (14.2) 2825 69.4 (13.0) 1521 70.7 (14.8) 3030 71.8 (14.4) 2064 71.6 (15.0) 
  All Non Obese Male Non Obese Female Obese Male Obese Female 
SUs n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) 
Age diag (y) 11419 59.3 (10.8) 2976 60.2 (10.4) 1603 64.5 (10.9) 2856 55.6 (9.6) 2103 57.8 (10.2) 
Age (y) 11419 64.6 (10.8) 2976 65.8 (10.3) 1603 69.7 (10.8) 2856 60.7 (9.9) 2103 62.9 (10.3) 
Duration Diabetes* (y) 11419 4.2 (2.1, 8.5) 2976 4.4 (2.1, 9.1) 1603 4.2 (2.1, 8.4) 2856 4.2 (2.2, 8.1) 2103 4.2 (2.1, 8.2) 
BMI* (kg/m
2
) 9539 30.6 (25.4, 36.8) 2976 26.5 (24.1, 29.1) 1603 26.0 (23.3, 29.1) 2856 34.6 (30.9, 38.8) 2103 36.0 (31.4, 41.2) 
Male (%) 11419 61% 2976 100% 0 0% 2856 100% 0 0% 
Dose (weighted mean % max)** 10958 25 (25, 44.5) 2853 25 (25, 37.8) 1541 25 (23.9, 33.2) 2745 25 (25, 50) 2011 25 (25, 47.7) 
Adherence (%) 11419 101.0 (8.6) 2976 100.7 (8.4) 1603 101.4 (8.5) 2856 100.8 (8.7) 2103 101.4 (8.7) 
HbA1c (mmol/mol) 11419 70.7 (16.0) 2976 69.4 (15.7) 1603 68.4 (15.0) 2856 71.9 (15.5) 2103 71.3 (16.1) 
*skewed data so presented as geometric mean (SD range).  **Dose presented as median (IQR) 
 Supplementary Figure 3: Coefficients for predictors of one year response with thiazolidinediones (TZDs) or 
sulfonylureas (SUs) in CPRD.  Data presented as beta coefficient from regression analysis (change in HbA1c per one unit 
increase in each predictor) with 95% confidence intervals as error bars.  All predictors, except for baseline HbA1c, are 
adjusted for baseline HbA1c.  
 
  
* TZD n=8291, SU n=8055 with valid baseline eGFR measure. TZD n=6184, SU n=5623 with valid baseline HDL measure. 
** Duration results presented but association was non-linear and showed poor model fit  
 Supplementary Figure 4a: CPRD one year response with a) Pioglitazone and b) Rosiglitazone (red dots), compared to 
sulfonylurea (blue triangles), by sex and obesity defined subgroups.  Data are presented as baseline adjusted mean 
change in HbA1c ± 95% CI 
 
 
  
 
 Supplementary Figure 4b: CPRD one year response with a) Gliclazide and b) Non-gliclazide sulfonylureas (blue 
triangles), compared to thiazolidinediones (red dots), by sex and obesity defined subgroups.  Data are presented as 
baseline adjusted mean change in HbA1c ± 95% CI 
 
 
  
 Supplementary Table 2: Baseline characteristics for patients in the ADOPT trial, by sex and obesity defined subgroup 
and therapy.  Data presented as mean (SD) or *median (IQR) 
 
 Non-obese Male Obese Male Non-obese Female Obese Female 
 TZD SU TZD SU TZD SU TZD SU 
Patients (n) 373 395 402 387 208 174 407 379 
Age (years) 57.8 (10.0) 57.9 (9.9) 55.2 (9.5) 55.4 (9.3) 58.2 (10.1) 59.7 (10.4) 55.0 (9.9) 54.7 (10.6) 
Ethnic origin (white) 330 (88%) 362 (92%) 358 (89%) 347 (90%) 173 (83%) 161 (93%) 356 (87%) 326 (86%) 
Time since diagnosis 0.80 (0.89) 0.89 (0.91) 0.80 (0.88) 0.84 (0.89) 0.85 (0.85) 0.86 (1.23) 0.79 (0.83) 0.77 (0.82) 
Weight (kg) 81.9 (9.3) 82.6 (9.8) 106.7 (17.7) 108.1 (17.8) 68.7 (8.4) 69.2 (7.9) 97.2 (17.2) 97.1 (18.4) 
BMI 26.9 (2.1) 27.0 (2.0) 34.9 (4.7) 35.2 (4.6) 26.6 (2.5) 26.5 (2.5) 37.2 (6.0) 37.2 (5.9) 
Waist to hip ratio 0.97 (0.06) 0.96 (0.08) 1.00 (0.08) 1.00 (0.06) 0.89 (0.09) 0.89 (0.09) 0.90 (0.08) 0.90 (0.08) 
HbA1c (mmol/mol) 56.7 (11.0) 56.2 (11.2) 57.1 (10.1) 57.3 (9.5) 57.6 (10.3) 56.7 (10.3) 56.8 (9.1) 57.2 (9.3) 
Fasting glucose (mmol/l) 8.4 (1.6) 8.4 (1.4) 8.5 (1.5) 8.6 (1.6) 8.4 (1.3) 8.5 (1.8) 8.4 (1.3) 8.4 (1.4) 
Insulin sensitivity HOMA-S (%)* 46 (31-64) 45 (32-63) 28 (20-39) 28 (20-39) 43 (32-59) 41 (29-56) 27 (19-39) 26 (20-36) 
Beta-cell function HOMA-B (%)* 59 (46-79) 59 (47-73) 75 (59-95) 74 (57-94) 58 (46-73) 64 (46-81) 74 (58-91) 76 (59-94) 
Triglycerides (mmol/l)* 1.7 (1.2-2.4) 1.6 (1.1-2.4) 2.0 (1.4-3.0) 1.9 (1.4-2.7) 1.7 (1.2-2.3) 1.6 (1.2-2.3) 1.9 (1.4-2.6) 1.8 (1.4-2.4) 
LDL cholesterol (mmol/l)* 3.1 (2.5-3.7) 3.0 (2.5-3.6) 3.1 (2.5-3.6) 3.1 (2.5-3.7) 3.3 (2.6-3.9) 3.4 (2.7-4.0) 3.2 (2.7-3.8) 3.1 (2.6-3.8) 
HDL cholesterol (mmol/l)* 1.2 (1.0-1.4) 1.2 (1.0-1.4) 1.1 (0.9-1.3) 1.1 (0.9-1.3) 1.4 (1.2-1.6) 1.4 (1.2-1.6) 1.3 (1.1-1.5) 1.3 (1.1-1.5) 
 
  
 Supplementary Table 3: Baseline characteristics for patients in the RECORD trial, by sex and obesity defined 
subgroup and therapy.  Data presented as mean (SD) or *median (IQR) 
 
 
 Non-obese Male Obese Male Non-obese Female Obese Female 
 TZD SU TZD SU TZD SU TZD SU 
Patients (n) 240 228 361 356 137 127 379 394 
Age (years) 58.2 (8.4) 57.9 (8.5) 55.5 (7.8) 55.7 (8.0) 59.1 (7.7) 59.2 (8.2) 56.9 (7.8) 57.5 (7.8) 
Ethnic origin (white) 237 (99%) 223 (98%) 359 (99%) 351 (99%) 135 (99%) 122 (96%) 374 (99%) 391 (99%) 
Time since diagnosis 6.4 (4.4) 6.9 (4.4) 5.7 (3.7) 6.0 (4.4) 6.9 (4.9) 7.1 (4.7) 6.1 (4.2) 6.1 (4.3) 
Weight (kg) 85.7 (8.2) 86.2 (8.2) 106.6 (14.8) 106.0 (14.4) 72.9 (7.2) 73.1 (7.3) 93.4 (13.1) 92.4 (14.1) 
BMI 27.8 (1.5) 27.8 (1.5) 34.7 (3.9) 34.3 (4) 27.7 (1.5) 27.6 (1.7) 36.0 (4.4) 35.8 (4.9) 
Waist to hip ratio 0.97 (0.05) 0.98 (0.06) 1.01 (0.06) 1.01 (0.06) 0.90 (0.07) 0.91 (0.07) 0.92 (0.07) 0.92 (0.07) 
HbA1c (mmol/mol) 61.4 (7.3) 61.2 (7.2) 62.1 (7.5) 62.9 (7.7) 61.5 (7.3) 62.0 (6.8) 62.4 (7.3) 62.0 (6.7) 
Fasting glucose (mmol/l) 9.5 (2.0) 9.4 (2.0) 9.6 (2.3) 9.9 (2.2) 9.1 (2.0) 9.1 (1.9) 9.4 (1.9) 9.5 (2.2) 
Insulin sensitivity HOMA-S (%)* 87 (60-131) 93 (60-123) 52 (38-74) 52 (34-77) 80 (55-127) 79 (57-130) 58 (41-79) 58 (39-83) 
Beta-cell function HOMA-B (%)* 29 (21-39) 30 (20-42) 42 (30-60) 42 (25-58) 33 (23-42) 32 (22-47) 40 (30-54) 41 (28-57) 
Triglycerides (mmol/l)* 1.8 (1.3-2.5) 1.8 (1.2-2.7) 2.2 (1.7-3.0) 2.1 (1.4-3.1) 1.8 (1.3-2.7) 1.8 (1.3-2.3) 2.1 (1.6-2.7) 2.0 (1.5-2.8) 
LDL cholesterol (mmol/l)* 3.2 (2.6-3.6) 3.2 (2.6-3.7) 3.0 (2.5-3.6) 3.0 (2.4-3.6) 3.3 (2.8-3.9) 3.3 (2.8-3.9) 3.3 (2.7-3.9) 3.3 (2.6-3.9) 
HDL cholesterol (mmol/l)* 1.1 (1.0-1.3) 1.2 (1-1.3) 1.1 (0.9-1.2) 1.1 (0.9-1.2) 1.3 (1.1-1.5) 1.3 (1.1-1.5) 1.2 (1.1-1.4) 1.2 (1.1-1.4) 
 
  
 Supplementary Figure 5: ADOPT Kaplan–Meier estimates of the cumulative incidence of monotherapy failure with 
thiazolidinediones (red) and sulfonylureas (blue) over 5 years by sex and obesity defined subgroup.  Failure defined as 
confirmed fasting plasma glucose ≥ 180 mg/dl.
 
 Supplementary Figure 6: RECORD Kaplan–Meier estimates of the cumulative incidence of dual therapy failure with 
thiazolidinediones (red) and sulfonylureas (blue) over 5 years by sex and obesity defined subgroup.  Failure defined as 
confirmed HbA1c ≥8.5% 
 
 Supplementary Figure 7: RECORD percentage weight change from baseline over 5 years with thiazolidinediones (red 
dots) and sulfonylureas (blue triangles), by sex and obesity defined subgroup. Data are presented as means at each 
study visit ± standard error from mixed effects models, adjusted for baseline weight. Number (n) per year presented below 
plots for each therapy and subgroup. 
  
 Supplementary Figure 8: ADOPT & RECORD combined Kaplan–Meier estimates of the cumulative incidence of 
moderate/severe oedema over 5 years with thiazolidinediones (red) and sulfonylureas (blue) 
 
 Supplementary Figure 9: ADOPT & RECORD combined Kaplan–Meier estimates of the cumulative incidence of 
fracture (any) over 5 years with thiazolidinediones (red) and sulfonylureas (blue). 
 
 Supplementary Figure 10: ADOPT & RECORD combined Kaplan–Meier estimates of the cumulative incidence of 
moderate/severe hypoglycaemia over 5 years with thiazolidinediones (red) and sulfonylureas (blue) 
  
 Supplementary Table 4: ADOPT absolute and relative risk of side effects over 5 years with thiazolidinediones (TZD) and sulfonylureas (SU), 
by sex and obesity defined subgroup.  Relative risks presented as hazard ratios (95% CI) for TZD compared to SU. 
Side effect No.  of patients 
No. 
of events 
Absolute  
5 year risk (%) 
Hazard  
ratio* p value 
 TZD SU TZD SU TZD SU   
Non-obese males 
Oedema 367 392 16 12 6% 5% 1.44 (0.68-3.03) 0.34 
Oedema 
(Moderate/Severe) 367 392 6 3 2% 2% 2.16 (0.54-8.63) 0.28 
Fracture 373 395 12 12 4% 5% 1.06 (0.48-2.37) 0.88 
Hypoglycaemia 
(All) 373 395 33 161 10% 49% 0.18 (0.12-0.25) <0.01 
Hypoglycaemia 
(Moderate/Severe) 373 395 12 74 4% 22% 0.16 (0.09-0.29) <0.01 
Hypoglycaemia 
(Severe) 
  24 events total across all 4 subgroups with both therapies - 21 SU, 3 TZD  
Obese males 
Oedema 379 363 52 34 19% 13% 1.33 (0.86-2.05) 0.20 
Oedema 
(Moderate/Severe) 379 363 13 10 5% 4% 1.10 (0.48-2.51) 0.83 
Fracture 402 387 18 14 6% 5% 1.09 (0.54-2.20) 0.81 
Hypoglycaemia 
(All) 402 387 36 120 11% 40% 0.23 (0.16-0.33) <0.01 
Hypoglycaemia 
(Moderate/Severe) 402 387 8 52 2% 16% 0.13 (0.06-0.28) <0.01 
Hypoglycaemia 
(Severe) 
  24 events total across all 4 subgroups with both therapies - 21 SU, 3 TZD  
Non-obese females 
Oedema 203 166 31 12 19% 9% 2.07 (1.06-4.03) 0.03 
Oedema 
(Moderate/Severe) 203 166 10 4 6% 3% 1.94 (0.61-6.19) 0.26 
Fracture 208 174 19 4 18% 3% 3.42 (1.16-10.07) 0.03 
Hypoglycaemia 
(All) 208 174 20 64 13% 52% 0.20 (0.12-0.33) <0.01 
Hypoglycaemia 
(Moderate/Severe) 208 174 6 34 3% 26% 0.13 (0.05-0.31) <0.01 
Hypoglycaemia 
(Severe) 
  24 events total across all 4 subgroups with both therapies - 21 SU, 3 TZD  
Obese females 
Oedema 370 352 78 46 29% 20% 1.36 (0.94-1.96) 0.10 
Oedema 
(Moderate/Severe) 370 352 32 19 12% 11% 1.30 (0.74-2.31) 0.36 
Fracture 407 379 41 14 16% 9% 2.17 (1.18-3.98) 0.01 
Hypoglycaemia 
(All) 407 379 50 137 15% 45% 0.26 (0.19-0.36) <0.01 
Hypoglycaemia 
(Moderate/Severe) 407 379 14 59 5% 19% 0.19 (0.10-0.33) <0.01 
Hypoglycaemia 
(Severe) 
  24 events total across all 4 subgroups with both therapies - 21 SU, 3 TZD  
 Supplementary Table 5: RECORD absolute and relative risk of side effects over 5 years with thiazolidinediones (TZD) and sulfonylureas (SU), 
by sex and obesity defined subgroup.  Relative risks presented as hazard ratios (95% CI) for TZD compared to SU. 
Side effect No.  of patients 
No. 
of events 
Absolute  
5 year risk (%) 
Hazard  
ratio* 
p  
value* 
 TZD SU TZD SU TZD SU   
Non-obese males 
Oedema 240 228 13 9 7% 5% 1.59 (0.68-3.71) 0.29 
Oedema 
(Moderate/Severe) 240 228 7 1 4% 1% 7.84 (0.96-63.7) 0.05 
Fracture 240 228 14 6 9% 3% 2.66 (1.02-6.94) 0.04 
Hypoglycaemia 
(All) 240 228 5 38 2% 18% 0.12 (0.05-0.31) <0.01 
Hypoglycaemia 
(Moderate/Severe) 240 228 2 16 1% 8% 0.12 (0.03-0.54) <0.01 
Hypoglycaemia 
(Severe) 
  10 events total across all 4 subgroups with both therapies - 10 SU, 0 TZD  
Obese males 
Oedema 361 356 48 21 17% 7% 2.61 (1.56-4.35) <0.01 
Oedema 
(Moderate/Severe) 361 356 24 6 9% 2% 4.45 (1.82-10.90) <0.01 
Fracture 361 356 12 14 5% 5% 0.94 (0.43-2.03) 0.88 
Hypoglycaemia 
(All) 361 356 10 51 3% 16% 0.19 (0.10-0.38) <0.01 
Hypoglycaemia 
(Moderate/Severe) 361 356 5 18 2% 6% 0.29 (0.11-0.79) 0.015 
Hypoglycaemia 
(Severe)   
10 events total across all 4 subgroups with both therapies - 10 SU, 0 TZD 
 
Non-obese females 
Oedema 137 127 17 4 15% 4% 4.13 (1.39-12.2) 0.01 
Oedema 
(Moderate/Severe) 137 127 3 1 3% 1% 2.77 (0.29-26.60) 0.38 
Fracture 137 127 12 4 11% 3% 2.86 (0.92-8.88) 0.07 
Hypoglycaemia 
(All) 137 127 3 26 3% 22% 0.10 (0.03-0.31) <0.01 
Hypoglycaemia 
(Moderate/Severe) 137 127 4 10 4% 9% 0.36 (0.11-1.3) 0.08 
Hypoglycaemia 
(Severe)   
10 events total across all 4 subgroups with both therapies - 10 SU, 0 TZD 
 
Obese females 
Oedema 379 394 75 20 23% 6% 4.37 (2.67-7.16) <0.01 
Oedema 
(Moderate/Severe) 379 394 28 6 9% 2% 5.16 (2.14-12.46) <0.01 
Fracture 379 394 36 19 12% 5% 2.12 (1.21-3.70) <0.01 
Hypoglycaemia 
(All) 379 394 14 73 4% 21% 0.19 (0.11-0.34) <0.01 
Hypoglycaemia 
(Moderate/Severe) 379 394 4 24 1% 7% 0.17 (0.06-0.50) <0.01 
Hypoglycaemia 
(Severe)   
10 events total across all 4 subgroups with both therapies - 10 SU, 0 TZD 
 
 Supplementary Figure 11: CPRD HbA1c over 5 years with thiazolidinediones (red dots) and sulfonylureas (blue 
triangles), by sex and obesity defined subgroup. Data are presented as 3 monthly means ± standard error from mixed 
effects models, adjusted for baseline HbA1c. Number (n) per year presented below plots for each therapy and subgroup. 
 
 Supplementary Figure 12: CPRD Kaplan–Meier estimates of the cumulative incidence of failure of therapy over 5 
years with thiazolidinediones (red) and sulfonylureas (blue). Failure defined as two consecutive HbA1cs >8.5% or one 
HbA1c >8.5% followed by an additional oral hypoglycaemic agent being added. 
 
 Supplementary Figure 13: CPRD percentage weight change from baseline over 5 years with thiazolidinediones (red 
dots) and sulfonylureas (blue triangles), by sex and obesity defined subgroup. Data are presented as 6 monthly means 
± standard error from mixed effects models, adjusted for baseline HbA1c.  Number (n) per year presented below plots for each 
therapy and subgroup. 
 
 Supplementary Figure 14: CPRD Kaplan–Meier estimates of the cumulative incidence of oedema over 5 years with 
thiazolidinediones (red) and sulfonylureas (blue) 
 
 
 Supplementary Figure 15: CPRD Kaplan–Meier estimates of the cumulative incidence of fracture (any) over 5 years 
with thiazolidinediones (red) and sulfonylureas (blue) 
 
 Supplementary Table 6: GoDARTs population baseline characteristics, split by cohorts treated with 
thiazolidinediones (TZD) and sulfonylureas (SU).  Data presented for the whole group and 4 subgroups defined by obesity 
(BMI>30kg/m2) and sex. 
 
All Non Obese Male Non Obese Female Obese Male Obese Female 
TZD n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) 
Age diag (y) 719 55.6 (9.3) 176 56.7 (9.2) 97 59.9 (8.5) 267 52.9 (9.0) 174 56.1 (9.1) 
Age (y) 719 63.7 (9.6) 176 65.9 (9.0) 97 69.0 (8.8) 267 60.7 (9.3) 174 63.3 (9.3) 
Duration Diabetes (y) 719 8.2 (5.1) 176 9.2 (5.9) 97 9.2 (5.2) 267 7.8 (4.9) 174 7.2 (4.0) 
BMI (kg/m
2
) 714 32.2 (5.7) 176 27.3 (2.0) 97 26.8 (2.5) 267 34.9 (4.6) 174  36.0 (5.6) 
Male (%) 719 62 176 100 97 0 267 100 174 0 
Dose (weighted mean % max) 686 50 (23) 170 51 (25) 95 49 (22) 252 51 (23) 164 48 (22) 
Adherence (%) 719 97 (5) 176 97 (5) 97 98 (3) 267 97 (5) 174 97 (5) 
HbA1c (mmol/mol) 719 73.1 (12.5) 176 70.8 (12.0) 97 71.0 (11.6) 267 74.3 (12.5) 174 74.6 (13.0) 
  All Non Obese Male Non Obese Female Obese Male Obese Female 
SU n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) 
Age diag (y) 1258 58.8 (10.4) 350 59.8 (10.0) 219 64.0 (10.5) 336 56.1 (9.6) 285 57.2 (10.3) 
Age (y) 1258 64.6 (10.2) 350 66.0 (9.9) 219 69.3 (9.8) 336 61.9 (9.6) 285 62.9 (10.3) 
Duration Diabetes (y) 1258 5.8 (3.9) 350 6.2 (4.4) 219 5.4 (3.5) 336 5.8 (3.7) 285 5.7 (3.7) 
BMI (kg/m
2
) 1190 31.2 (5.5) 350 27.1 (2.1) 219 26.4 (2.5) 336 34.6 (4.1) 285 35.8 (4.8) 
Male (%) 1258 57 350 100 219 0 336 100 285 0 
Dose (weighted mean % max) 1167 29 (22) 330 26 (14) 202 24 (14) 307 30 (15) 268 37 (31) 
Adherence (%) 1258 96 (6) 350 96 (6) 219 96 (6) 336 96 (5) 285 97 (5) 
HbA1c (mmol/mol) 1258 70.9 (14.5) 350 68.8 (14.3) 219 69.0 (12.8) 336 71.4 (13.8) 285 72.9 (14.9) 
 
  
 Supplementary Figure 16: GoDARTs  HbA1c over 5 years with thiazolidinediones (red dots) and sulfonylureas (blue 
triangles), by sex and obesity defined subgroup. Data are presented as 3 monthly means ± standard error from mixed 
effects models, adjusted for baseline HbA1c. Number (n) per year presented below plots for each therapy and subgroup. 
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SU (n)
179 156 115 92 65 38
200 201 149 109 81 61
332 300 225 174 122 70
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 CPRD – data supplement 
Code lists for the CPRD analysis are provided in the published online data 
supplement, available from: 
http://care.diabetesjournals.org/highwire/filestream/55298/field_highwire_
adjunct_files/0/DC180344SupplementaryData.pdf  
 Subgroup Data summary 
Summary for males BMI ≤30 on thiazolidinedione (red) and sulfonylurea (blue dotted/dashed). HbA1c and weight data from 
ADOPT, side effects from ADOPT and RECORD. 
 
  
 Summary for males BMI >30 on thiazolidinedione (red) and sulfonylurea (blue dotted/dashed). HbA1c and weight data from 
ADOPT, side effects from ADOPT and RECORD. 
 
  
 Summary for females BMI ≤30 on thiazolidinedione (red) and sulfonylurea (blue dotted/dashed). HbA1c and weight data from 
ADOPT, side effects from ADOPT and RECORD. 
 
  
 Summary for females BMI >30 on thiazolidinedione (red) and sulfonylurea (blue dotted/dashed). HbA1c and weight data from 
ADOPT, side effects from ADOPT and RECORD. 
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Abstract 
Aim 
Precision medicine drug therapy seeks to maximise efficacy and minimise harm 
for individual patients. This will be difficult if drug response and side-effects are 
positively associated, meaning patients likely to respond best are at increased 
risk of side-effects. We applied joint longitudinal-survival models to evaluate 
associations between drug response (longitudinal outcome) and risk of side-
effects (survival outcome) for people initiating type 2 diabetes therapy. 
Study Design and Setting 
Participants were randomised to metformin, sulfonylurea or thiazolidinedione 
therapy in the ADOPT drug-efficacy trial (n=4,351). Joint models were 
parameterised for: 1) current HbA1c response (change from baseline in HbA1c); 
2) cumulative HbA1c response (total HbA1c change).  
Results 
With metformin, greater HbA1c response did not increase risk of gastrointestinal 
events (Hazard ratio (HR) per 1% absolute greater current response 0.82 (95% 
confidence interval 0.67,1.01); HR per 1% higher cumulative response 0.90 
(0.81,1.00)). With sulfonylureas, greater current response was associated with 
increased risk of hypoglycaemia (HR 1.41 (1.04,1.91)). With thiazolidinediones, 
greater response was associated with increased risk of oedema (current HR 
1.45 (1.05,2.01); cumulative 1.22 (1.07,1.38)) but not fracture.  
Conclusion 
Joint modelling provides a useful framework to evaluate the association 
between response to a drug and risk of developing side-effects. There may be 
great potential for widespread application of joint modelling to evaluate the risks 
and benefits of both new and established medications. 
 
  
Introduction 
There is increasing interest in applying a precision medicine approach to select 
the most appropriate drug for a patient or subgroup of patients, in order to either 
improve response or to reduce side-effects.(1, 2) An important but overlooked 
question, particularly if side-effects are a result of the primary pharmacological 
effect of the drug, is whether the patients most likely to benefit are also at 
greatest risk of side-effects. Type 2 diabetes is an ideal candidate for precision 
medicine as there are many drug options to lower blood glucose (as measured 
by HbA1c), but each drug has a different mechanism of action and specific side-
effects. However, the association between HbA1c response and side-effects is 
unknown for all drug options. If people likely to have a greater HbA1c response 
to a specific drug are also at increased risk of side-effects this may limit the 
clinical utility of any precision approach to type 2 diabetes therapy. 
To date, no robust framework has been proposed to evaluate the association 
between drug response and risk of side-effects. In type 2 diabetes, HbA1c is 
measured repeatedly over time (a longitudinal process), whilst side-effect risk 
can be modelled as a time-to-event process. In this scenario, joint longitudinal-
survival modelling is the preferred approach to evaluate the association 
between both processes.(3-6) Joint models attempt to capture the true, 
unobserved, longitudinal trajectory (in reality HbA1c is measured intermittently 
and is subject to measurement error from random noise and biological 
variation). This means joint models can reduce bias and improve efficiency 
compared with simpler approaches.(5, 7) Joint models have been applied in 
many diseases including recently in type 1 diabetes (autoantibodies and time to 
disease onset),(8-11) but not to our knowledge in type 2 diabetes, or more 
broadly to evaluate the association between drug response and risk of side-
effects. 
In this study we applied joint modelling to evaluate the association between 
drug response and risk of established side-effects for 3 widely used type 2 
diabetes drugs, and thus further evaluate the potential for precision drug 
therapy in type 2 diabetes.  
 
Material and Methods 
Overview 
Our aim was to understand whether the degree of glycaemic response to three 
common glucose-lowering drugs altered the risk of developing a side-effect. To 
answer this question we examined the association between two outcomes: 1) 
HbA1c response (as measured by change from baseline in HbA1c) and 2) risk of 
developing a side-effect (gastro-intestinal (GI) events, hypoglycaemia, oedema 
and fracture).  
Setting and design 
We used individual participant level data from the ADOPT randomised trial,(12) 
accessed through Clinical Trial Data Transparency Portal under approval from 
GSK (Proposal-930).(13) ADOPT was a prospective head-to-head drug trial 
including treatment-naïve participants with type 2 diabetes who were 
randomised to Metformin (MFN), the sulfonylurea (SU) glyburide or the 
thiazolidinedione (TZD) rosiglitazone (n=4,351 participants). The aim of ADOPT 
was to evaluate the long-term efficacy of the TZD compared to SU and MFN 
and the primary outcome was time to therapy failure (confirmed fasting plasma 
glucose ≥180 mg/dl). Study visits were every 2 months in year 1, then every 3 
months up to 5 years. Clinically determined adverse events were recorded at 
each study visit, including records of GI events, hypoglycaemia, oedema and 
fracture. Biomarkers including HbA1c were recorded at each visit. ADOPT 
participants in the intention to treat population with a valid baseline HbA1c were 
eligible for our study. Participants were censored if they reached the trial 
primary endpoint of glycaemic failure, trial-recorded study withdrawal, or at 5 
years after starting therapy as in the ADOPT main analysis.  
Study outcomes  
Our time-to-event outcomes were the first occurrence of 4 established drug-
specific side-effects, over a 5 year period. For MFN the outcome of interest was 
a GI event, for SU it was a hypoglycaemia event (participant self-reported) and 
for TZD we evaluated oedema events and bone fractures.(12) Each drug and 
side-effect was analysed separately. We excluded participants s with a pre-trial 
history of oedema from the oedema analysis (6% of participants), but pre-trial 
hypoglycaemia, gastro-intestinal and fracture records were not available to do 
the same for other side-effects. Due to the high number of GI events we 
repeated the GI analysis restricted to only moderate/severe and severe events 
as sensitivity analysis. The longitudinal outcome of interest was HbA1c response 
as measured by change from baseline in HbA1c (HbA1c at each study visit (%) – 
baseline HbA1c (%)). Throughout HbA1c percentages refer to absolute values 
rather than percentage changes. To test the specificity of our findings we 
repeated the analysis for each side-effect for the other drugs. 
  
Figure 1: Approaches to estimating HbA1c (%) response 
Model 1: estimate current HbA1c response using a joint model (red line with 
black dotted 95% confidence intervals). 
Model 2: estimate cumulative HbA1c response using a joint model (grey shaded 
area). 
Model 3: carry forward the most recently observed value of HbA1c response 
until the next measurement (LOCF approach, black step function). 
Model 4: take the observed HbA1c response at a single time point of 6 months 
(blue line). 
 
Statistical analysis 
We used a joint model with two parameterisations (Models 1-2) and two 
standard time-to-event models (Models 3-4), for comparison, to evaluate the 
association between HbA1c response and the risk of developing a side-effect. A 
fundamental difference between each model was in the method to estimate 
HbA1c response, as illustrated in Figure 1. Each side-effect was evaluated 
separately and the same modelling approach was applied for each side-effect. 
Participants were followed-up for up to five years from randomisation. As we 
were assessing the association between side-effects and response, all 
participants required at least one pre-side-effect HbA1c measure (meaning 4% 
of participants with very early side-effects were excluded from oedema analysis, 
3% fracture, 20% hypoglycaemia, 12% GI). All models were adjusted for 
baseline HbA1c.(14) Model setups were as follows: 
Joint longitudinal-survival models 
We used a maximum likelihood joint longitudinal-survival model to 
simultaneously assess the association between HbA1c response (longitudinal 
process) and the risk of developing a side-effect (survival process). The joint 
model consisted of a two parts: a longitudinal submodel and a survival 
submodel linked through shared subject-specific random effects.(6)  
In the general survival submodel, the hazard for individual 𝑖𝑖 (ℎ𝑖𝑖(𝑡𝑡)) can be 
represented as:  
ℎ𝑖𝑖(𝑡𝑡) = ℎ0(𝑡𝑡) exp(𝑤𝑤𝑖𝑖𝑇𝑇𝛾𝛾 + 𝛼𝛼𝑚𝑚𝑖𝑖(𝑡𝑡)), 
where ℎ0(𝑡𝑡) is the baseline hazard, 𝑤𝑤𝑖𝑖 are baseline covariates, 𝛾𝛾 are regression 
coefficients, 𝑚𝑚𝑖𝑖(𝑡𝑡) is the “true, unobserved” longitudinal biomarker (estimated 
from the longitudinal submodel) and 𝛼𝛼 quantifies the association between the 
longitudinal biomarker and the time-to-event process.(6)  
We derived 𝑚𝑚𝑖𝑖(𝑡𝑡) from the observed HbA1c response data using a linear mixed 
effects model with a non-linear term for time (as HbA1c response is typically 
non-linear): 
𝑦𝑦𝑖𝑖(𝑡𝑡) =  𝑚𝑚𝑖𝑖(𝑡𝑡) +  𝜖𝜖𝑖𝑖(𝑡𝑡) 
         = 𝛽𝛽0 + 𝛽𝛽1𝑁𝑁(𝑡𝑡𝑖𝑖)1 + 𝛽𝛽2𝑁𝑁(𝑡𝑡𝑖𝑖)2  +  𝛽𝛽3Baseline HbA1c +  𝑏𝑏𝑖𝑖0 +  𝑏𝑏𝑖𝑖1𝑁𝑁(𝑡𝑡𝑖𝑖)1 + 𝑏𝑏𝑖𝑖2𝑁𝑁(𝑡𝑡𝑖𝑖)2 +  𝜖𝜖𝑖𝑖(𝑡𝑡), 
where 𝑦𝑦𝑖𝑖 is the observed HbA1c change from baseline and 𝑚𝑚𝑖𝑖 the “true”, 
unobserved HbA1c change from baseline. 𝑁𝑁(𝑡𝑡𝑖𝑖)1 𝑎𝑎𝑎𝑎𝑎𝑎 𝑁𝑁(𝑡𝑡𝑖𝑖)2 denote the basis for 
a non-linear natural cubic spline of time with 1 internal knot at the 50th 
percentile of follow-up time (included in both the fixed and random effect parts 
of the longitudinal HbA1c submodel), 𝑏𝑏𝑖𝑖 is a vector of subject specific random 
effects, 𝑏𝑏𝑖𝑖 ~ 𝛮𝛮(O, D�) where D� is the unstructured covariance matrix of random 
effects, 𝜖𝜖𝑖𝑖 is the vector of residuals, and 𝜖𝜖𝑖𝑖 ~ 𝛮𝛮(O,𝜎𝜎2) where 𝜎𝜎2 𝑖𝑖s the 
covariance matrix of the residuals.(6) For models of hypoglycaemia with 
metformin and oedema with sulfonylureas we used a linear term for the random 
effect of time to achieve model convergence. 
Model 1: Joint model current value (JMcv). To assess the association between 
the current value of HbA1c response and risk of side-effects (the standard 
formulation of the joint model) we incorporated 𝑚𝑚𝑖𝑖 from the longitudinal 
submodel as a time-dependent covariate in the survival submodel: 
ℎ𝑖𝑖(𝑡𝑡) = ℎ0(𝑡𝑡) exp{𝛾𝛾0Baseline HbA1c + 𝛼𝛼𝑚𝑚𝑖𝑖(𝑡𝑡)} 
Model 2: Joint model cumulative HbA1c (JMcum). To evaluate whether the risk 
of side-effects was associated with total rather than current HbA1c response we 
specified a second formulation of the joint model to assess the association 
between cumulative HbA1c response (total HbA1c response estimated as area-
under-the-curve) and risk of side-effects, by including ∫ 𝑚𝑚𝑖𝑖(𝑠𝑠) 𝑎𝑎𝑠𝑠}𝑡𝑡0 , the integral 
of the longitudinal HbA1c response trajectory up to time t, in the time-to-event 
submodel:(6, 15) 
ℎ𝑖𝑖(𝑡𝑡) = ℎ0(𝑡𝑡)exp {𝛾𝛾0Baseline HbA1c + 𝛼𝛼� 𝑚𝑚𝑖𝑖(𝑠𝑠) 𝑎𝑎𝑠𝑠}𝑡𝑡
0
 
For models 1 and 2 we used a B-spline with 5 internal knots to flexibly model 
the baseline hazard function. We examined the fit of submodels using residual 
plots. Models 1 and 2 were fitted using the JM package in R.(16) 
Model 3: Last-observation-carried-forward analysis (LOCF). We included 
observed HbA1c response (HbA1c at time t – baseline HbA1c) as a time-
dependent covariate in a Cox proportional hazards model. This approach does 
not correct for measurement error and assumes HbA1c response is constant 
between measurements. Hazard ratios represent the increased risk of a side-
effect for a 1-unit (%) absolute increase in the most recent value of HbA1c 
change from baseline at time t. 
Model 4: single estimate of HbA1c response at 6 months (6mR). We evaluated 
the association between HbA1c response at six months and subsequent risk of 
developing a side-effect. In this two-stage approach we first estimated a single 
estimate of HbA1c response as a change score at 6 months. In the second 
stage we used this estimate as the exposure in a Cox hazards survival model 
with delayed entry to 6 months. Participants who developed a side-effect prior 
to 6 months or had no HbA1c record at 6 months were excluded from this 
analysis (Supplementary Table 4).  
Ethics approval 
Data for the ADOPT trial were accessed through the Clinical Trial Data 
Transparency Portal, with study approval from GlaxoSmithKline (Proposal 930). 
  
Results 
The most common side-effects were GI side-effects with metformin (37%), 
followed by hypoglycaemia with sulfonylurea therapy (26%). Thiazolidinedione 
side-effects were less common (oedema 13%, fracture 7%, Table 1). Median 
follow-up was greater than 2.5 years in each cohort. For other participant 
characteristics see Supplementary table 1. Each side-effect occurred more 
frequently on these therapies than on the comparator drugs (Supplementary 
table 2).  
Table 1: Participant numbers and study follow-up for each primary 
drug:side-effect cohort (Models 1-3). Data are median (IQR) unless stated. 
See Supplementary table 4 for participants included in Model 4.  
  Metformin - GI SU - Hypo TZD - Oedema TZD - Fracture 
No. of participants 1200 1052 1241 1311 
No. of events (%) 440 (37%) 270 (26%) 164 (13%) 88 (7%) 
Baseline HbA1c % 7.3 (6.7;7.9) 7.3 (6.7;7.9) 7.3 (6.7;7.9) 7.3 (6.7;7.9) 
No. recorded HbA1c 13 (6;19) 12 (5;19) 18 (9;20) 18 (10;21) 
Study follow-up (years) 2.8 (1.0;4.2) 2.5 (0.9;4.2) 4.0 (1.8;4.7) 4.0 (2.1;4.7) 
 
 
Joint-model associations between HbA1c response and risk of side-effects 
GI events. With metformin we found consistent evidence for an association 
between greater HbA1c response and reduced risk of a GI side-effect (Figure 
2a). We observed a similar association for moderate/severe GI events (20% of 
participants) and no association for severe GI events (3% of participants) 
(Supplementary table 3). We found no evidence of an association with 
thiazolidinediones and sulfonylureas (Table 2, Supplementary table 3).  
 
Hypoglycaemia. With sulfonylureas we found greater current HbA1c response 
was associated with an increased risk of hypoglycaemia (Model 1:JMcv, Figure 
Figure 2: Hazard ratios for the association between HbA1c response and risk of a drug-specific side-effect (Models 1-
3). Hazard ratios (95% confidence intervals) represent the increase in risk of a side-effect for a 1% greater absolute HbA1c 
response. A hazard ratio greater than 1 indicates an increased risk of a side-effect with greater HbA1c response. 
2b). We found no evidence for an association between the risk of 
hypoglycaemia and cumulative HbA1c response (Model 2:JMcum). With 
thiazolidinedione therapy, although the absolute risk of hypoglycaemia was 
much lower than with sulfonylurea therapy (8% versus 26%, p<0;001),  greater 
current and cumulative HbA1c response were associated with an increased risk 
of hypoglycaemia. There was no evidence of an association between response 
and hypoglycaemia with metformin (Table 2). 
 
Oedema: With thiazolidinediones, greater current (Model 1:JMcv) and 
cumulative (Model 2:JMcum) HbA1c response were associated with an 
increased risk of oedema (Figure 2c). We found no evidence of an association 
between HbA1c response and risk of oedema with metformin and sulfonylureas 
(Table 2). 
 
Fracture: With thiazolidinediones we found no evidence for an association 
between HbA1c response and the risk of a fracture (Figure 2d). There was also 
no evidence of an association with metformin and sulfonylureas (Table 2, 
Supplementary table 6).                                                                          
 
  
Table 2: Hazard ratios for the Association between HbA1c Response and 
Risk of Side-effects (Models 1-3). Hazard ratios (95% Confidence Intervals) 
represent the increase in risk of a side-effect for a 1% greater absolute HbA1c 
response. A hazard ratio greater than 1 indicates an increased risk of a side-
effect with greater HbA1c response. 
 
Side-effect Model 1: JMcv Model 2: JMcum Model 3: LOCF 
 MFN   
Gastrointestinal 0.82 (0.67, 1.01), P=0.06 0.90 (0.81, 1.00), P=0.06 0.85 (0.74, 0.96), P=0.01 
Hypoglycaemia 1.01 (0.63, 1.62), P=0.96 1.22 (0.93, 1.60), P=0.15 1.19 (0.88, 1.60), P=0.25 
Oedema 1.16 (0.70, 1.92), P=0.58 1.09 (0.88, 1.36), P=0.42 1.07 (0.74, 1.56), P=0.71 
Fracture 0.83 (0.48, 1.44), P=0.51 1.00 (0.78, 1.27), P=0.98 0.98 (0.69, 1.39), P=0.92 
 SU 
Gastrointestinal 0.88 (0.69, 1.11), P=0.28 1.03 (0.92, 1.17), P=0.58 0.90 (0.77, 1.05), P=0.19 
Hypoglycaemia 1.41 (1.04, 1.91), P=0.03 1.09 (0.93, 1.29), P=0.28 1.41 (1.12, 1.77), P=0.003 
Oedema 1.31 (0.85, 2.02), P=0.23 1.09 (0.87, 1.36), P=0.45 0.87 (0.67, 1.13), P=0.28 
Fracture 1.16 (0.70, 1.92), P=0.58 1.09 (0.88, 1.36), P=0.42 1.00 (0.64, 1.58), P=0.68 
 TZD 
Gastrointestinal 1.21 (0.94, 1.55), P=0.13 1.05 (0.93, 1.18), P=0.44 1.04 (0.87, 1.26), P=0.65 
Hypoglycaemia 1.98 (1.25, 3.15), P=0.004 1.37 (1.11, 1.7), P=0.003 1.44 (0.98, 2.12), P=0.07 
Oedema 1.45 (1.05, 2.01), P=0.03 1.22 (1.07, 1.38), P=0.003 1.01 (0.80, 1.27), P=0.94 
Fracture 1.10 (0.72, 1.68), P=0.65 1.09 (0.93, 1.29), P=0.28 1.05 (0.72, 1.52), P=0.81 
 
 
Associations using standard time-to-event approaches 
Results using the last-observation-carried-forward approach (Model 3:LOCF) 
were generally consistent with those from the current value joint model (Model 
1:JMcv) (Table 2, Figure 2). The exception was for thiazolidinediones and 
oedema, for which, in contrast to the joint model, we found no evidence of an 
association using the LOCF model. Using Model 4:6mR (where HbA1c response 
was estimated from a single 6 month value) we found no evidence of any 
association between HbA1c response and risk of side-effects except for 
gastrointestinal events with Metformin (hazard ratio per 1% absolute increase in 
6 month HbA1c response 0.74 (95% CI 0.60, 0.91, Supplementary Table 4-5). 
  
Discussion  
Our study shows joint modelling can be a useful approach for evaluating 
associations between the benefits and risks of drug therapy. Using joint models 
for longitudinal and time-to-event data we were able to show important 
differences in the associations between drug response and risk of established 
side-effects for three widely-used type 2 diabetes drugs. We also found 
differences in the association between each of current and cumulative drug 
response and risk of side-effects, suggesting underlying differences in the 
nature of associations for the different drugs. Our results have implications for 
any precision medicine approach to type 2 diabetes therapy. More generally, 
they highlight the potential for widespread application of joint longitudinal-
survival modelling to evaluate the benefits and risks of both new and 
established medications. 
 
Advantages and disadvantages of joint models to evaluate the association 
between drug response and risk of side-effects 
We found a key advantage of joint modes to be their flexibility. Different 
specifications of the joint model gave important additional insight into the 
underlying nature of associations between HbA1c response and side-effects. 
These insights fitted with what is known about the pharmacological action of the 
different drugs. Current, but not cumulative, HbA1c response was associated 
with an increased risk of hypoglycaemia with sulfonylureas. This is expected as 
hypoglycaemia is a side-effect related to short term fluctuations in blood 
glucose, rather than long term exposure. In contrast, for oedema with 
thiazolidinediones, which is less likely to relate to short-term fluctuations in 
blood glucose, we observed associations for both current and cumulative HbA1c 
response. 
We also found associations with joint models that were missed by simpler 
approaches. With oedema with thiazolidinedione therapy there was no 
association using the last-observation-carried-forward approach but a clear 
association using both specifications of the joint model. This is likely due to the 
reduced bias and increased efficiency of the joint model compared with the last-
observation-carried-forward approach which does not correct for measurement 
error in the longitudinal HbA1c response.(5, 7) In general, hazard ratios using 
the last-observation-carried-forward approach had the same direction of 
association but were attenuated compared with those obtained from the current 
value joint model, in keeping with previous comparisons.(4, 17) We found a 
single measure of HbA1c at 6 months was insufficient to show evidence of an 
association between HbA1c response and side-effects, with the exception of GI 
side-effects with metformin where the association was consistent with the joint 
model.  
There are some settings where joint models may be more limited. ADOPT was 
a large randomised, double-blinded trial and in this dataset we found joint 
models to be useful to evaluate the association between response and relatively 
common side-effects. Increasingly, similar trial datasets are available for 
researchers to address secondary research questions.(13, 18) It may be more 
challenging to apply joint modelling in other datasets. In particular, the potential 
of recording bias should be considered if conducting similar studies in electronic 
health records, although greater sample size may offer the opportunity to study 
rarer side-effects. Testing the specificity of results to drugs known to cause the 
side-effect by comparison with ‘negative control’ drugs may be a useful starting 
point. Joint models may also be harder to apply to study associations between 
drug response and acute or allergic side effects that occur immediately after 
starting therapy. This was apparent in our analysis, as although we included 
over 1000 participants for each drug, participants who developed an early side-
effect prior to their on-therapy HbA1c were excluded, and this is a particular 
limitation of our analysis of hypoglycaemia with sulfonylureas. Another limitation 
of the joint modelling framework applied in this study is the assumption of a 
fixed association between longitudinal HbA1c and risk of each side effect. Whilst 
inspection of residual plots indicated this was an appropriate strategy, it is 
certainly plausible that associations could change with therapy duration, and 
incorporating duration of therapy as a time-varying effect within the joint 
modelling framework would be of considerable interest. Similarly, an extension 
of the joint modelling framework to robustly incorporate drug dose and drug 
adherence could yield further insight to complement the response:side-effect 
associations evaluated in this study. Evaluating the impact of dose is a 
particular challenge in trials of drug efficacy such as ADOPT, as participants 
could be both uptitrated based on reaching glycaemic thresholds and down-
titrated if a randomised medication was poorly tolerated. Adherence was not 
fully captured for participants in ADOPT, and poor adherence may have 
attenuated the associations observed in this study, as poor adherence is likely 
to be associated with both lesser drug response and increased side-effects. 
Consideration of adherence will be especially important if similar studies are 
conducted using routine clinical data, where adherence is likely to be much 
lower than in clinical trials. 
 
 
Implications for a precision medicine approach to type 2 diabetes therapy 
Our findings for the different drugs have implications for any future precision 
medicine approach to type 2 diabetes therapy. Greater metformin drug 
response was not associated with an increased risk of gastro-intestinal side-
effects and this suggests great potential to target therapy if individuals likely to 
have greater drug response can be robustly identified.(19) However, targeting 
sulfonylureas and thiazolidinediones to individuals may be difficult as good 
responders are likely to be at increased risk of, respectively, hypoglycaemia and 
oedema. Our findings highlight the vital importance of considering both 
differential drug response and risk of side-effects in precision medicine studies, 
and this has been overlooked in previous work.(20, 21) 
Our findings do not however preclude a precision medicine approach for 
sulfonylureas and thiazolidinediones. Identification of characteristics associated 
with either, but not both, improved drug response and lower risk of side-effects 
may allow the targeting of these therapies. Furthermore, decisions on therapy 
should ultimately be informed by absolute rather than relative risks of benefit or 
harm.(1) For example, if people likely to respond well to a thiazolidinedione can 
be identified then a thiazolidinedione may still be an appropriate option for 
people whose absolute risk of developing a side-effect is sufficiently low. 
 
Comparison with other studies  
To our knowledge this is the evaluation of the association between HbA1c 
response and risk of side-effects for any of the three drugs, except for 
hypoglycaemia with sulfonylureas. Our results for sulfonylureas are consistent 
with previous observational studies that have examined the association 
between hypoglycaemia and achieved on-therapy HbA1c (rather than HbA1c 
response).(22, 23) In the ACCORD trial, participants with greatest HbA1c 
response at 4 months had a reduced rather than increased risk of 
hypoglycaemia, although this can be explained by the fact that in ACCORD the 
participants with least initial response were more likely to be on Insulin, the 
therapy with by far the strongest association with hypoglycaemia.(24)   
In this study we found an unexpected association between greater response to 
TZD therapy and increased risk of hypoglycaemia, but no evidence of an 
association with metformin response, which would have indicated a positive 
association between increased drug response and increased risk of 
hypoglycaemia was a more general characteristic of glucose-lowering therapy. 
This is an interesting finding and one for which there is not a clear biological 
explanation, and it would be of interest to examine whether the TZD association 
can be replicated in other datasets. The association between oedema and 
HbA1c response with thiazolidinediones is not unexpected as the mechanisms 
underlying both glucose-lowering and fluid retention are both thought to relate to 
PPARy stimulation.(25) With metformin there is no clear biological reason for 
the association between greater HbA1c response and a lower risk of gastro-
intestinal events. One possible explanation is decreased drug adherence in 
people experiencing mild gastro-intestinal symptoms prior to the event being 
recorded.  
Future work 
There is great potential to apply joint modelling to evaluate the association 
between drug response and risk of side-effects for the other drug options in type 
2 diabetes and to study drug therapy in other diseases. Our findings also 
suggest a potential application of joint modelling as an efficient tool for 
understanding the risk-benefit trade-off at the individual-level in drug 
development.(26) For precision medicine, the joint models used in this study 
could be extended to explore clinical features and biomarkers associated with 
drug response, risk of side-effects, or both.(27, 28) Alternative model 
specifications, such as evaluation of the effect of HbA1c response slope,(6) the 
weighting of cumulative HbA1c effects by recency,(15) the incorporation of 
multiple longitudinal biomarkers,(29) or incorporation of time-varying drug 
effects, may provide further insight into the nature of associations between 
response and side-effects. Similarly, incorporation of robust dose adjustment 
within the joint modelling framework, for example testing weighted cumulative 
drug associations,(30, 31) could allow much greater understanding of the 
impact of different levels of drug exposure on both response and adverse 
events. These are areas of current methodological development; a general 
mathematical presentation of joint modelling for simultaneously evaluating risks 
and benefits of medication would be a useful next step.            
 
Conclusions 
Joint modelling is a useful and efficient method to evaluate associations 
between continuous drug response and time to side-effects. Our study suggests 
the potential for application of joint modelling in both drug development and 
precision medicine research to evaluate the benefits and risks of medications. 
In type 2 diabetes, any future precision approach to sulfonylurea and 
thiazolidinedione therapy should consider the likely increased risk of 
respectively, hypoglycaemia and oedema, if targeting these therapies at people 
likely to have the greatest drug response. 
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Supplementary Material 
Supplementary table 1: Participant baseline characteristics for all 
drug:side-effect cohorts (Models 1-3). Data are mean (SD) unless stated. 
  MFN:GI SU:HYPO TZD:OEDEMA TZD:FRAC 
No. of participants 1206 1052 1198 1311 
Baseline HbA1c (%) 7.3 (0.9) 7.3 (0.9) 7.3 (0.9) 7.3 (0.9) 
Age at therapy (years) 57 (10) 57 (10) 56 (10) 56 (10) 
Sex (% male) 61% 60% 56% 55% 
Duration diabetes (years) 1.0 (1.0) 1.0 (1.0) 1.0 (0.9) 1.0 (1.0) 
BMI (kg/m2) 32 (6) 32 (6) 31 (6) 31 (6) 
 
 
 
Supplementary table 2: Patient outcomes and study follow-up for all 
drug:side-effect cohorts (Models 1-3).  
  No. of participants 
No. of events 
(%) 
Mean (SD) 
study follow-
up 
Gastro-intestinal    
MFN 1200 440 (37%) 2.8 (1.7) 
SU 1206 281 (23%) 2.8 (1.7) 
TZD 1252 293 (23%) 3.1 (1.6) 
Hypoglycaemia    
MFN 1286 119 (9%) 3.3 (1.6) 
SU 1052 270 (26%) 2.6 (1.7) 
TZD 1281 104 (8%) 3.3 (1.6) 
Oedema    
MFN 1248 78 (6%) 3.4 (1.6) 
SU 1198 91 (8%) 3.5 (1.6) 
TZD 1241 164 (13%) 3.3 (1.6) 
Fracture    
MFN 1320 53 (4%) 3.4 (1.6) 
SU 1320 53 (4%) 3.4 (1.6) 
TZD 1311 88 (7%) 3.4 (1.6) 
 
  
Supplementary table 3: Hazard ratios for the association between HbA1c 
response and risk of gastrointestinal side-effects of all, moderate/severe 
and severe intensity (Models 1-3). Hazard ratios (95% Confidence Intervals) 
represent the increase in risk of a GI side-effect for a 1% greater absolute 
HbA1c response. A hazard ratio greater than 1 indicates an increased risk of a 
GI side-effect with greater HbA1c response. 
 
 
 
Model 1: JMcv Model 2: JMcum Model 3: LOCF 
 MFN 
All 0.82 (0.67, 1.01), P=0.06 0.90 (0.81, 1.00), P=0.06 0.85 (0.74, 0.96), P=0.01 
Moderate/Severe 0.73 (0.56, 0.95), P=0.02 0.89 (0.77, 1.03), P=0.10 0.76 (0.65, 0.89), P<0.001 
Severe 1.28 (0.60, 2.74), P=0.53 1.04 (0.74, 1.48), P=0.80 0.98 (0.69, 1.40), P=0.91 
                                                                  SU 
All 0.88 (0.69, 1.11), P=0.28 1.03 (0.92, 1.17), P=0.58 0.90 (0.77, 1.05), P=0.19 
Moderate/Severe 0.85 (0.62, 1.17), P=0.32 0.91 (0.78, 1.07), P=0.25 0.91 (0.73, 1.14), P=0.43 
Severe 1.07 (0.51, 2.22), P=0.87 0.96 (0.69, 1.34), P=0.81 0.87 (0.55, 1.36), P=0.54 
 TZD 
All 1.21 (0.94, 1.55), P=0.13 1.05 (0.93, 1.18), P=0.44 1.04 (0.87, 1.26), P=0.65 
Moderate/Severe 1.16 (0.75, 1.31), P=0.38 1.06 (0.90, 1.24), P=0.51 0.99 (0.75, 1.31), P=0.95 
Severe 1.15 (0.53, 2.52), P=0.72 1.02 (0.73, 1.43), P=0.90 1.13 (0.67, 1.13), P=0.64 
 
  
Supplementary table 4: Number of participants and side effect events for 
Model 4: 6 month response. Participants were included if they had a valid 
baseline HbA1c and a valid on-therapy HbA1c at 6 months, and had no record 
of the side effect of interest prior to the 6 month HbA1c. 
 
Side-effect No. of patients (No. of events) 
 MFN SU TZD 
Gastro-intestinal 1025 (329) 1057 (212) 1114 (238) 
Hypoglycaemia 1149 (78) 879 (162) 1156 (79) 
Oedema 1145 (68) 1094 (73) 1129 (144) 
Fracture 1210 (38) 1167 (34) 1200 (80) 
 
Supplementary table 5: Hazard ratios for the association between HbA1c response and risk of side-effects for Model 4: 6m 
Response. Hazard ratios represent the increase in risk of a side-effect for a 1% greater absolute HbA1c response at 6 months. A hazard 
ratio greater than 1 indicates an increased risk of a side-effect with greater HbA1c response. 
 
  Gastrointestinal Hypoglycaemia Oedema Fracture 
MFN 0.74 (0.60-0.91), p<0.01 1.21 (0.78-1.88), p=0.38 1.28 (2.11-2.93), p=1.29 0.82 (0.43-1.57), p=0.55 
SU 0.86 (0.71-1.06), p=0.16 1.04 (0.79-1.35), p=0.79 0.94 (0.65-1.36), p=0.75 0.94 (0.55-1.63), p=0.84 
TZD 1.24 (0.97-1.57), p=0.08 1.01 (0.67-1.53), p=0.95 1.06 (0.78-1.43), p=0.72 1.20 (0.79-1.80), p=0.39 
 
 
  
Supplementary Table 6: Hazard ratios for the association between HbA1c response and risk of side-effects, adjusted for drug 
dose as a time-varying covariate (Models 1-3). Hazard ratios (95% Confidence Intervals) represent the increase in risk of a side-effect 
for a 1% greater absolute HbA1c response. A hazard ratio greater than 1 indicates an increased risk of a side-effect with greater HbA1c 
response. Bold = p<0.05. 
 
Side-effect Model 1: JMcv Model 2: JMcum Model 3: LOCF 
 MFN 
Gastrointestinal 0.83 (0.67-1.02), p=0.08 0.93 (0.83-1.04), p=0.19 0.87 (0.76-0.99), p=0.04 
Hypoglycaemia 0.90 (0.56-1.45), p=0.66 0.94 (0.70-1.25), p=0.65 1.21 (0.90-1.64), p=0.21 
Oedema 1.05 (0.63-1.76), p=0.85 1.17 (0.94-1.46), p=0.17 1.04 (0.71-1.51), p=0.85 
Fracture 0.79 (0.45-1.38), p=0.35 0.95 (0.74-1.22), p=0.40 0.99 (0.69-1.40), p=0.94 
 SU 
Gastrointestinal 0.98 (0.76-1.26), p=0.86 1.00 (0.88-1.14), p=0.97 0.96 (0.82-1.14), p=0.67 
Hypoglycaemia 1.48 (1.07-2.06), p=0.02 1.22 (1.04-1.44), p=0.01 1.46 (1.15-1.86), p<0.01 
Oedema 1.54 (0.96-1.54), p=0.07 1.26 (1.01-1.56), p=0.04 0.92 (0.71-1.20), p=0.53 
Fracture 1.05 (0.63-1.76), p=0.54 1.17 (0.94-1.46), p=0.17 1.09 (0.67-1.77), p=0.73 
 TZD 
Gastrointestinal 1.11 (0.86-1.44), p=0.42 1.06 (0.94-1.19), p=0.37 1.00 (0.83-1.20), p=0.99 
Hypoglycaemia 1.94 (1.22-3.10), p<0.01 1.68 (1.37-2.07), p<0.01 1.53 (1.03-2.29), p=0.04 
Oedema 1.47 (1.05-2.07), p=0.02 1.26 (1.11-1.43), p<0.001 1.03 (0.81-1.31), p=0.82 
Fracture 1.00 (0.65-1.55), p=0.99 1.17 (0.99-1.39), p=0.06 0.99 (0.68-1.44), p=0.96 
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Abstract 
Background 
Recent research using data-driven cluster analysis has proposed five 
subgroups of diabetes with differences in diabetes progression and risk of 
complications.  We aimed to compare the clinical utility of this subgroup-based 
approach for predicting patient outcomes with an alternative strategy of 
developing models for each outcome using simple patient characteristics. 
 
Methods 
We identified clusters in the ADOPT (n=4,351) trial cohort using the cluster 
analysis reported by Ahlqvist and colleagues (Lancet Diabetes Endocrinology 
2018;6:361-69). Differences between clusters in glycaemic and renal 
progression were evaluated, and contrasted with stratification using simple 
continuous clinical features (respectively, age at diagnosis and baseline renal 
function). We tested the performance of a strategy of selecting glucose-lowering 
therapy using clusters with one combining simple clinical features (sex, BMI, 
age at diagnosis, baseline HbA1c) in an independent trial (RECORD (n=4,447)).   
 
Findings 
Clusters identified in trial data were similar to those described in the original 
study. Clusters showed differences in glycaemic progression, but a model with 
age at diagnosis alone explained a similar amount of variation in progression. 
We found differences in CKD incidence between clusters however baseline 
eGFR was a better predictor of time to CKD. Clusters differed in glycaemic 
response, with a particular benefit for cluster 3 (insulin-resistant) with 
thiazolidinediones and cluster 5 (older) with sulfonylureas. However simple 
clinical features outperformed clusters to select therapy for individual patients. 
 
Interpretation 
The proposed data-driven clusters differ in diabetes progression and treatment 
response, but models based on simple continuous clinical features are more 
useful to stratify patients. This suggests precision medicine in type 2 diabetes is 
likely to have most clinical utility if based on an approach of using specific 
phenotypic measures to predict specific outcomes, rather than assigning 
individuals into subgroups. 
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Introduction 
Type 2 diabetes is a heterogeneous multifactorial condition, comprising 90-95% 
of all diabetes and affecting over 400 million people worldwide. There is 
currently great interest in better characterising the heterogeneity in type 2 
diabetes, and in exploiting this heterogeneity to improve care and outcomes for 
individuals with type 2 diabetes.(1-3)  
In a recent study, Ahlqvist and colleagues identified five replicable clusters of 
individuals with diabetes in Scandinavian registry data.(4) The smallest cluster 
was defined by the presence of glutamic acid decarboxylase (GAD) 
autoantibody positivity, regardless of other characteristics (Cluster 1: severe 
autoimmune diabetes (SAID)). Four ‘type 2’  like clusters were then 
characterised by the absence of GAD positivity and varying degrees of 
differences in age at diagnosis, and baseline measures of BMI, HbA1c, and 
HOMA2 measured insulin resistance and beta-cell function. The four ‘type 2’ 
clusters were named as follows; Cluster 2: severe insulin deficient diabetes 
(SIDD); Cluster 3: severe insulin resistant diabetes (SIRD); Cluster 4: mild 
obesity-related diabetes (MOD); Cluster 5: mild age-related diabetes (MARD). 
Ahlqvist and colleagues then showed potentially clinically important differences 
in disease progression and risk of complications between the clusters in 
observational follow-up, most notably a striking increase in the risk of diabetic 
kidney disease in the cluster characterised by insulin resistance (Cluster 3: 
SIRD).  
The key question for any subgroup analysis is its clinical utility, and in particular 
whether the proposed subgroups differ in response to therapy which could help 
inform treatment strategies.(2) Ahlqvist and colleagues suggested but did not 
demonstrate that the clusters could be useful to guide choice of therapy.(5) To 
date the only stratified approaches in type 2 diabetes showing large differences 
in response between treatments have used subgroups defined by routine 
clinical measures such as sex and BMI.(6)  A further key question, raised by 
van Smeden and colleagues in response to the original study, is whether 
assigning individuals to clusters has greater clinical utility for predicting 
outcomes than an approach that combines continuous clinical features to 
predict outcomes for individual patients.(7) 
We aimed to establish the clinical utility of the clusters by analysing two large 
existing trial datasets of individuals randomised to metformin, sulfonylurea and 
thiazolidinediones therapy, ADOPT and RECORD.(8, 9) In contrast to the 
observational follow-up in the original study of Scandinavian registry data, these 
trial datasets provided protocol-driven, randomised follow-up to evaluate clinical 
outcomes and differences in response to therapy. We compared the utility of the 
data-driven clusters with simpler approaches based on routine clinical 
measures available in any diabetes clinic. 
Methods 
Study population 
The primary study population comprised newly diagnosed, drug-naïve, 
individuals with type 2 diabetes participating in the ADOPT trial of glycaemic 
durability, randomised to metformin, sulfonylurea (glibenclamide) or 
thiazolidinedione (rosiglitazone) monotherapy up to five years (n=4,351).(8) 
Eligibility criteria at screening included: Age 30-75 years, fasting plasma 
glucose 7-13 mmol/l, no evidence of renal impairment (serum creatinine >114 
μmol/l for males or >106 μmol/l for females). As a replication dataset we used 
the RECORD study (n=4,447), a cardiovascular outcomes trial in individuals 
with established type 2 diabetes (mean duration of diabetes 7 years) initiating 
the same drug classes as ADOPT but as dual second-line therapy, for up to six-
years.(9) Sulfonylurea type was based on local practice (glibenclamide[18%], 
gliclazide[30%], or glimepiride[52%]), rosiglitazone was the thiazolidinedione 
used. Eligibility criteria included: Age 40-75 years, BMI >25.0 kg/m², HbA1c 
>7.0% and ≤9.0%, and no evidence of renal impairment (serum creatinine >130 
μmol/l). 
We followed individuals in both trials from randomisation until the earliest of: the 
primary outcome of the original trial; censor date, five years, or the occurrence 
of an outcome of interest. Full individual level trial data were accessed through 
Clinical Trial Data Transparency Portal (Proposal 930). 
Measurements 
We calculated HOMA2 measures of insulin resistance and beta-cell function 
using fasting C-peptide and fasting-glucose measures using the HOMA 2 
calculator.(10) In ADOPT GAD antibody positivity (yes or no) was measured 
using a commercially available radioimmunoassay.(11) In RECORD all required 
measures except GAD were measured at baseline, we calculated HOMA2 
measures using fasting insulin as fasting C-peptide was not available. Sex, age 
at diagnosis, baseline BMI and baseline HbA1c comprised the other measures 
required for cluster analysis.  
Definitions of study outcomes 
Glycaemic progression 
Glycaemic progression was defined as the change in HbA1c from one year up to 
five years (HbA1c at time t – HbA1c at one year), thus allowing for an initial 
period of treatment response up to one year. 
Kidney disease 
Chronic kidney disease (CKD) was defined as progression from normal GFR 
(eGFR ≥60 ml/min per 1.73m²) to confirmed CKD Stage 3 (two consecutive 
measures of eGFR <60 ml/min per 1.73m²). eGFR was calculated using CKD-
EPI; as a sensitivity analysis eGFR was also calculated using MDRD.(12) 
Measures of renal function were recorded at baseline, six months and annually. 
If progression was confirmed, the first of the two study visits was used to define 
CKD onset. Albuminuria was defined as progression from normal urinary 
albumin to creatinine ratio (UACR) (UACR <30 mg/g) to either microalbuminuria 
(UACR 30-300 mg/g) or macroalbuminuria (UACR ≥300 mg/g). Individuals with 
eGFR <60 and UACR ≥30 at their baseline visit were excluded from, 
respectively, the analysis of CKD and albuminuria outcomes.  
Glycaemic response 
HbA1c was evaluated as achieved HbA1c and as cumulative HbA1c reduction at 
three years as measured by area-under-the-curve (3 year AUC HbA1c). AUC 
HbA1c is equivalent to the time-updated HbA1c measure used in the UK 
Prospective Diabetes Study outcomes model.(13) Three years was chosen as 
the time point at which average AUC HbA1c was approximately equal between 
the three drugs.(8) Other time points will tend to favour a specific therapy; early 
time points will favour sulfonylureas as these agents have greater short-term 
response, whilst later time points favour thiazolidinediones which have greater 
glycaemic durability.(8) 
Statistical analysis 
Cluster analysis 
In ADOPT, we repeated the clustering approach of Ahlqvist and colleagues.(4) 
Males and females were clustered separately then pooled, continuous 
measures were mean centred and standardised, and continuous measures >5 
standard deviations from the mean were excluded. K-means clustering 
specifying four clusters was applied to the GAD-negative subset of individuals 
as K-means clustering does not incorporate binary variables; all GAD-positive 
individuals were manually assigned to a separate cluster.(4) The same R 
command (kmeansrun), number of runs (100) and measure of cluster stability 
(Jaccard coefficient >0.75 after 2000 bootstraps) were applied.(14) Once 
clusters were defined we assigned the same cluster names as in the original 
study, based on the distribution of cluster characteristics. In RECORD, we 1) 
assigned each individual to their ADOPT-derived cluster based on their 
Euclidean distance from each cluster centre; 2) repeated the cluster analysis to 
derive RECORD-specific clusters. As GAD was not available, all individuals in 
RECORD were assumed to be GAD-negative. 
Glycaemic progression 
In both trials, mean HbA1c trajectories from randomisation up to five years for 
each cluster were first estimated using a repeated-measures mixed-effects 
model, including fixed effects for study visit, assigned cluster, and a study visit 
by cluster interaction. Patient-level random effects and an unstructured 
covariance matrix were specified for this and subsequent mixed-effects models. 
All individuals within a trial were pooled, regardless of randomised therapy. To 
estimate glycaemic progression by cluster the same model was then fitted but 
with HbA1c change from one year as the outcome. We estimated the mean 
annual rate of glycaemic progression for each cluster by updating the cluster 
model to replace study visit with time as a linear covariate. Mean HbA1c by age 
was estimated using the same model but a linear term for continuous age at 
diagnosis replacing the clusters. For each model we estimated the proportion of 
variance explained (R²) by the fixed effects, the AIC, and the adequacy 
index.(15, 16) 
Kidney disease 
We compared the cumulative incidence of CKD by cluster, using Kaplan-Meier 
plots and unadjusted and baseline eGFR (a continuous linear term) adjusted 
Cox proportional hazard models with cluster as a categorical variable. We 
estimated R² and the discrimination ability (Harrell’s C-index) of the unadjusted 
cluster Cox model, compared with a Cox model with continuous baseline eGFR 
as a linear term.(16) We repeated the same analysis for time to a 30% decline 
in eGFR, and for time to albuminuria with and without adjustment for baseline 
UACR as a continuous linear term. We also compared continuous relative 
changes from baseline in eGFR and UACR progression over 0-5 years by 
cluster using a mixed-effects models with fixed effects for study visit, cluster, 
and study visit by cluster interaction. 
Glycaemic response 
We first evaluated whether HbA1c response to the three drugs differed across 
the clusters in ADOPT. Average HbA1c trajectories by drug were estimated up 
to three years for each cluster separately, using repeated-measures mixed-
effects models with fixed effects for study visit, drug, visit by drug interaction 
and visit by baseline HbA1c interaction. 3 year AUC HbA1c was estimated for 
each drug in each cluster as the integral of the area under the mean HbA1c 
trajectory using the trapezoidal rule. 
Treatment selection based on HbA1c – are clusters or clinical features 
more useful to guide therapy? 
We evaluated whether clusters were more useful than simple clinical features to 
select a drug for individual patients based on predicted 3 year AUC HbA1c. 
Models to predict HbA1c were developed in ADOPT using two strategies: A) 
using the clusters and B) using clinical features. For the clusters strategy we 
simply estimated HbA1c response for each drug at the cluster level and applied 
this to all individuals within the cluster. This strategy treats individuals within a 
cluster as homogenous for treatment response to a particular drug. For the 
clinical features strategy we combined sex and linear terms for age at 
diagnosis, baseline BMI and baseline HbA1c (the 4 routine clinical features 
informing the clusters) in a multivariable model to estimate HbA1c response 
specific to each individual for each drug. The benefit of using each strategy 
developed in ADOPT to select treatment for individuals was then tested in an 
external trial population: RECORD. 
1) Model development - ADOPT 
Strategy A) clusters model: 3 year AUC HbA1c for each drug was estimated at 
cluster level as detailed in the first step (Statistical analysis: Glycaemic 
response). Strategy B) clinical features model: 3 year AUC HbA1c, as defined 
above, was estimated for each individual based on their precise clinical 
characteristics, using multivariable repeated-measures mixed-effects models for 
each drug. Each model had HbA1c up to 3 years as the outcome with age at 
diagnosis, BMI, baseline HbA1c and study visit by baseline HbA1c interaction as 
continuous linear terms, and study visit and sex as fixed effects. Model 
performance for each strategy was assessed using R².  
2) Assessment of the treatment selection strategy in independent data – 
RECORD 
The purpose of a treatment selection model is to select the most effective 
therapies for individual patients, and therefore improve outcome at a population 
level, rather than to predict drug response accurately. This means the true test 
of a treatment selection model is whether it can robustly identify individuals 
likely to benefit from particular therapies.(17) Standard model performance 
metrics test the ability of a model to predict the outcome, and are therefore of 
limited use in this context.(17, 18) 
We therefore applied the following steps to test the effectiveness of each 
treatment selection strategy. For each individual in RECORD, we applied the 
models developed in ADOPT to obtain estimates of 3 year AUC HbA1c on each 
drug. Under Strategy A) these predictions were according to the individual’s 
assigned cluster (the same for all individuals within a cluster). Under Strategy B) 
predictions were at the individual level estimated from precise clinical features. 
For each strategy, we then applied a simple decision rule to assign individuals 
into two groups, one ‘concordant’ and one ‘discordant’. Discordant individuals 
were those randomised to a drug with a predicted 3 mmol/mol higher 3 year 
AUC HbA1c (i.e. less improvement in HbA1c) than the drug predicted to be their 
best drug; all other individuals were defined as concordant.(19) The 
effectiveness of each treatment selection strategy was determined by the 
difference in 3 year AUC HbA1c between the concordant and discordant groups. 
3 year AUC HbA1c by concordant/discordant group was estimated as previously 
described from a mixed-effects model with study visit, concordant/discordant 
group, baseline HbA1c, study visit by concordant/discordant group interaction 
and visit by baseline HbA1c interaction as fixed effects. We tested the sensitivity 
of results to the HbA1c threshold used to define concordance by repeating the 
analysis at HbA1c thresholds of 0, 1, 2 and 4 mmol/mol. All analyses were 
conducted using R version 3.4.1. 
Cardiovascular outcomes 
In RECORD we compared the time to the trial primary outcome, cardiovascular 
hospitalisation or cardiovascular death, by cluster using unadjusted and 
baseline age adjusted Cox proportional hazard models. 
Assignment of clusters in ADOPT based on cluster centre coordinates 
from the Swedish ANDIS cohort  
We assigned individuals in ADOPT to their ANDIS cluster based on their 
Euclidean distance from the cluster centres published by Ahlqvist and 
colleagues for the ANDIS cohort.(4) We then estimated glycaemic and renal 
progression and HbA1c response for each ANDIS-derived cluster, and 
compared model performance of the ADOPT defined clusters and ANDIS 
clusters. 
Role of the funding source 
The funders had no role in the study design, collection, analysis, data 
interpretation or writing of the report. The corresponding author had full access 
to all data and had final responsibility for the decision to submit for publication. 
Results 
We found the clusters identified by Ahlqvist and colleagues were reproducible in 
trial populations. 4,003 individuals in ADOPT had valid baseline measures for 
cluster assignment. Of these, 3,802 were in the intention-to-treat population and 
so were eligible for analysis of patient outcomes. We found a clear pattern of 
differences between clusters in clinical characteristics (Figure 1A, 
Supplementary Tables 1, 3, 4), and were able to assign the same cluster names 
as Ahlqvist and colleagues (Figure 1B). Clusters were reasonably stable 
(Jaccard mean range: males 0.76-0.82; females 0.69-0.82). Cluster-centre 
coordinates are shown in Supplementary Table 2. In RECORD 4,148 
individuals were eligible for cluster assignment (4,057 in intention-to-treat 
population). RECORD clusters were similar to the ADOPT clusters whether 
assigned from ADOPT or defined de-novo in RECORD (Supplementary Figure 
1). 
Average HbA1c trajectories by cluster from randomisation to five years are 
shown in the Supplementary Figure 2. Glycaemic progression from one year 
differed by cluster in ADOPT (Figure 2A), with a higher rate of progression in 
Clusters 1 (SAID), 2 (SIDD) and 4 (MOD). In RECORD only Cluster 4 (MOD) 
had a higher rate of progression (Supplementary Figure 3). However, in both 
trials older age at diagnosis was associated with a lower rate of glycaemic 
progression (mean annual difference in rate of HbA1c change per year increase 
in age at diagnosis: ADOPT -0.06 mmol/mol (95% confidence intervals -0.07 to 
-0.05; RECORD -0.05 mmol/mol (95%CI -0.06 to -0.04)) (Figure 2B, 
Supplementary Figure 3). Age at diagnosis explained a similar proportion of 
variation in progression to the clusters (ADOPT R²=0.09 age at diagnosis, 
R²=0.08 clusters; RECORD R²=0.05 age at diagnosis, R²=0.05 clusters). Other 
measures of model performance were also similar (Supplementary Table 5). 
Figure 1: Cluster distribution and cluster characteristics in ADOPT (n=4,003). SAID=severe autoimmune diabetes. 
SIDD=severe insulin-deficient diabetes. SIRD=severe insulin-resistant diabetes. MOD=mild obesity-related diabetes. 
MARD=mild age-related diabetes. HOMA2-B=homoeostatic model assessment 2 estimates of β-cell function. HOMA2-
IR=homoeostatic model assessment 2 estimates of insulin resistance. 
(A) Distribution of ADOPT participants according to k-means clustering  
 
(B) Distributions of HbA1c, BMI, age at diagnosis, HOMA2-B, and HOMA2-IR at baseline for each cluster 
Figure 2: Glycaemic progression by cluster in ADOPT from one to five 
years A) HbA1c change by cluster (n=3,016); B) HbA1c change by age at 
diagnosis (10th, 50th and 90% percentile of ADOPT participants) (n=3,016). Data 
are estimates from repeated measures mixed-effects models. 
 
We found differences in the incidence of CKD between clusters after excluding 
patients with pre-existing CKD; clusters 1, 3 and 5 had the highest incidence of 
CKD (Figure 3A, Supplementary Figure 4). However, there were differences 
between the clusters in baseline renal function: the clusters with the highest 
incidence of CKD had the lowest eGFR (Supplementary Table 4). After 
adjustment for baseline eGFR there was no evidence of a difference in time to 
CKD across the clusters (Table 1, Supplementary Table 6). Results were similar 
using MDRD calculated eGFR (Supplementary Table 7). In ADOPT baseline 
eGFR explained a greater proportion of variation (R²=0.18) and discrimination 
ability (C-statistic 0.90) than the clusters (R²=0.01, C-statistic=0.58); this was 
similar to results in RECORD (baseline eGFR R²=0.15, C-statistic 0.86; clusters 
R²=0.01, C-statistic=0.57). Relative change from baseline in eGFR and time to 
30% decline in eGFR did not differ by cluster (Supplementary Figures 5-6, 
Supplementary Table 8). 
There was no clear pattern of difference between clusters in baseline UACR 
(Supplementary Table 4), in incidence of albuminuria (Figure 3B, 
Supplementary Figure 4), or in relative change in UACR (Supplementary Figure 
7). After adjustment for baseline UACR time to albuminuria was shorter for 
cluster 3 (SIRD) versus cluster 2 (SIDD) in ADOPT, but not RECORD (Table 1, 
Supplementary Table 6). The clusters had no prediction and discrimination 
ability (ADOPT R²=0.00, C-statistic=0.52; RECORD R²=0.00, C-statistic=0.52), 
baseline UACR was a more useful measure (ADOPT R²=0.12, C-statistic=0.74; 
RECORD R²=0.10, C-statistic=0.73). 
  
Figure 3: Renal progression by cluster in ADOPT over five years.  
(A) Cumulative incidence of CKD Stage 3 (confirmed eGFR <60) in individuals 
with eGFR ≥60 at baseline (n=3,694)
 
(B) Cumulative incidence of albuminuria (UACR ≥30 mg/g) in individuals with 
UACR <30 mg/g at baseline (n=3,168). 
 
Patterns of HbA1c response to the different drugs differed across clusters in 
ADOPT (Figure 4, Supplementary Figure 8). There was an overall HbA1c benefit 
with thiazolidinedione therapy in cluster 3 (SIRD), and for sulfonylurea therapy 
in cluster 5 (MARD) (Table 2). However, the combined clinical features 
explained more variation in response than the clusters: R² was lower for 
Strategy A) clusters than Strategy B) clinical features (ADOPT R² clusters: 0.15 
for metformin, 0.20 sulfonylureas, 0.17 thiazolidinediones; R² clinical features: 
0.35 metformin, 0.33 sulfonylureas, 0.32 thiazolidinediones). 
Figure 4: Change in HbA1c by drug for clusters 2-5 in ADOPT over three 
years (n=3,607). Adjusted mean HbA1c over three years by drug. Grey shading 
shows 95% CIs. For cluster 1 (n=158) see Supplementary Figure 8. 
  
In the independent trial (RECORD) we found clinical features outperformed the 
clusters for treatment selection. In RECORD we tested the performance for 
treatment selection of the two strategies developed in ADOPT (Strategy A: 
selecting therapy based on predicted response to each drug at cluster level; 
Strategy B selecting therapy based on predicted response to each drug at the 
individual level based on precise clinical features (see Supplementary Table 9 
for ADOPT model coefficients for the clinical features)).  Each individual in each 
trial was assigned as concordant or discordant with the treatment selection rule 
under Strategy A) clusters and Strategy B) clinical features (Table 2, 
Supplementary Tables 10-13). 
In ADOPT, with both Strategy A) Clusters and Strategy B) clinical features, 
there was a greater overall HbA1c reduction in the concordant group compared 
with the discordant group (Figure 5A). In RECORD (validation dataset) there 
was a greater benefit in the concordant group with Strategy B) clinical features 
(Figure 5B) than Strategy A) clusters. Strategy B) clinical features outperformed 
the clusters at all HbA1c thresholds assessed to define concordant and 
discordant groups in RECORD (Supplementary Table 14). 
Figure 5: Change in HbA1c over three years in concordant and discordant 
treatment selection groups for i) clusters model and ii) clinical features model 
 
(A) ADOPT development cohort (n=3,785) 
 
 
(B) RECORD validation cohort (n=4,057) 
  
There was no evidence of differences between clusters in the risk of cardiovascular 
hospitalisation or death in RECORD after adjustment for age (Supplementary Figure 
9, Supplementary Table 15).  
Clusters assigned in ADOPT using the ANDIS cluster centre coordinates were 
broadly similar to those defined de-novo in ADOPT (Figure 1, Supplementary Figure 
10). 58% of individuals were assigned to the same cluster using both the ANDIS 
derived clusters and de-novo ADOPT clusters (Supplementary Table 16). 
Differences in outcomes by ANDIS-assigned cluster are shown in the Supplementary 
Figures 11-13. ADOPT clusters outperformed the ANDIS clusters for treatment 
response; model performance measures were similar for glycaemic and renal 
progression (Supplementary Table 17). 
Discussion 
We found the data-driven clusters of Ahlqvist and colleagues were reproducible in 
trial data. Clusters differed in glycaemic and renal progression but simple clinical 
factors features (respectively, age at diagnosis and baseline renal function) 
performed as well or better to predict progression. To our knowledge, for the first 
time we show differences by cluster in treatment response. However, clusters were 
markedly outperformed by models using simple clinical features for both the 
prediction of glucose-lowering response and for treatment selection. Overall the 
results suggest there will be greater clinical utility from modelling clinical features 
directly, rather than from using clinical features to place individuals into subgroups 
(Figure 6). 
 
Even though there were restricted entry criteria for both the ADOPT and RECORD 
trials, cluster analysis defined subgroups were very similar to those seen in non-
selective Scandinavian cohorts, and subsequently Chinese and US cohorts.(4, 20) 
This suggests that if the cluster analysis is repeated in the specified way in new 
datasets it will routinely produce similar clusters.  
 
A key strength of trial data over previous observational data is the availability of 
protocol driven follow-up, meaning we were able to conduct a systematic 
assessment and demonstrate the clusters do differ in disease progression. This is a 
considerable advantage over the previously described routine follow-up where 
therapy introduction is not protocol driven.(4) Independently of therapy, clusters 1 
(SAID), 2 (SIDD) and 4 (MOD) had an increased rate of glycaemic progression. 
Differences in the development of renal failure had previously been shown in 
observational follow-up, and we replicated a faster progression of renal disease in 
clusters 3 (SIRD) and 5 (MARD), although there was no evidence of a difference in 
renal progression after accounting for baseline renal function.  
 
We were able to establish that the clusters differ in response to different glucose-
lowering therapies. This was possible due to the randomised, systematic therapy 
given. We found a particular benefit for cluster 3 (SIRD) with thiazolidinediones, and 
for cluster 5 (MARD) with sulfonylureas.  
 
The fact that clusters are reproducible and can help predict progression and 
response to therapy is important. However a key question raised in response to the 
original article is whether it is more clinically useful to use clinical features to assign 
an individual to a subgroup and then treat in a way that is best for that subgroup, or 
to use clinical features to predict patient outcomes directly using outcome-specific 
models.(7) We found simple clinical features were similar or better than the clusters 
to stratify disease progression and to personalise therapy. A simple model 
incorporating just age at diagnosis was able to predict glycaemic progression as well 
as the clusters, having been identified as a key predictor of progression in recent 
observational analysis.(21) Similarly, baseline renal function explained differences 
between the clusters in risk of renal progression.  
 
For treatment response we found that models combining four simple clinical 
measures (age, sex, baseline HbA1c and BMI) explained more variation in response 
than the clusters. However, this gives little insight into which of the two approaches 
is more useful to select between treatment options for an individual patient.(17, 18) A 
more useful test in this context is to compare the population-level effect on glycaemic 
response of applying each approach to select treatment.(18) We were able to 
directly assess this, by comparing the two approaches developed in ADOPT in an 
independent trial dataset (RECORD). This was possible as some participants in 
RECORD were randomised to the drug estimated to be ‘best’ for them using the 
ADOPT models (concordant group) whilst the remainder were randomised to a not 
‘best’ drug (discordant group). The difference in HbA1c between the two groups 
provided a measure of the population-level effect of each treatment selection 
strategy. In RECORD we found a small benefit (1.8 mmol/mol over three years) of 
selecting therapy by cluster; in contrast there was a greater benefit (3.9 mmol/mol) 
selecting treatment using the clinical features model. These results suggest that 
attempts to personalise treatment in type 2 diabetes will have most clinical utility if 
based on the use of continuous phenotypic measures, rather than subgroup 
assignment. 
 
Strengths of this study include the use of data from two large, long-term, randomised 
trials, in which we were able to not only reproduce the clustering approach of 
Ahlqvist and colleagues, but to describe diabetes progression and treatment 
response in protocol-driven follow-up. Furthermore we were able to test treatment 
selection based on clusters compared to clinical features in an independent 
validation dataset. The treatment selection rule we applied was designed to test 
clinical utility in this study, rather than to maximise outcomes for the population or 
individuals. Approaches to evaluate treatment selection strategies are not well-
developed and are the subject of on-going methodological research.(17) A limitation 
of our study is the potential non-representativeness of participants due to the original 
trial exclusion criteria. Both ADOPT and RECORD had exclusion criteria based on 
blood glucose levels and age (and BMI in RECORD); these clinical variables 
informed the cluster analysis. Despite this we found that the clusters were 
reproducible, with a pattern of differences in phenotypic measures that closely 
matched those previously reported. Given the variables informing the cluster 
analysis are not independent and are likely to be similarly correlated in most people 
with diabetes, this reproducibility is not surprising,(7) although similarly to the original 
study we lacked data on non-white ethnicities (ADOPT was 88% Caucasian, 
RECORD 99%). Due to the design of the trials we were unable to evaluate some 
outcomes explored in the original study such as time to insulin, and we lacked power 
to evaluate other outcomes including development of end-stage renal disease. A 
further limitation was the therapy used in the trials; evaluation of heterogeneity in 
treatment response for the newer drug classes DPP4 inhibitors, SGLT2 inhibitors 
and GLP-receptor agonists would be of considerable interest. 
An important difference between this study and the original study by Ahlqvist and 
colleagues was in the analysis of renal progression. Whilst we excluded individuals 
with pre-existing kidney disease, in the Scandinavian population-based cohorts 
people with pre-existing kidney disease when diagnosed with diabetes were not 
excluded and the onset of renal dysfunction was set to the first time that an abnormal 
value was found on clinical testing post diabetes diagnosis. 
 
Precision medicine is successfully established in monogenic and neonatal diabetes, 
where it has been possible to define discrete etiological subtypes with differing 
genetic causes that have very different optimal treatment requirements.(22-24) A key 
difference from type 2 diabetes is that in these cases the subgroups have discrete 
and non-overlapping aetiologies and can be robustly defined by genetic sequencing. 
In contrast, the study of Ahlqvist and colleagues and other recent attempts to 
characterise the heterogeneity in type 2 diabetes have identified clusters with limited 
clinical utility as they are non-aetiological, overlapping, highly dependent on the 
variables used to classify them and cannot be robustly defined at an individual 
level.(4, 25) Even genetic susceptibility clusters, which do have the advantage of 
being fixed throughout life, have not led to the identification of discrete etiological 
diabetes subtypes, although they offer insight into mechanistic pathways underlying 
heterogeneity.(26)  
 
The known heterogeneity in type 2 diabetes, together with the differences we have 
observed in clinical outcomes, raises the possibility of a practical clinical application 
of precision medicine in type 2 diabetes in the near future. Our study supports the 
suggestion that the optimal approach to tailor management based on risk of 
progression and therapeutic response will be to use ‘precise’ continuous phenotypic 
measures to predict specific outcomes for individuals using multivariable models, 
rather than define subgroups and assume all individuals are homogenous within 
each subgroup.(7) In particular, individual clinical characteristics have been shown to 
have robust associations with response to specific type 2 diabetes drug options.(6, 
27-29) These studies raise the possibility that the relative glucose-lowering benefit of 
the different drugs might be identifiable by combining simple clinical measures in a 
model for treatment selection. This will require systematic assessment of 
associations between other patient features (including lifestyle factors, biomarkers 
and concomitant medications) beyond those assessed in this study. The advantage 
of such an approach is that the clinical features used are already part of routine 
clinical care. Similarly, further systematic assessment of associations between 
clinical patient features and glycaemic and renal progression will be required to 
determine whether individuals at high or low risk of progression can be robustly 
identified. 
 
The methodology we have applied in this study, harnessing existing individual-level 
trial data to test a precision medicine strategy developed in other data, offers an 
exciting, low-cost framework to evaluate novel precision medicine approaches 
without a prospective trial. Such trial datasets are increasingly available to 
researchers to answer secondary research questions.(30) The approach we used of 
a direct comparison of different approaches in an independent data set is a good 
model for defining their relative performance. When defining utility of models in future 
studies it will be important to interrogate multiple relevant outcomes as well as 
glycaemia, including cardiovascular outcomes, microvascular complications, and 
non-glycaemic effects of specific drugs including weight change and side-effects 
 
In conclusion, we have shown cluster-defined subgroups are reproducible and can 
help to define individuals that differ in the risk of diabetes progression and in 
glycaemic response to common therapeutic options. Our study demonstrates a 
‘prediction model’ approach combining phenotypic measures to predict specific 
outcomes for individual patients is likely to have greater clinical utility than subgroup 
assignment. Existing trial data offer an exciting opportunity to evaluate the potential 
of precision medicine approaches to improve clinical outcomes in type 2 diabetes. 
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Supplementary Material 
Cluster assignment and characteristics (ADOPT and RECORD) 
 
Supplementary Table 1: ADOPT cluster distributions, overall and by sex (n=4,003). SAID=severe autoimmune diabetes. 
SIDD=severe insulin-deficient diabetes. SIRD=severe insulin-resistant diabetes. MOD=mild obesity-related diabetes. MARD=mild 
age-related diabetes.  
 
 Male Female Overall 
Cluster N % N % N % 
1 SAID 94 4% 74 4% 168 4% 
2 SIDD 506 22% 302 18% 808 20% 
3 SIRD 448 19% 369 22% 817 20% 
4 MOD 411 18% 447 26% 858 21% 
5 MARD 844 37% 508 30% 1352 34% 
 
 
Supplementary Table 2: Cluster centre coordinates in ADOPT 
 Cluster HbA1c BMI Age at 
diagnosis 
HOMA2-B HOMA2-IR 
Females C2 (SIDD) 1.357582 -0.438702 0.209430 -0.873420 -0.508708 
 C3 (SIRD) -0.207560 0.801772 -0.048181 1.168571 1.276217 
 C4 (MOD) -0.283972 0.282755 -0.956176 -0.257172 -0.274304 
 C5 (MARD) -0.406427 -0.570389 0.751853 -0.103295 -0.383230 
 
Males C2 SIDD) 1.146754 -0.334983 -0.300259 -0.780702 -0.448964 
 C3 (SIRD) -0.419911 0.021167 0.587122 1.132740 0.960985 
 C4 (MOD) 0.102709 1.357982 -0.838457 0.480047 0.743829 
 C5 (MARD) -0.514633 -0.471697 0.276666 -0.366980 -0.603150 
  
Supplementary Table 3: ADOPT Cluster characteristics by sex (n=4,003). SAID=severe autoimmune diabetes. SIDD=severe 
insulin-deficient diabetes. SIRD=severe insulin-resistant diabetes. MOD=mild obesity-related diabetes. MARD=mild age-related 
diabetes. HOMA2-B=homoeostatic model assessment 2 estimates of β-cell function. HOMA2-IR=homoeostatic model assessment 
2 estimates of insulin resistance. 
A) Females 
 
Number of 
participants (%) 
HbA1c  
(mmol/mol) 
BMI 
kg/m2 
Age at diagnosis 
(years) 
HOMA2-B  
(%) 
HOMA2-IR  
(%) 
Cluster   Median IQR Median IQR Median IQR Median IQR Median IQR 
1 SAID 74 (4%) 59 50-65 33 28-38 59 51-64 63 46-87 2.4 1.5-3.4 
2 SIDD 302 (18%) 69 65-75 30 27-34 57 52-64 49 38-59 2.2 1.7-2.8 
3 SIRD 369 (22%) 55 49-61 39 35-43 55 49-62 102 87-125 4.3 3.8-5.0 
4 MOD 447 (26%) 54 50-58 35 31-40 46 41-50 67 54-79 2.6 2.1-3.1 
5 MARD 508 (30%) 53 49-57 30 27-33 64 58-68 70 58-83 2.5 1.9-3.0 
 
B) Males 
 
Number of 
participants (%) 
HbA1c  
(mmol/mol) 
BMI 
kg/m2 
Age at diagnosis 
(years) 
HOMA2-B  
(%) 
HOMA2-IR  
(%) 
Cluster   Median IQR Median IQR Median IQR Median IQR Median IQR 
1 SAID 94 (4%) 57 53-64 29 27-33 57 49-64 60 46-77 2.4 1.7-3.1 
2 SIDD 506 (22%) 67 63-73 29 27-32 53 46-60 49 38-59 2.3 1.8-2.8 
3 SIRD 448 (19%) 52 48-57 31 29-34 63 57-68 100 86-117 3.7 3.2-4.6 
4 MOD 411 (18%) 57 52-63 37 34-42 49 41-54 83 68-98 3.5 3.0-4.3 
5 MARD 844 (37%) 52 48-56 28 26-31 59 53-65 60 51-72 2.2 1.7-2.6 
 
 
Supplementary Table 4: Cluster characteristics for each trial population 
ADOPT (n=4,003). Median (interquartile range) unless stated. 
 1 SAID 2 SIDD 3 SIRD 4 MOD 5 MARD 
N. participants (%) 168 (4%) 808 (20%) 817 (20%) 858 (21%) 1352 (34%) 
HbA1c (mmol/mol) 58 (52-64) 67 (64-74) 53 (48-60) 55 (51-61) 53 (49-56) 
BMI (kg/m²) 30 (27-36) 29 (27-32) 34 (30-38) 36 (33-40) 29 (26-31) 
Age at diagnosis (years) 57 (49-64) 55 (48-61) 59 (53-66) 47 (41-52) 61 (55-66) 
HOMA2-B (%)* 61 (46-83) 49 (38-59) 101 (87-121) 74 (59-89) 64 (53-76) 
HOMA2-IR* 2.4 (1.6-3.3) 2.3 (1.8-2.8) 4.0 (3.4-4.7) 3.1 (2.4-3.7) 2.3 (1.8-2.7) 
Male sex (%)  94 (56%) 506 (63%)  448 (55%) 411 (48%)  844 (62%) 
Ethnicity (% White) 158 (94%) 745 (92%) 804 (98%) 801 (93%) 1327 (98%) 
Fasting glucose (mmol/l) 8.3 (7.6-9.3) 9.2 (8.4-10.2) 7.9 (7.2-8.7)  8.3 (7.5-9.2) 8.0 (7.4-8.6) 
Fasting insulin (pmol/L) 108 (70-150) 93 (72-129) 208 (150-280) 158 (114-215) 96 (72-126) 
Fasting C-peptide (nmol/L) 0.9 (0.6-1.3) 0.8 (0.7-1.0) 1.6 (1.4-1.8) 1.2 (1.0-1.4) 0.9 (0.7-1.1) 
eGFR (ml/min per 1.73m²)** 93 (82-103) 98 (87-106) 90 (77-100) 104 (96-112) 93 (82-100) 
eGFR <60 at baseline (%)** 4 (2%) 14 (2%) 41 (5%) 8 (1%) 44 (3%) 
Albuminuria (mg/g)*** 7 (4-16) 8 (4-17) 8 (4-18) 7 (4-19) 6 (4-13) 
Albuminuria ≥ 30 at baseline (%)*** 26 (16%) 126 (16%) 145 (18%) 154 (18%) 158 (12%) 
HDL (mmol/L) 1.2 (1.1-1.5) 1.2 (1.0-1.5) 1.1 (1.0-1.3) 1.1 (1.0-1.4) 1.3 (1.1-1.5) 
LDL (mmol/L) 3.0 (2.4-3.6) 3.3 (2.7-4.0 2.9 (2.4-3.6) 3.1 (2.5-3.7) 3.2 (2.6-3.8) 
ALT (U/L) 21 (16-31) 22 (17-31) 26 (19-36) 26 (18-37) 21 (16-29) 
 *Calculated with HOMA2 calculator using fasting glucose and fasting C-peptide 
** Calculated with CKD-EPI formula ***71 individuals with missing albuminuria at baseline 
 
RECORD (n=4,148; ADOPT-defined clusters). Median (interquartile range) 
unless stated. 
 1 SAID 2 SIDD 3 SIRD 4 MOD 5 MARD 
N. participants (%) NA 974 (23%) 803 (19%) 852 (21%) 1519 (37%) 
HbA1c (mmol/mol)  72 (68-75) 58 (55-64) 62 (57-66) 60 (55-63) 
BMI (kg/m²)  29 (27-32) 34 (31-37) 35 (31-37) 29 (27-31) 
Age at diagnosis (years)  50 (44-55) 54 (48-59) 44 (40-48) 56 (51-61) 
HOMA2-B (%)*  18 (13-24) 57 (45-74) 32 (23-42) 28 (20-36) 
HOMA2-IR*   1.1 (0.7-1.5) 2.4 (1.9-3.1) 1.4 (1.0-2.0) 1.0 (0.7-1.3) 
Diabetes duration (years)  7 (4-11) 5 (3-7) 6 (4-10) 5 (3-8) 
Male sex (%)  571 (59%) 361 (45%) 313 (37%) 898 (59%) 
Ethnicity (% White)  964 (99%) 795 (99%) 841 (99%) 1510 (99%) 
Fasting glucose (mmol/l)  11 (10-13) 9 (8-10) 10 (8-11) 9 (8-10) 
Fasting insulin (pmol/L)  48 (32-66) 114 (91-146) 67 (48-91) 45 (32-61) 
Fasting C-peptide (nmol/L)  NA NA NA NA 
eGFR (ml/min per 1.73m²)**  100 (91-106) 97 (88-105) 106 (99-112) 96 (87-102) 
eGFR <60 at baseline (%)**  13 (1%) 28 (3%) 9 (1%) 30 (2%) 
Albuminuria (mg/g)***  9 (5-25) 9 (5-23) 9 (5-24) 8 (4-17) 
Albuminuria ≥ 30 at baseline (%)***  190 (22%) 142 (20%) 149 (20%) 209 (16%) 
HDL (mmol/L)  1.2 (1.0-1.4) 1.1 (0.9-1.3) 1.2 (1.0-1.4) 1.2 (1.0-1.4) 
LDL (mmol/L)  3.4 (2.8-4.0) 3.2 (2.5-3.8) 3.2 (2.6-3.8) 3.3 (2.6-3.8) 
ALT (U/L)  25 (19-36) 29 (21-41) 26 (19-39) 23 (17-31) 
*Calculated with HOMA2 calculator using fasting glucose and fasting insulin as fasting C-peptide not 
available 
** Calculated with CKD-EPI formula, 2 individuals missing eGFR at baseline ***479 individuals with 
missing albuminuria at baseline  
Supplementary Figure 1: clusters characteristics in RECORD. Cluster distribution and 
cluster characteristics (n=4,148). RECORD participants assignment and distributions of 
baseline clinical characteristics according to k-means clustering (A) Clusters derived in ADOPT 
and assigned to RECORD participants (B) Clusters derived in RECORD and assigned to 
RECORD participants. 
SAID=severe autoimmune diabetes. SIDD=severe insulin-deficient diabetes. SIRD=severe 
insulin-resistant diabetes. MOD=mild obesity-related diabetes. MARD=mild age-related 
diabetes. HOMA2-B=homoeostatic model assessment 2 estimates of β-cell function. HOMA2-
IR=homoeostatic model assessment 2 estimates of insulin resistance. 
(A) ADOPT derived clusters 
  
 
(B) RECORD derived clusters 
 
 
 
 
 
 
 
 
  
Glycaemic progression 
 
Supplementary Figure 2: HbA1c over time from randomisation by cluster 
in ADOPT (n=3,802). 
   
 
Supplementary Figure 3: HbA1c in RECORD  
(A) HbA1c over time from randomisation by cluster (n=4,057);  
  
  
Supplementary Figure 3 (cont.): HbA1c in RECORD.  
(B) Glycaemic progression from 1 year by ADOPT derived cluster (n=3,586); 
(C) Glycaemic progression from 1 year by age at diagnosis (10th, 50th and 90% 
percentile of RECORD participants) (n=3,586). Data are estimates from 
repeated measures mixed effects models.  
 
 
Supplementary Table 5: Glycaemic progression model performance 
measures to compare model using clusters and model using age at 
diagnosis. A higher adequacy index suggests a better model (calculated as 
model LR x² / Combined model LR x²) 
 
A) ADOPT 
 
  R² AIC LR x² Adequacy Index 
Clusters 0.084 221404 1225 0.95 
Age at diagnosis 0.088 221318 1210 0.94 
Combined model (clusters + age at 
diagnosis) 0.093 221371 1292 1.00 
 
 
B) RECORD 
 
  R² AIC LR x² Adequacy Index 
Clusters 0.048 274658 1065 0.89 
Age at diagnosis 0.052 274624 1099 0.92 
Combined model (clusters + age at 
diagnosis) 0.055 274642 1196 1.00 
 
  
Renal progression 
 
Supplementary Figure 4: Renal progression by cluster in RECORD 
(clusters derived from ADOPT) 
(A) Cumulative incidence of CKD Stage 3 (confirmed eGFR <60) in individuals 
with eGFR ≥60 at baseline (n=4,066). eGFR calculated using CKD-EPI formula. 
 
(B) Cumulative incidence of albuminuria (UACR ≥30 mg/g) in individuals with 
UACR <30 mg/g at baseline (n=2,979).  
 
Supplementary Table 6: Risk of renal progression by cluster in RECORD 
(clusters derived from ADOPT) 
(A) Time to CKD Stage 3 (n=4,066). eGFR calculated using CKD-EPI formula. 
  
No. Person years at risk Events Hazard ratio (95% CI) 
        Unadjusted Adjusted* 
Time to CKD 
Cluster           
    C1 (SAID) NA NA NA NA NA 
    C2 (SIDD) 961 2551 17 1.00 (ref) 1.00 (ref) 
    C3 (SIRD) 775 2789 22 1.12 (0.60-2.11) 0.96 (0.51-1.81) 
    C4 (MOD) 842 2811 6 0.31 (0.12-0.78) 0.57 (0.22-1.45) 
    C5 (MARD) 1488 5658 55 1.37 (0.79-2.36) 1.16 (0.67-2.00) 
*Adjusted for baseline eGFR 
(B) Time to albuminuria (n=2,979) 
  
No. Person years at risk Events Hazard ratio (95% CI) 
        Unadjusted Adjusted* 
Time to albuminuria 
Cluster           
    C1 (SAID) NA NA NA NA NA 
    C2 (SIDD) 680 1679 103 1.00 (ref) 1.00 (ref) 
    C3 (SIRD) 580 1860 113 1.04 (0.80-1.36) 1.02 (0.78-1.34) 
    C4 (MOD) 605 1869 90 0.82 (0.62-1.09) 0.82 (0.62-1.09) 
    C5 (MARD) 1114 3906 188 0.85 (0.66-1.08) 0.92 (0.72-1.17) 
*Adjusted for baseline UACR 
  
Supplementary Table 7: Time to CKD Stage 3. eGFR calculated using MDRD 
formula. 
 (A) ADOPT (n=3,650) 
  
No. Person years at risk Events Hazard ratio (95% CI) 
        Unadjusted Adjusted* 
Time to CKD 
Cluster           
    C1 (SAID) 152 492 7 3.00 (1.16-7.72) 1.67 (0.64-4.32) 
    C2 (SIDD) 748 2235 11 1.00 (ref) 1.00 (ref) 
    C3 (SIRD) 729 2427 35 2.99 (1.53-5.92) 1.65 (0.84-3.26) 
    C4 (MOD) 799 2406 11 0.93 (0.40-2.14) 1.33 (0.57-3.06) 
    C5 (MARD) 1222 4325 41 2.00 (1.03-3.90) 1.52 (0.78-2.97) 
*Adjusted for baseline eGFR 
(B) RECORD (n=4,032) 
  
No. Person years at risk Events Hazard ratio (95% CI) 
        Unadjusted Adjusted* 
Time to albuminuria 
Cluster           
    C1 (SAID) NA NA NA NA NA 
    C2 (SIDD) 956 2528 20 1.00 (ref) 1.00 (ref) 
    C3 (SIRD) 769 2753 30 1.31 (0.74-2.31) 1.10 (0.91-1.94) 
    C4 (MOD) 838 2781 15 0.66 (0.34-1.28) 0.98 (0.50-1.91) 
    C5 (MARD) 1469 5570 74 1.58 (0.96-2.59) 1.41 (0.86-2.32) 
*Adjusted for baseline eGFR 
  
Supplementary Figure 5: Relative change in eGFR from baseline, by 
cluster. eGFR calculated using CKD-EPI formula. Estimates are from mixed 
effects models. 
A) ADOPT (n=3,694) 
 
B) RECORD (n=4,066) 
 
  
Supplementary Figure 6: Cumulative incidence of 30% relative change in 
eGFR from baseline, by cluster. eGFR calculated using CKD-EPI formula. 
A) ADOPT (n=3,694) 
 
B) RECORD (n=4,066) 
 
  
Supplementary Table 8: Risk of 30% relative change in eGFR from 
baseline by cluster. eGFR calculated using CKD-EPI formula. 
(A) ADOPT (n=3,694) 
  
No. Person years at risk Events Hazard ratio (95% CI) 
        Unadjusted Adjusted* 
Time to 30% relative change in eGFR 
Cluster           
    C1 (SAID) 155 508 7 0.88 (0.39-1.97) 0.78 (0.35-1.77) 
    C2 (SIDD) 758 2239 35 1.00 (ref) 1.00 (ref) 
    C3 (SIRD) 743 2452 51 1.33 (0.87-2.05) 1.16 (0.75-1.79) 
    C4 (MOD) 808 2387 34 0.92 (0.57-1.48) 1.05 (0.65-1.69) 
    C5 (MARD) 1230 4359 54 0.79 (0.51-1.20) 0.72 (0.47-1.10) 
*Adjusted for baseline eGFR 
(B) RECORD (n=4,066) 
  
No. Person years at risk Events Hazard ratio (95% CI) 
        Unadjusted Adjusted* 
Time to 30% relative change in eGFR 
Cluster           
    C1 (SAID) NA NA NA NA NA 
    C2 (SIDD) 961 2547 58 1.00 (ref) 1.00 (ref) 
    C3 (SIRD) 775 2771 57 0.83 (0.58-1.20) 0.78 (0.54-1.12) 
    C4 (MOD) 842 2773 40 0.59 (0.39-0.88) 0.74 (0.49-1.11) 
    C5 (MARD) 1488 5625 122 0.85 (0.62-1.16) 0.78 (0.57-1.07) 
*Adjusted for baseline eGFR 
Supplementary Figure 7: Relative change in urinary albumin to creatinine 
ratio from baseline, by cluster. Estimates are from mixed effects models with 
UACR modelled on log scale. 
A) ADOPT (n=3,168) 
 
  
B) RECORD (n=2,979) 
  
HbA1c response 
 
Supplementary Figure 8: Changes in HbA1c (ADOPT trial, n=3,785). 
Adjusted mean HbA1c over 3 years by drug for clusters 1-5 (repeated 
measures mixed model). Grey shading shows 95% CIs. 
 
 
Supplementary Table 9: Beta coefficients from mixed effects models for clinical features, 
by drug. For continuous features beta coefficients represent the change in HbA1c response for 
a 1-unit increase in the clinical feature. A negative coefficient indicates a higher value of the 
clinical feature is associated with greater reduction in HbA1c.  
 
 Metformin Sulfonylureas Thiazolidinediones 
Baseline HbA1c (time 0)* 0.69 (0.66;0.72) 0.59 (0.55;0.63) 0.69 (0.65;0.73) 
BMI -0.02 (-0.07;0.03) 0.03 (-0.02;0.09) -0.11 (-0.16;-0.06) 
Age at diagnosis 0.00 (-0.03;0.03) -0.02 (-0.05;0.01) -0.02 (-0.06;0.01) 
Sex: Male 0.53 (-0.07;1.13) -1.54 (-2.19;-0.89) 0.59 (-0.06;1.23) 
*Full baseline HbA1c:study visit interaction terms not reported for brevity.  
Treatment selection 
 
 
 
Supplementary Table 10 
 
ADOPT number of concordant individuals, by cluster, for treatment 
selection at 3 years based on Strategy A) treatment selection based on 
clusters 
 
 
 
Discordant Concordant 
Cluster   
    C1 (SAID) 
93 65 
    C2 (SIDD) 257 502 
    C3 (SIRD) 
510 265 
    C4 (MOD) 
272 539 
    C5 (MARD) 838 424 
 
 
 
 
Supplementary Table 11 
 
ADOPT number (%) of concordant individuals, by drug at 3 years, for 
 
Strategy A) treatment selection based on clusters 
 
 Discordant Concordant 
Overall 1970 (52%) 1795 (48%) 
By randomised drug:   
    Metformin 702 (55%) 569 (45%) 
    Sulfonylureas 555 (45%) 672 (55%) 
    Thiazolidinedione 713 (56%) 554 (44%) 
 
 
Strategy B) treatment selection based on clinical features 
 
 Discordant Concordant 
Overall 1227 (33%) 2538 (67%) 
By randomised drug:     
    Metformin 225 (18%) 1046 (82%) 
    Sulfonylureas 455 (37%) 772 (63%) 
    Thiazolidinedione 547 (43%) 720 (57%) 
 
 
  
Supplementary Table 12 
 
RECORD number of concordant individuals, by cluster, for treatment 
selection at 3 years based on Strategy A) treatment selection based on 
clusters 
 Discordant Concordant 
Cluster   
    C1 (SAID) - - 
    C2 (SIDD) 455 493 
    C3 (SIRD) 406 386 
    C4 (MOD) 239 594 
    C5 (MARD) 1121 363 
 
 
 
Supplementary Table 13 
 
RECORD number (%) of concordant individuals, by drug at 3 years, for 
a) treatment selection based on clusters 
 
Strategy A) treatment selection based on clusters 
 
 Discordant Concordant 
Overall 2221 (55%) 1836 (45%) 
By randomised drug:   
    Metformin 540 (54%) 463 (46%) 
    Sulfonylureas 469 (46%) 546 (54%) 
    Thiazolidinedione 1212 (59%) 827 (41%) 
 
 
Strategy B) treatment selection based on clinical features 
 
 Discordant Concordant 
Overall 1117 (28%) 2940 (72%) 
By randomised drug:   
    Metformin 23 (2%) 980 (98%) 
    Sulfonylureas 494 (49%) 521 (51%) 
    Thiazolidinedione 600 (29%) 1439 (71%) 
 
  
Supplementary Table 14: Cumulative HbA1c reduction at 3 years in 
concordant and discordant treatment selection groups using different 
HbA1c thresholds to define concordant/discordant groups, for clusters 
model and clinical features model (RECORD n=4,057) 
 
 
HbA1c threshold 
(mmol/mol 
Clusters 3 Year AUC HbA1c Continuous features 3 Year AUC HbA1c 
 Concordant Discordant Concordant Discordant 
0 -18.0 (-19.6;-16.4) -15.0 (-16.1;-14.0) -18.3 (-20.0;-16.7) -14.8 (-15.9;-13.8) 
1 -17.0 (-18.4;-15.6) -15.2 (-16.3;-14.0) -18.3 (-19.6;-16.9) -13.9 (-15.1;-12.7) 
2 -17.0 (-18.4;-15.6) -15.2 (-16.3;-14.0) -17.6 (-18.7; -16.5) -13.2 (-14.7;-11.8) 
3 -16.9 (-18.2;-15.6) -15.1 (-16.3;-13.9) -17.0 (-18.0;-15.9) -13.1 (-14.9;-11.4) 
4 -16.9 (-18.1;-15.7) -14.9 (-16.2;-13.6) -16.6 (-17.5;-15.6) -13.4 (-15.4;-11.4) 
 
  
Cardiovascular outcomes (RECORD trial) 
 
Supplementary Figure 9: Cumulative incidence of cardiovascular 
hospitalisation or death, by ADOPT-derived cluster. 
RECORD (n=4,057) 
 
 
Supplementary Table 15: Risk of cardiovascular hospitalisation or death 
by cluster in RECORD (clusters derived from ADOPT) 
RECORD (n=4,057) 
  
No. Person years at risk Events Hazard ratio (95% CI) 
        Unadjusted Adjusted* 
Time to cardiovascular hospitalisation or death 
Cluster           
    C1 (SAID) NA NA NA NA NA 
    C2 (SIDD) 948 3172 88 1.00 (ref) 1.00 (ref) 
    C3 (SIRD) 792 3038 94 1.11 (0.83-1.49) 1.06 (0.79-1.41) 
    C4 (MOD) 833 3141 62 0.71 (0.51-0.98) 1.02 (0.73-1.43) 
    C5 (MARD) 1484 5996 161 0.97 (0.74-1.25) 0.79 (0.61-1.03) 
*Adjusted for age at trial entry 
  
Application of clusters from the Swedish All New Diabetics in Scania 
cohort (ANDIS) to ADOPT 
 
Supplementary Figure 10: Characteristics of clusters assigned in ADOPT 
from the cluster centre coordinates in ANDIS (n=4,003). Cluster centre 
coordinates originally published in Table S3, Ahlqvist et al., Lancet Diabetes 
Endocrinology 2018;6:361-69.  
SAID=severe autoimmune diabetes. SIDD=severe insulin-deficient diabetes. 
SIRD=severe insulin-resistant diabetes. MOD=mild obesity-related diabetes. 
MARD=mild age-related diabetes. HOMA2-B=homoeostatic model assessment 
2 estimates of β-cell function. HOMA2-IR=homoeostatic model assessment 2 
estimates of insulin resistance. 
(A) Distribution of ADOPT participants according to ANDIS clustering  
 
(B) Distributions of HbA1c, BMI, age at diagnosis, HOMA2-B, and HOMA2-
IR at baseline for each ANDIS-derived cluster. 
 
 
Supplementary Table 16: Concordance between clusters defined de-novo 
in ADOPT and clusters assigned in ADOPT from ANDIS cluster centre 
coordinates 
  ANDIS clusters    
ADOPT clusters     C1 (SAID) C2 (SIDD) C3 (SIRD) C4 (MOD) C5 (MARD) 
    C1 (SAID) 100% 0% 0% 0% 0% 
    C2 (SIDD) 0% 56% 9% 25% 9% 
    C3 (SIRD) 0% 1% 59% 2% 38% 
    C4 (MOD) 0% 2% 12% 43% 43% 
    C5 (MARD) 0% 11% 3% 18% 68% 
  
Supplementary Figure 11: Glycaemic progression by cluster in ADOPT 
from one to five years using ANDIS-derived clusters (n=3,016) 
 
 
 
Supplementary Figure 12: Renal progression by cluster in ADOPT over 
five years using ANDIS-derived clusters. 
(A) Cumulative incidence of CKD Stage 3 (confirmed eGFR <60) in individuals 
with eGFR ≥60 at baseline (n=3,694). eGFR calculated using CKD-EPI formula. 
 
  
(B) Cumulative incidence of albuminuria (UACR ≥30 mg/g) in individuals with 
UACR <30 mg/g at baseline (n=3,168). 
 
 
 
Supplementary Figure 13: Change in HbA1c by drug for each cluster in 
ADOPT over three years using ANDIS-derived clusters (n=3,785). Adjusted 
mean HbA1c over three years by drug. Grey shading shows 95% CIs.  
 
 
  
Supplementary Table 17: Model performance measures to compare 
clusters defined de-novo in ADOPT and clusters assigned in ADOPT from 
ANDIS cluster centre coordinates  
A) Glycaemic progression from one to five years (n=3,016) 
  R² AIC 
ADOPT clusters 0.084 221404 
ANDIS clusters 0.078 221446 
 
B) Time to CKD Stage 3 (confirmed eGFR <60) in individuals with eGFR ≥60 at 
baseline (n=3,694). eGFR calculated using CKD-EPI formula. 
  C-statistic R² 
ADOPT clusters 0.58 0.01 
ANDIS clusters 0.59 0.01 
 
C) Time to albuminuria (UACR ≥30 mg/g) in individuals with UACR <30 mg/g at 
baseline (n=3,168). 
  C-statistic R² 
ADOPT clusters 0.52 0.002 
ANDIS clusters 0.52 0.003 
 
D) Explained variation (R²) in treatment response (changes in HbA1c over 3 
years)  
  Metformin Sulfonylurea Thiazolidinedione 
ADOPT clusters 0.15 0.20 0.17 
ANDIS clusters 0.10 0.12 0.09 
 
 
 
 
 
 
Chapter 7 
 
 
Discussion 
  
Chapter 7: Discussion 
 
The work presented in this thesis evaluated the potential for a precision 
medicine approach in type 2 diabetes. We first described current and recent 
prescribing in the prescribing of glucose-lowering therapy in the UK for people 
with type 2 diabetes, and the relatively modest impact of recent prescribing 
changes on important short-term clinical outcomes including HbA1c reduction 
and weight change after initiating new therapy.  
We then explored the potential for a precision medicine approach with 4 
common therapy options: DPP4 inhibitors, GLP1 receptor agonists, 
sulfonylureas and thiazolidinediones. Two studies demonstrated that routinely 
measured clinical characteristics are associated with glucose-lowering response 
to these therapies, with findings validated in independent datasets including 
randomised trials. Higher values of markers of insulin resistance are associated 
with lesser response to DPP4 inhibitors but are not associated with response to 
GLP1 receptor agonists. Female sex and higher BMI are associated with 
greater response to thiazolidinediones but lesser response to sulfonylureas. 
We went on to evaluate whether the risks and benefits of therapy are 
associated. With sulfonylureas and thiazolidinediones, we found that increased 
glucose-lowering response is associated with an increased risk of common 
drug-specific side effects (respectively, hypoglycaemia and oedema). Finally, 
we compared a precision medicine strategy based on assigning individuals to 
type 2 diabetes subgroups with an individual-level strategy of using the specific 
clinical characteristics of individual patients to predict disease progression and 
treatment response, and found that the second ‘individual-level’ strategy had 
greater clinical utility. This final study also provides an early insight into the 
potential population-level benefit of selecting treatment for individual people with 
type 2 diabetes based on their clinical characteristics. 
This chapter gives an overview of the main findings of the thesis and discusses 
the works’ conclusions, implications, limitations and potential areas for further 
research. 
 
  
Chapter 2: Time trends in prescribing of type 2 diabetes drugs, glycemic 
control and risk factors: a retrospective analysis of primary care data, 
2010-2017 
The number of glucose-lowering medications available to patients and clinicians 
has increased markedly in recent years, and type 2 diabetes treatment 
guidelines have been updated to include a much greater choice of these 
medications. Despite this, up-to-date information on prescribing patterns and 
the impact of any changes in prescribing on the outcomes of people with type 2 
diabetes is lacking. 
In this study we described recent changes in prescribing of initial, second, third 
and fourth line medication for people with type 2 diabetes in the UK. We then 
estimated concomitant temporal changes in population-level short-term clinical 
outcomes: HbA1c reduction, weight change, rates of hypoglycaemia, blood 
pressure change, and treatment discontinuation. 
Conclusions 
There have been drastic changes in the prescribing of glucose-lowering 
medication after first-line metformin. Most notably, use of DPP4 inhibitors 
second-line near doubled over 2010 to 2017 (41% of new prescriptions in 2017 
compared to 22% 2010), while second-line use of sulfonylureas decreased 
(29% of new prescriptions in 2017 compared to 53% in 2010). SGLT2 inhibitor 
use increased rapidly following their introduction in 2013 for second to fourth 
line therapy; these agents comprised 17% of new first-fourth line prescriptions 
in 2017. 
Despite the marked changes in prescribing we found relatively little change in 
short-term clinical outcomes over the same period. Average HbA1c reduction 
and the proportion of people discontinuing therapy were stable over the period 
studied, and although change in systolic blood pressure improved, this change 
was clinically small (for example, improvement in 6 month systolic blood 
pressure change 2017 vs. 2010 for second-line therapy: -2.1 mmHg (95% 
confidence interval -3.2;-2.0). Potentially clinical important improvements were 
observed in weight change second to fourth line, where use of SGLT2-inhibitors 
(which are associate with weight loss) increased, and in rates of recorded 
hypoglycaemia second-line, where use of sulfonylureas (known to cause 
hypoglycaemia) decreased. 
Implication of Findings 
This study provides timely ‘real-world’ information on recent prescribing trends 
for glucose-lowering medication in the UK, a setting where unlike many 
countries, such as the US, prescribing choice does not reflect the ability of 
people to pay for their medication. Interestingly, the marked changes in 
prescribing do not solely reflect changes in treatment guidelines, as they largely 
pre-empt the updates to UK NICE guidance that positioned DPP4 inhibitors 
(2015) and then SGLT2 inhibitors (2017) alongside sulfonylureas and 
pioglitazone as second and third-line treatment options.(1) This is in keeping 
with a recent study that found extensive geographical variation in prescribing of 
second-line therapy across the UK.(2) Taken together, these studies strongly 
suggest that the changes in prescribing are not entirely evidence based; 
possible external influences include local prescribing policy, drug safety 
awareness and pharmaceutical company marketing.(2) 
To our knowledge, this is the first study to examine time trends in these clinical 
outcomes in the UK. The key finding is that, in terms of the clinical outcomes 
examined, the population-level impact of the change in prescribing towards 
newer, more expensive medications has been relatively modest. For HbA1c 
reduction the results are reassuring, given the increase second-line in use of 
DPP4-inhibitors which have been associated with lower glycaemic response 
compared to other agents in some studies.(3, 4) Similarly, improvements in 
weight change and a reduction in hypoglycaemia rates are likely to have led to 
improved quality of life for patients and a possible cost-benefit for the NHS.(5) 
However, these improvements should be considered in the context of the much 
higher cost of newer drug options. Based on the prescribing data we have 
presented and 2016 costs per drug in England the cost of treating diabetes 
second-line has doubled from on average £13 per prescription in 2010 to £27 
per prescription in 2017.(6) Given the increasing prevalence of type 2 diabetes 
(estimated as over 3 million in England in 2015/16 compared to 2.3 million in 
2010/11),(7) the trend towards prescribing of more expensive therapy has 
important implications for the NHS at a time budgets are constrained.  
Subsequent work 
The first and second line prescribing trends described in this study are similar to 
trends recently reported using the same dataset over a similar time period.(8) 
However, we are aware of no other studies that have examined third and fourth 
line prescribing, and no studies have used individual level data to examine 
concomitant changes in clinical outcomes alongside changes in prescribing.  
The work in this chapter provides important context to subsequent chapters 
evaluating a precision medicine approach to guide type 2 diabetes therapy. The 
rapid changes in prescribing towards much more costly therapy after metformin 
highlights a consequence of a lack of clear guidance to inform treatment choice. 
Better understanding the risks and benefits of the treatment options commonly 
prescribed after metformin offers the potential of more evidence based 
prescribing and improved clinical outcomes. 
Limitations 
A limitation of this study is the outcomes evaluated, given the recent evidence 
from placebo-controlled randomised trials of cardiovascular benefit with newer 
drug classes SGLT2 inhibitors and GLP1 receptor agonists an analysis of 
cardiovascular trends would be of considerable interest.(9) These trial results 
are directly applicable to 15-20% of individuals with type 2 diabetes and 
established cardiovascular disease.(4, 10)  
A further limitation is the lack of available data to accurately capture hospital 
admission records of hypoglycaemia, or mild hypoglycaemia unrecorded in 
general practice. The absolute hypoglycaemia rates reported will therefore be 
an underestimate of the true population rates. However estimates of time trends 
are unlikely to be biased unless recording of hypoglycaemia has changed over 
time.  
For HbA1c, weight and blood pressure change there was substantial missing 
outcome data. This was mitigated by evaluation of 6 and 12 month outcomes 
(some individuals had a valid 6 month outcome but missing 12 month outcome 
and vice versa). Although, the characteristics of individuals included and 
excluded from the analysis were similar, we cannot be sure that differences 
between individuals with missing data did not account for our findings for the 
different outcomes assessed, thereby limiting the generalisability of the results 
of this study.  
  
Future research  
The findings complements other recent work which has suggested further 
studies are needed to evaluate the cost-effectiveness of increased prescribing 
of the newer glucose-lowering agents,(2) although this would require evaluation 
of cardiovascular outcomes as well at the outcomes reported here. Hospital 
episode linked (HES) linked data would facilitate this cardiovascular outcomes 
analysis and also allow examination of hospital admissions data for 
hypoglycaemia. 
The fact that rapid changes in prescribing occurred without clear guidance 
highlights an important need for research that can establish a more evidence–
based approach to selecting therapy. This could involve 1) comparative 
effectiveness analysis of the different drugs head-to-head using either 
prospective trials and/or observational data to better understand differences in 
average treatment effects 2) precision medicine evaluation of the relative 
benefits and risks of the different medications for individual patients. 
  
Chapter 3: Precision Medicine in Type 2 Diabetes: Clinical Markers of 
Insulin Resistance Are Associated With Altered Short- and Long-Term 
Glycemic Response to DPP-4 Inhibitor Therapy 
The previous chapter identified DPP4 inhibitors as the most commonly initiated 
second-line therapy at the end of 2017. This makes identification of clinical 
characteristics and biomarkers robustly associated with glucose-lowering 
response to DPP4 inhibitors a priority for any precision medicine strategy 
aiming to match therapy to people with type 2 diabetes likely to have the 
greatest drug response. 
A major mechanism of action of DPP4-inhibitors is potentiation of pancreatic 
beta-cell insulin secretion. This aim of this chapter was to evaluate associations 
between markers of insulin secretion and resistance and glucose-lowering 
response to DPP4 inhibitor therapy.  
Conclusions 
The key finding of this chapter is that markers of higher insulin resistance were 
consistently associated with lesser glucose-lowering response after initiating 
DPP4 inhibitor therapy. This finding was demonstrated in the PRIBA 
prospective study (n=254), with validation in UK primary care data (CPRD, 
n=23,001). In PRIBA, baseline HbA1c adjusted 6 month response was --5.3 
mmol/mol (95%CI -1.8;-8.6) [-0.5% (95%CI -0.2;-0.8)] for a subgroup defined by 
obesity (BMI≥30) and high triglycerides (≥2.3mmol/L) [31% of participants], half 
that of a subgroup defined by non-obesity (BMI<30) and low triglycerides 
(<2.3mmol/L) [22% of participants; 6 month response -11.3 mmol/mol (95%CI -
8.4;-14.1) [-1.1% (95%CI -0.8;-1.3)]].  
Importantly, in PRIBA both non-routine (HOMA2 measured insulin resistance 
(HOMA2-IR)) and routinely available markers (BMI, triglycerides) showed 
consistency of effect. In CPRD, results for routinely available markers closely 
matched PRIBA. Associations were demonstrated to be independent of other 
clinical characteristics and were robust to sensitivity analysis including 
adjustment for co-therapy change (PRIBA only, in CPRD all individuals were on 
stable therapy) and stratification by sex. In contrast, there was no evidence of 
an association between markers of insulin resistance and glucose-lowering 
response for non-insulin treated individuals initiating GLP1 receptor agonists 
(PRIBA n=339, CPRD n=4,464). 
Implication of Findings 
The clinically relevant associations between markers of higher insulin resistance 
and reduced glycaemic response to DPP4 inhibitors suggests a potential role 
for using routine clinical characteristics to target DPP4 inhibitor therapy to those 
likely to have greater glycaemic response. BMI and triglycerides are available in 
clinical practice in the UK and many countries at no or little cost. This means 
use of these markers to identify people more or less likely to respond well to 
DPP4 inhibitors may be a cost-effective strategy even if the difference in likely 
glucose-lowering for many people is relatively modest. However, investigation 
of whether these and other clinical features are robustly associated with 
response to other glucose-lowering therapies is needed before the clinical utility 
of these findings can be fully evaluated.  
Mechanistically, our results suggest there may be important differences 
between DPP4 inhibitors and the other incretin-based drug class, GLP1 
receptor-agonists, for which there was no consistent association in non-insulin 
treated individuals for markers of insulin resistance. 
Subsequent work 
Although this study has informed several commentaries,(11-13) to our 
knowledge there have been no further published empirical studies testing the 
reported associations for DPP4-inhibitors in other datasets. We followed up this 
study in Chapter 4 to examine clinical factors associated with glucose-lowering 
response to sulfonylureas and thiazolidinediones, two other second-line options 
in current treatment guidelines.  
Limitations 
As many of the markers of insulin resistance collected in PRIBA are not 
routinely recorded, we were unable to validate several important associations in 
CPRD the validation dataset, notably fasting C-peptide and HOMA2-IR. 
Similarly, triglyceride measurements differed between the two studies; in PRIBA 
fasting measures were available, however in primary care most triglyceride 
measures are likely to be collected non-fasting. This may explain the diminished 
association between triglyceride levels and response in CPRD; alternatively the 
size of effect in PRIBA may be a chance finding.  
We lacked follow-up beyond 6 months in PRIBA meaning we were unable to 
evaluate durability of response in the primary dataset. Durability (time to 
glycaemic failure, defined as >69 mmol/mol [8.5%]) was explored in CPRD 
using survival analysis, and although there were significant relative differences 
between obesity and triglyceride-defined subgroups differences were modest on 
the absolute risk scale. Any analysis of time to glycaemic failure in routine data 
is however especially limited by the likelihood of informative dropout (for 
example, if individuals with a poor 6 month response are more likely to then 
stop a therapy before a second HbA1c is measured to confirm glycaemic 
failure). Missing data is a further limitation in CPRD, as 42% of individuals 
initiating DPP4 inhibitor therapy then did not have a valid HbA1c measure at 6 
months so were not included in the analysis. We do not believe these 
individuals are likely to be missing at random, as the missing outcome data 
were likely to depend on their actual value (missing not at random). Replication 
of effect in independent datasets is therefore likely to provide a more robust 
strategy than multiple imputation. 
Future research  
GLP1 receptor agonists provided the only comparator group available in both 
datasets to demonstrate specificity of effect. An important area for future work is 
head to head evaluation with other second-line therapy options; sulfonylureas, 
SGLT2 inhibitors and thiazolidinediones. The ongoing TRIMASTER clinical trial 
will, using a crossover design, directly test the hypothesis that obese (BMI>30) 
participants will have a lesser response to the DPP4 inhibitor sitagliptin but a 
greater response to the thiazolidinedione pioglitazone compared to non-obese 
participants.(14) 
Individual-level data from completed drug efficacy clinical trials are increasingly 
available to evaluate secondary research questions. This provides an important 
opportunity to further validate the associations identified in this study. Trials 
provide longer-term (up to 2 years) protocol-driven follow up with multiple 
regular HbA1c measurements, facilitating use of more robust methods such as 
repeated measures mixed effects models to test associations and evaluate 
durability of effect. We are currently conducting analysis of several existing trials 
of DPP4 inhibitor therapy and results appear consistent with this analysis 
(Dennis, Shields, Jones, Hattersley; unpublished). 
Although DPP4 inhibitors are thought to be a relatively safe treatment option 
and are not associated with weight gain,(15, 16) evaluation of differences 
between individuals in tolerance and risk of side-effects is a requirement for a 
clinically useful precision medicine approach. The small number of participants 
in PRIBA meant evaluation of these outcomes was not possible in this study, 
however existing protocol-driven trials and routine datasets are likely to provide 
the information required. 
  
Chapter 4: Sex and BMI alter the benefits and risks of sulfonylureas and 
thiazolidinediones in type 2 diabetes: A framework for evaluating 
stratification using routine clinical and individual trial data 
Sulfonylureas and thiazolidinediones are the two low-cost, off-patent, glucose-
lowering therapies recommended after metformin in current treatment 
guidelines. In this chapter we used a novel research framework of ‘discovery’ in 
routine primary care data followed by validation in existing trial data to compare 
these two therapies head-to-head, and thus evaluate potential for applying a 
precision medicine approach based on likely glucose lowering response and 
risk of developing side-effects. 
Conclusions 
The key finding of this chapter is that sex and BMI are associated with marked 
differences in glucose lowering response to sulfonylureas and 
thiazolidinediones. More obese and female individuals respond better to 
thiazolidinediones, less obese and male individuals respond better to 
sulfonylureas. Differences were first observed for 12 month response in primary 
care data (CPRD, n=22,379), and then confirmed up to 5 years for four 
subgroups defined by sex and obesity (BMI </≥30) in two large trials in which 
participants were randomised to therapy (ADOPT and RECORD, n=4,947). 
Importantly, these subgroups also differed in weight change and risk of side-
effects. In particular, with thiazolidinediones obese females had a much greater 
response relative to sulfonylureas but were also at increased risk of oedema 
and had much greater weight gain.  
  
Implication of Findings 
To our knowledge this is the first robust demonstration of differential response 
when directly comparing two type 2 diabetes therapy options, and the first study 
to evaluate systematically how the benefits and risk of type 2 diabetes therapy 
vary with clinical characteristics. The results suggest that, if the clinical decision 
is between sulfonylureas and thiazolidinediones, it is possible to robustly 
identify people that are likely to have a much greater glucose-lowering response 
with one agent over the other.  
This study also demonstrates that precision medicine cannot just be focused on 
the likely benefits of therapy. With thiazolidinediones, risk of side-effects and 
weight change appeared to increase with greater glucose-lowering response. 
Even using relatively crude subgroups we were able to provide information on 
likely risks and benefits that are more tailored to individuals than the current 
approach based on average outcomes.  
This study also presents a novel, practical, and low-cost methodological 
framework for evaluating a precision medicine approach in type 2 diabetes 
without the need for expensive prospective studies. Drug efficacy trial data for 
the major drug options after metformin are now available upon application from 
open research portals.(17, 18) The framework using routine data and trial data 
is potentially applicable in many other chronic diseases where precision 
medicine is of interest and there are multiple treatment options, for example 
hypertension and epilepsy. 
Subsequent work 
Chapter 5 extends the evaluation of risks and benefits for the two therapies by 
specifically examining associations between glucose-lowering response and 
risk of side-effects; the analysis in the current chapter suggested an association 
based on subgroup estimates but did not formally test this. In Chapter 6 we also 
examine the clinical utility of selecting glucose-lowering treatment based on 
subgroups with an approach using a model that combines continuous patient 
clinical features. 
Limitations 
Methodologically, a limitation of this analysis is the subgroup based approach 
used, in particular the dichotomisation of BMI into obese and non-obese 
categories. The main advantage of a subgroup based approach is in terms of 
presentation and interpretation of results, which in this study was an important 
factor as it is an early demonstration of the potential of precision medicine in 
type 2 diabetes. Statistically, there are however significant drawbacks to 
applying cut-offs to define subgroups compared with using continuous 
measures, most notably a substantial loss of statistical power.(19, 20)  
Whilst in this study clear and consistent differences for glycaemic response 
between subgroups were observed, a clear disadvantage to this modelling 
approach is the assumption that individuals within a subgroup are homogenous. 
For example, a male with a BMI of 30.1 was estimated to have the same 
response as a male with BMI of 40.1. This may or may not be the case but it 
cannot be tested using the subgroups defined in this study. This limits the 
clinical utility of the reported subgroups, although it does not diminish the main 
finding: that glucose-lowering response varies predictably by easily measured 
clinical characteristics.  
Use of subgroups also further reduced power to evaluate differences between 
people in risk of side-effects. For this reason further formal evaluation of the 
association between response and risk of side-effects was conducted in 
Chapter 5.  
Further limitations of this study include the limited range of characteristics 
evaluated. The study focused on sex and BMI as these were the routine clinical 
factors associated with the greatest differential response in primary care data; 
however duration of diabetes and, to a lesser extent, HDL were also associated 
with differential response (Chapter 4, Supplementary Figure S3). Older age at 
diagnosis was associated with greater response to both drugs, suggesting a 
utility for prediction of response but not for guiding decisions on therapy. As well 
as sex and BMI, evaluation of a broad range of clinical characteristics across all 
relevant therapy options will be required for a comprehensive evaluation of the 
potential of a precision medicine approach to type 2 diabetes therapy.  
Future research  
This study and the previous study reported in Chapter 3 have demonstrated 
BMI is a potential key clinical measure for guiding therapy. Higher BMI has 
been found to be associated with lesser response to both DPP4 inhibitors and 
sulfonylureas. Head-to-head evaluation of these two drug classes would be of 
great interest to determine if the size of effect is comparable or if at higher BMI 
levels one drug class is superior to the other.  
A key strength of this study is replication of effect across 3 independent 
datasets. However, to ultimately confirm the results a blinded prospective trial 
with one arm allocated therapy based on their sex and obesity and the other 
arm randomised without allocation would be required. Given the methodological 
limitations of using subgroups and the limited therapies evaluated this is not 
likely to be a cost-effective or practical study. Instead, more appropriate use of 
the results would be to inform the development of a model incorporating 
multiple validated continuous clinical features to predict response to multiple 
therapies. The model could then be used to select the optimal medication(s) for 
individuals based on likely glucose-lowering. The model could then be tested 
prospectively to examine to what degree selection of medication based on likely 
glucose-lowering alters glycaemic response as well as secondary outcomes 
such as weight change and development of side-effects.  
Finally, for thiazolidinediones, although CPRD data suggested a class effect, it 
would be of interest to validate findings in trials of pioglitazone. Both ADOPT 
and RECORD used rosiglitazone which has the same principal mechanism of 
action as pioglitazone but is no longer used in clinical practice in many 
countries. Pioglitazone trial data was requested for this study but was not made 
available by Takeda.  
  
Chapter 5: Evaluating associations between the benefits and risks of drug 
therapy in type 2 diabetes: A joint modelling approach 
The previous chapter suggested people with increased glycaemic response 
may be at increased risk of developing side effects with thiazolidinedione 
therapy in particular, but did not test this directly. No methodological framework 
has previously been proposed for direct evaluation of the association between 
the benefits and risks of drug therapy. In this chapter we applied joint 
longitudinal-survival modelling to formally evaluate the association between 
glycaemic response over time (a longitudinal process) and the risk of common 
side effects (a time-to-event process) for metformin, thiazolidinedione and 
sulfonylurea therapy in the ADOPT blinded randomised trial (n=4,351). 
Conclusions 
For sulfonylurea and thiazolidinedione therapy, estimates from joint models 
suggested greater glycaemic response was associated with an increased risk of 
developing side-effects (respectively, hypoglycaemia and oedema). In contrast, 
with metformin there was no evidence that greater response was associated 
with an increased risk of gastrointestinal side-effects.  
Implication of Findings 
Joint modelling was a useful approach to directly evaluate associations between 
the benefits and risks of type 2 diabetes drug therapy. The findings for 
sulfonylurea and thiazolidinedione therapy suggest application of a precision 
medicine strategy to target therapy at people likely to respond well without 
being at increased risk of developing side-effects will be difficult. This may only 
be possible if future studies can identify biomarkers or clinical features 
association with either, but not both, greater response and lower risk of side-
effects. Joint models provide an ideal framework to identify such markers. 
However, an important point is that the results of this study do not preclude a 
precision medicine approach for sulfonylureas and thiazolidinediones, as 
decision making should be based on absolute rather than relative estimates of 
risk or benefit.(21, 22) It may be that individuals can still be identified who are 
likely to respond well to these drugs without being at substantially increased 
absolute risk of side-effects. 
Joint modelling is an analytic approach generalisable to any set of longitudinal 
efficacy markers and associated set of adverse events. This study suggests an 
opportunity for a much more general application of joint modelling to more 
robustly evaluate the benefits and risk of therapy of medications in double 
blinded trials, like ADOPT, where participants are randomised to therapy. This 
would apply to most drug efficacy trials, in diabetes and in other diseases. 
Currently in drug efficacy trials side-effects are typically reported as a simple 
table contrasted with the placebo arm, with no temporal information, and 
potential associations between side-effects and drug response are not 
evaluated. A key advantage of joint models for this purpose is their flexibility. As 
demonstrated in this study different parameterisations of joint models offered 
differed insights into the underlying nature of response:side-effect associations. 
Correctly parameterised joint models are likely to be more efficient and less 
biased than standard approaches as they capture the true, unobserved, 
biomarker trajectory.(23) This suggests they may be an especially valuable 
method in smaller datasets such as clinical trials. 
  
Subsequent work 
We are aware of no studies published that have used joint modelling or 
alternative approaches to test associations between the benefits and risks of 
drug therapy in type 2 diabetes. 
Limitations 
Limitations of this analysis include the absence of a replication dataset. Data 
from primary care were not included due to concerns over the influence of 
recording bias, as discussed below. As this is the first application of joint-
modelling in this context we did not consider more complicated joint models, for 
example we did not consider time-varying associations which may be relevant 
for progressive side-effects that develop over time. We did also not incorporate 
changes in drug dose, which may have provided further insight into 
response:side-effect associations. Full elaboration of these and other 
challenges in a more general mathematical presentation of joint modelling of 
risks and benefits of drug therapy would be of considerable interest. 
Future research  
Evaluation of associations between risks and benefits of therapy for the newer 
glucose-lowering medications would be of considerable interest. A further key 
question is whether joint modelling provides a useful framework to evaluate the 
association between drug response and risk of side-effects in ‘real-world’ 
primary care datasets where a much wider range of people are initiated on 
glucose-lowering medications compared to the trials which have restricted 
inclusion criteria. However, in primary care follow-up is not protocol driven, 
meaning HbA1c and side-effects are recorded less frequently and systematically 
than in trials. There may also be recording biases, for example if more 
conscientious individuals are more likely to 1) take their medication and so 
attain better glycaemic response; 2) attend their general practice and have their 
HbA1c recorded; 3) report side-effects during their general practice visit. 
We have conducted initial evaluation of the joint modelling approach in primary 
care data (CPRD). Achieving model convergence has been a major challenge 
due to the much larger sample size. With the potential challenges discussed 
above in mind, we have implemented negative control analysis by testing 
associations between response and risk of a side-effect for individuals initiating 
drugs not expected to cause that particular specific side-effect. This has 
revealed a common finding that side-effects and response are often positively 
associated, regardless of drug (Dennis, Henley, unpublished). These early 
results suggest recording bias may limit inferences into the association between 
benefits and risks of drug therapy in routine primary care data. It may be that 
this question can only be evaluated in blinded trial datasets where recording 
biases should be minimal.  
Chapter 6: Disease progression and treatment response in data-driven 
subgroups of type 2 diabetes compared to models based on simple 
clinical features: an evaluation using clinical trial data 
A recent study proposed a novel substratification of diabetes, using a data-
driven cluster analysis in Scandinavian registry data to identify five reproducible 
subgroups of adult-onset diabetes.(24) The authors went on to show differences 
between the clusters in disease progression and risk of complications in 
observational follow-up. The authors suggested the clusters might help with 
therapy selection in the future but did not test whether the clusters could inform 
therapy choice.  
This chapter aimed to test the clinical utility of the proposed data-driven cluster 
approach.(24) The cluster analysis was repeated, and differences by cluster in 
disease progression and treatment response were evaluated in participants in 
the ADOPT and RECORD trials with randomised, protocol-driven follow-up data 
available. We then compared the utility of simpler clinical measures to the 
clusters for stratifying each outcome assessed. 
Conclusions 
The proposed clusters were reproducible in trial data and did differ in 
progression and treatment response. However, the key finding of this chapter is 
that simpler routine clinical measures were as or more useful than the clusters 
for stratifying each outcome assessed. In particular, models developed in 
ADOPT using just 4 simple clinical features (sex and continuous measures of 
BMI, age at diagnosis and baseline HbA1c) markedly outperformed the clusters 
to select therapy for individuals in the independent dataset RECORD. 
  
Implication of Findings 
People with type 2 diabetes differ in treatment response and risk of disease 
progression, raising the possibility of a practical, clinically orientated stratified 
approach in the near future. Our study suggests a ‘prediction model’ approach, 
combining phenotypic measures to predict specific outcomes for individual 
patients, is likely to have greater clinical utility than approaches that use clinical 
features to assign individuals into subgroups. Even four simple measures 
combined in a multivariable model showed the potential to improve glycaemic 
response if used to select therapy for individual patients. 
Subsequent work 
Prior to submission we searched Scopus, Web of Science, and Google Scholar 
to track the citations of the original Scandinavian study that proposed the 
subgroups, searching for follow-up studies assessing the reproducibility, clinical 
utility and role in treatment selection of the proposed data-driven clusters up to 
January 1, 2019. We identified a study that identified similar clusters in Chinese 
and a small mixed American population but did not examine any aspect of 
clinical utility as clinical follow-up was not available.(25) A second study of 
Danish people applied similar cluster analysis and, with duration of diabetes as 
an additional input variable, identified five subgroups of type 2 diabetes that 
differed to those in the original study, and differed in the prevalence of diabetes 
complications.(26) No studies were found that tested the clinical utility and 
particularly the role in treatment of the proposed cluster-based approach. 
  
Limitations 
A limitation of this study is the original exclusion criteria of the trials, with 
exclusions at screening based on clinical variables that informed the cluster 
analysis (blood glucose levels and age (and BMI in RECORD)). Despite this the 
clusters were identifiable with a very similar pattern of differences in clinical 
characteristics to the original study and with a similar proportion of individuals 
allocated to each cluster. The trial design, sample size and limited follow-up 
meant power was limited to evaluate heterogeneity in cardiovascular outcomes 
or other complications such as retinopathy.  
Future research  
This analysis suggests a number of follow up studies relating to precision 
medicine in type 2 diabetes. Age alone was identified as a useful predictor of 
glycaemic progression, in keeping with a recent observational study,(27) and 
further evaluation of predictors of progression in trial datasets with protocol 
driven long-term follow-up would be of considerable interest. 
It would also be interesting to see how the recently proposed genetically defined 
type 2 diabetes clusters of Udler and colleagues performed in a similar 
study,(28) although genetic information was not collected in RECORD or 
ADOPT and so other trial datasets will be required. 
The approach to evaluate treatment selection used in this study has not been 
widely applied elsewhere but is based on recent methodological 
developments.(29) Standard performance measures are focused on the ability 
of a model to predict response and this is of limited utility for treatment 
selection, as factors that predict response are much less useful than factors that 
predict differential response between therapies. It would be interesting to 
explore the robustness of the treatment selection strategy proposed in future 
work. On promising method is the ‘concordance-statistic for benefit’ metric put 
forward by van Klaveren and colleagues; this method aims to measure the 
performance of a model to predict treatment benefit when comparing two 
therapies or a therapy with placebo.(30) 
  
Final remarks 
This thesis demonstrates that routinely measured clinical features offer great 
potential to inform a precision medicine approach to aid the selection of 
glucose-lowering therapy for people with type 2 diabetes. For DPP4 inhibitors, 
sulfonylureas and thiazolidinediones, the studies in this thesis have identified 
simple features that robustly predict differential glucose lowering response to a 
potentially clinically significant degree. Initial work has also been undertaken to 
evaluate differences between people in the risk of side-effects. Future research 
is required to evaluate the other second-line option in the UK, SGLT2 inhibitors, 
as well as to further evaluate GLP1 receptor agonists which are now positioned 
as early treatment options in US/European guidelines.(4) 
Methodologically, the work in this thesis has demonstrated that trial and routine 
care datasets provide much of the data required to evaluate clinical factors 
associated with differential treatment effects of the different glucose-lowering 
therapies. A framework of discovery in routine data with validation in existing 
trial datasets offers a low-cost and principled way to evaluate the potential of 
precision medicine in this area, without the need for expensive and time 
consuming prospective trials. Starting with primary care data ensures that, in 
the first instance, the focus is on the utility of routine clinical features available 
at no or little cost to any doctor. Non-routine biomarkers and ‘omic’ approaches 
can then be integrated to this basic model if clinically relevant effects can be 
robustly demonstrated. 
This work also highlights the critical importance of evaluation of not just the 
benefits but also the risks of therapy. We have demonstrated that joint 
modelling offers a useful framework to test whether glucose-lowering response 
and side-effects are associated. However ultimately for individuals it is the 
absolute risk of side-effects compared to the likely glucose-lowering response 
that can provide the most useful information to guide decision making.  
The comparison of cluster analysis defined subgroups with models that 
combine multiple continuous features suggests that there is likely to be greater 
clinical utility from continuous feature models than type 2 diabetes subgroups. 
Continuous feature models will require integration of multiple differential 
features in a multivariable model, to enable separation of likely response 
between the different glucose-lowering therapies (Figure 1).  
 
Figure 1: Treatment response based precision medicine approach based 
on combining multiple continous clinical features. Reproduced under open 
licence from Hattersley and Patel, Diabetologia 2017.(31) 
 
Whether the effect sizes using a multivariable model to predict either glucose-
lowering response or side-effects are large enough to guide therapy is an 
important area for future research. Effect sizes are likely to be relatively modest 
for many individuals, in contrast to those observed in monogenic diabetes 
where specific genetic mutations result in up to 5-fold differences in treatment 
response.(32) For individuals for whom effect sizes are modest, this information 
is still important as it can provide an evidence-base for selecting therapy based 
on other key criteria, in particular cost and patient preference. Future research 
is also required on the acceptability of provision of this personalised information 
to clinicians and patients, and the most effective ways to communicate this. 
Ultimately, a prospective trial to test the utility of a treatment selection model as 
a decision aid for clinicians will be required.  
Given the recent demonstration of cardiovascular benefit for SGLT2 inhibitors 
and GLP1 receptor agonists, evaluation of differences between people in 
cardiovascular outcomes is now of clear importance alongside glucose-lowering 
and side-effects. Ultimately, integration of these three elements, alongside cost 
and patient preference, may in the near future allow a truly ‘precise’ approach to 
selecting therapy for people with type 2 diabetes.  
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